Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
34700.0 | 2018-07-14 00:00:00 UTC | 3 Biotech Stocks That Soared This Week: Are They Buys? | ABUS | https://www.nasdaq.com/articles/3-biotech-stocks-soared-week-are-they-buys-2018-07-14 | nan | nan | Who says the fireworks have to end on July 4th? There were still plenty of fireworks this week in the biotech industry.
Three biotech stocks turned in especially great performances over the last few days. The share prices of Benitec Biopharma (NASDAQ: BNTC) , Zogenix (NASDAQ: ZGNX) , and Arbutus Biopharma (NASDAQ: ABUS) soared 27% or more this week. What caused these biotech stocks to explode -- and are they buys now?
1. Benitec Biopharma: Let's make a deal
Shares of Benitec Biopharma skyrocketed 40% this week. The huge move came after Benitec announced on Monday that it was licensing exclusive global rights for gene therapy BB-301 to Axovant Sciences (NASDAQ: AXON) .
BB-301, which will now be known by the catchy name AXO-AAV-OPMD, uses a "silence-and-replace" approach to treat oculopharyngeal muscular dystrophy (OPMD). The PABPN1 gene mutation that causes OPMD is "silenced" by DNA-directed RNA interference. At the same time, the mutant version of the gene is replaced by a healthy version.
Under the terms of the deal, Axovant will pay Benitec $10 million upfront with payments of $17.5 million contingent upon achieving near-term milestones. Benitec could also receive other development, regulatory, and commercial milestones in the future, bringing the total potential payments to $187.5 million. In addition, the small biotech stands to receive 30% of net profits on global sales of the OPMD gene therapy if it wins approval down the road.
2. Zogenix: A Dravet hooray
Zogenix stock jumped nearly 32% this week. The catalyst for the stock was the company's update on Thursday of phase 3 clinical results for lead candidate ZX008 in treating Dravet syndrome, a rare form of childhood-onset epilepsy.
Those results were pretty impressive. Patients taking ZX008 experienced a 54.7% reduction in mean monthly convulsive seizures compared to patients on placebo. Zogenix's drug also appeared to reduce seizure frequency by a statistically significant level versus placebo. The good news was completely unexpected, though: Zogenix reported positive results from an earlier phase 3 study of ZX008 in treating Dravet syndrome last year.
Based on the encouraging data from both late-stage studies of ZX008, Zogenix plans to submit the drug for approval in the U.S. and in Europe in the fourth quarter of 2018. The company is also evaluating ZX008 in a phase 3 study as a treatment for Lennox-Gastaut syndrome (LGS), another severe form of epilepsy.
3. Arbutus Biopharma: The pipeline is percolating
Arbutus Biopharma wasn't too far behind Zogenix, with its share price rising 27% this week. On Tuesday, Arbutus presented an update on progress with its pipeline that made investors happy campers.
The biotech announced that the first patient has been dosed in a phase 1 study evaluating AB-506 in treating patients infected by the hepatitis B virus (HBV). Top-line results from this study should be available by Q2 of 2019. Arbutus also said that it expects to begin dosing in another study of AB-452 in the fourth quarter of this year. These studies should set up the biotech to initiate an all-oral combination study of both experimental HBV drugs in the second half of 2019.
Arbutus could soon have more money flowing in the doors. The Food and Drug Administration is expected to announce its decision on approval for Alnylam 's patisiran by Aug. 11, 2018. Arbutus stands to receive royalties if patisiran wins approval.
Are they buys?
Let's take this week's biotech winners in alphabetical order. In my view, Arbutus has plenty of potential. However, I'd prefer to wait and see how its pipeline candidates actually perform.
I think that it's way too early for most investors to buy shares of Benitec Biopharma. The Australian biotech's gene therapy probably won't even advance into clinical testing until next year.
What about Zogenix? The positive results for ZX008 set up the biotech to likely go head-to-head against GW Pharmaceuticals , which won FDA approval a few weeks ago for cannabidiol (CBD) product Epidiolex in treating Dravet syndrome and LGS. GW will have a nice head start, though, in the Dravet syndrome market and an even greater one in LGS. This assumes, of course, that Zogenix wins approval for ZX008 in both indications.
My take is that the odds of approval for ZX008 in treating Dravet syndrome look really good based on the phase 3 data. It's hard to say how the drug will fare in treating LGS, but my guess is that Zogenix could gain another victory in the indication down the road.
However, I don't think Zogenix is a great stock to buy right now. There are still several hurdles to jump. This week's big gain was warranted, but I'm not sure how much higher Zogenix will go.
10 stocks we like better than Zogenix
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Zogenix wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of June 4, 2018
Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The share prices of Benitec Biopharma (NASDAQ: BNTC) , Zogenix (NASDAQ: ZGNX) , and Arbutus Biopharma (NASDAQ: ABUS) soared 27% or more this week. The huge move came after Benitec announced on Monday that it was licensing exclusive global rights for gene therapy BB-301 to Axovant Sciences (NASDAQ: AXON) . The catalyst for the stock was the company's update on Thursday of phase 3 clinical results for lead candidate ZX008 in treating Dravet syndrome, a rare form of childhood-onset epilepsy. | The share prices of Benitec Biopharma (NASDAQ: BNTC) , Zogenix (NASDAQ: ZGNX) , and Arbutus Biopharma (NASDAQ: ABUS) soared 27% or more this week. The catalyst for the stock was the company's update on Thursday of phase 3 clinical results for lead candidate ZX008 in treating Dravet syndrome, a rare form of childhood-onset epilepsy. The good news was completely unexpected, though: Zogenix reported positive results from an earlier phase 3 study of ZX008 in treating Dravet syndrome last year. | The share prices of Benitec Biopharma (NASDAQ: BNTC) , Zogenix (NASDAQ: ZGNX) , and Arbutus Biopharma (NASDAQ: ABUS) soared 27% or more this week. Zogenix: A Dravet hooray Zogenix stock jumped nearly 32% this week. Arbutus Biopharma: The pipeline is percolating Arbutus Biopharma wasn't too far behind Zogenix, with its share price rising 27% this week. | The share prices of Benitec Biopharma (NASDAQ: BNTC) , Zogenix (NASDAQ: ZGNX) , and Arbutus Biopharma (NASDAQ: ABUS) soared 27% or more this week. Zogenix: A Dravet hooray Zogenix stock jumped nearly 32% this week. Arbutus Biopharma: The pipeline is percolating Arbutus Biopharma wasn't too far behind Zogenix, with its share price rising 27% this week. |
34701.0 | 2018-07-07 00:00:00 UTC | 3 Biotech Stocks That Soared This Week: Are They Buys? | ABUS | https://www.nasdaq.com/articles/3-biotech-stocks-soared-week-are-they-buys-2018-07-07 | nan | nan | Gaining 22% in a year is a very good return for most stocks. But racking up that much or more in just a week is better than very good -- it's fantastic.
Three biotech stocks that achieved this feat this week are Nightstar Therapeutics (NASDAQ: NITE) , Arbutus Biopharma (NASDAQ: ABUS) , and Biogen (NASDAQ: BIIB) . What caused these stocks to soar, and are they smart picks to buy now? Here's what you need to know.
1. Nightstar Therapeutics: Old news is still good news
Shares of Nightstar Therapeutics jumped 29% this week. By Thursday, the biotech stock was up more than 30%, | Three biotech stocks that achieved this feat this week are Nightstar Therapeutics (NASDAQ: NITE) , Arbutus Biopharma (NASDAQ: ABUS) , and Biogen (NASDAQ: BIIB) . Gaining 22% in a year is a very good return for most stocks. What caused these stocks to soar, and are they smart picks to buy now? | Three biotech stocks that achieved this feat this week are Nightstar Therapeutics (NASDAQ: NITE) , Arbutus Biopharma (NASDAQ: ABUS) , and Biogen (NASDAQ: BIIB) . Nightstar Therapeutics: Old news is still good news Shares of Nightstar Therapeutics jumped 29% this week. By Thursday, the biotech stock was up more than 30%, | Three biotech stocks that achieved this feat this week are Nightstar Therapeutics (NASDAQ: NITE) , Arbutus Biopharma (NASDAQ: ABUS) , and Biogen (NASDAQ: BIIB) . Gaining 22% in a year is a very good return for most stocks. Nightstar Therapeutics: Old news is still good news Shares of Nightstar Therapeutics jumped 29% this week. | Three biotech stocks that achieved this feat this week are Nightstar Therapeutics (NASDAQ: NITE) , Arbutus Biopharma (NASDAQ: ABUS) , and Biogen (NASDAQ: BIIB) . Gaining 22% in a year is a very good return for most stocks. But racking up that much or more in just a week is better than very good -- it's fantastic. |
34702.0 | 2017-11-27 00:00:00 UTC | Health Care Sector Update for 11/27/2017: MGCD,ABUS,MYO | ABUS | https://www.nasdaq.com/articles/health-care-sector-update-11272017-mgcdabusmyo-2017-11-27 | nan | nan | Top Health Care Stocks
JNJ +0.74%
PFE -0.08%
ABT +0.30%
MRK +0.20%
AMGN -0.03%
Health care stocks were staying slightly above today's starting point, with the NYSE Health Care Index climbing less than 0.1% while shares of health care companies in the S&P 500 were up slightly more than 0.1% as a group.
In company news, MGC Diagnostics ( MGCD ) reached a 43-month high on Monday, climbing almost 25% to a its best price since April 2014 at $10.98 a share, after the medical technology company agreed to a $50.3 million private-equity buyout offer from Altus Capital Partners.
Altus Capital will pay $11.03 in cash for each MGC Diagnostics share, a 25.3% premium over Friday's closing price. The transaction is expected before the end of the year or in early 2018, subject to a tender of a majority of the company's stock.
In other sector news,
(+) ABUS, (+3.3%) Today discloses plans for two oral presentations and one poster discussions at the HepDART 2017 conference on Dec. 5-6 in Kona, Ha., including a potential treatment for the hepatitis B virus by reducing or eliminating the number of surface antigens produced by the virus.
(-) MYO, (-8.5%) Late Friday discloses issuing almost 5.88 million shares of its common stock during 2017, including 2.62 million issued following the automatic conversion of an equal number of preferred shares and another 1.06 million shares from the conversion of convertible notes soon after its IPO closed in June.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news, (+) ABUS, (+3.3%) Today discloses plans for two oral presentations and one poster discussions at the HepDART 2017 conference on Dec. 5-6 in Kona, Ha., including a potential treatment for the hepatitis B virus by reducing or eliminating the number of surface antigens produced by the virus. Altus Capital will pay $11.03 in cash for each MGC Diagnostics share, a 25.3% premium over Friday's closing price. The transaction is expected before the end of the year or in early 2018, subject to a tender of a majority of the company's stock. | In other sector news, (+) ABUS, (+3.3%) Today discloses plans for two oral presentations and one poster discussions at the HepDART 2017 conference on Dec. 5-6 in Kona, Ha., including a potential treatment for the hepatitis B virus by reducing or eliminating the number of surface antigens produced by the virus. Health care stocks were staying slightly above today's starting point, with the NYSE Health Care Index climbing less than 0.1% while shares of health care companies in the S&P 500 were up slightly more than 0.1% as a group. In company news, MGC Diagnostics ( MGCD ) reached a 43-month high on Monday, climbing almost 25% to a its best price since April 2014 at $10.98 a share, after the medical technology company agreed to a $50.3 million private-equity buyout offer from Altus Capital Partners. | In other sector news, (+) ABUS, (+3.3%) Today discloses plans for two oral presentations and one poster discussions at the HepDART 2017 conference on Dec. 5-6 in Kona, Ha., including a potential treatment for the hepatitis B virus by reducing or eliminating the number of surface antigens produced by the virus. Health care stocks were staying slightly above today's starting point, with the NYSE Health Care Index climbing less than 0.1% while shares of health care companies in the S&P 500 were up slightly more than 0.1% as a group. In company news, MGC Diagnostics ( MGCD ) reached a 43-month high on Monday, climbing almost 25% to a its best price since April 2014 at $10.98 a share, after the medical technology company agreed to a $50.3 million private-equity buyout offer from Altus Capital Partners. | In other sector news, (+) ABUS, (+3.3%) Today discloses plans for two oral presentations and one poster discussions at the HepDART 2017 conference on Dec. 5-6 in Kona, Ha., including a potential treatment for the hepatitis B virus by reducing or eliminating the number of surface antigens produced by the virus. Top Health Care Stocks Health care stocks were staying slightly above today's starting point, with the NYSE Health Care Index climbing less than 0.1% while shares of health care companies in the S&P 500 were up slightly more than 0.1% as a group. |
34703.0 | 2017-11-03 00:00:00 UTC | Friday Sector Leaders: Music & Electronics Stores, Drugs | ABUS | https://www.nasdaq.com/articles/friday-sector-leaders-music-electronics-stores-drugs-2017-11-03 | nan | nan | In trading on Friday, music & electronics stores shares were relative leaders, up on the day by about 1.7%. Leading the group were shares of Rent A Center, up about 10.2% and shares of Jdcom Ads up about 1.5% on the day.
Also showing relative strength are drugs shares, up on the day by about 1.5% as a group, led by Arbutus Biopharma, trading up by about 16.5% and Aratana Therapeutics, trading higher by about 16.3% on Friday.
VIDEO: Friday Sector Leaders: Music & Electronics Stores, Drugs
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Friday, music & electronics stores shares were relative leaders, up on the day by about 1.7%. Also showing relative strength are drugs shares, up on the day by about 1.5% as a group, led by Arbutus Biopharma, trading up by about 16.5% and Aratana Therapeutics, trading higher by about 16.3% on Friday. VIDEO: Friday Sector Leaders: Music & Electronics Stores, Drugs The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Friday, music & electronics stores shares were relative leaders, up on the day by about 1.7%. VIDEO: Friday Sector Leaders: Music & Electronics Stores, Drugs The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also showing relative strength are drugs shares, up on the day by about 1.5% as a group, led by Arbutus Biopharma, trading up by about 16.5% and Aratana Therapeutics, trading higher by about 16.3% on Friday. VIDEO: Friday Sector Leaders: Music & Electronics Stores, Drugs The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Friday, music & electronics stores shares were relative leaders, up on the day by about 1.7%. Leading the group were shares of Rent A Center, up about 10.2% and shares of Jdcom Ads up about 1.5% on the day. VIDEO: Friday Sector Leaders: Music & Electronics Stores, Drugs The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
34704.0 | 2017-09-23 00:00:00 UTC | 3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher? | ABUS | https://www.nasdaq.com/articles/3-biotech-stocks-skyrocketed-week-can-they-go-higher-2017-09-23 | nan | nan | One great thing about the biotech industry is that there are nearly always some winners. Regardless of what's going on in the world or in the broader market, at least a few biotech stocks are likely to gain momentum week in and week out.
Three such winners over the past five days are Madrigal Pharmaceuticals (NASDAQ: MDGL) , Alnylam Pharmaceuticals (NASDAQ: ALNY) , and Arbutus Biopharma (NASDAQ: ABUS) . Here's why these three biotech stocks skyrocketed this week -- and a look at whether or not they can go even higher.
Madrigal Pharmaceuticals
For much of the last four years, Madrigal Pharmaceuticals stock had been anything but a winner. That changed this week, though, with the biotech's share price soaring close to 70%.
Madrigal announced good news on Tuesday from a pre-planned data safety monitoring board review of phase 2 studies of experimental drug MGL-3196 in treating heterozygous familial hypercholesterolemia (HeFH) and non-alcoholic steatohepatitis (NASH). The board gave a green light for both studies to move forward with no protocol changes.
Interestingly, though, the huge jump in Madrigal stock's price didn't come until later in the week. Trading volume for the stock on Friday was nearly 12 times higher than average for the biotech. This could indicate heavy buying by a large investor or even a bigger biotech, but there's no way to know for sure just yet. Regardless, Madrigal shareholders enjoyed tremendous gains -- higher than any other biotech stock on the market this week.
Alnylam Pharmaceuticals
It's been a great year for Alnylam Pharmaceuticals, with the biotech's market cap nearly doubling so far in 2017 as of last week. What a different five days makes, though. Alnylam stock surged more than 50% this week, causing the biotech's market cap to now stand more than three times higher than its level at the beginning of the year.
Unlike the situation with Madrigal, there's a clear reason why Alnylam stock shot up. On Wednesday, Alnylam and its partner, Sanofi (NYSE: SNY) , reported great results from a late-stage study of patisiran in treating hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy. hATTR is a rare disease impacting around 50,000 people across the world. The only approved treatment options right now are liver transplantation for patients in early stages of the disease and Pfizer 's tafamidis (which is approved in several countries but not in the U.S. yet).
Alnylam and Sanofi now plan to file for regulatory approval of patisiran in the U.S. before the end of this year. That will be followed soon afterwards by submission for approval of the drug in Europe. In addition, Sanofi is preparing for regulatory filings for patisiran in Japan, Brazil, and other countries beginning in the first quarter of 2018.
Arbutus Biopharma
Arbutus Biopharma stock has taken a similar trajectory to Alnylam. Prior to this week, Arbutus stock had doubled year to date. Shares of the biotech jumped 15% over the last five days and at one point had gains above 20%.
There's a good reason why Arbutus and Alnylam stocks correlate so well. Alnylam's patisiran uses Arbutus' lipid nanoparticle (LNP) delivery technology. Under the licensing agreement between the two biotechs, Arbutus stands to receive single-digit royalties on sales of patisiran if the drug is approved.
Patisiran's success could also bode well for Arbutus' own lead candidate, ARB-1467. Both drugs rely on a process called RNA interference (RNAi) and both use Arbutus' LNP technology. ARB-1467 is currently in a phase 2 clinical study targeting treatment of chronic hepatitis B virus (HBV) patients.
Can they go higher?
All three of these biotech stocks could move higher. Madrigal expects to announce results from its studies of MGL-3196 in treating HeFH and NASH in early 2018. Positive news would likely fuel an even greater boost for its stock. Arbitus has several potential catalysts coming up, including top-line results from an early stage study of AB-423 in treating HBV patients.
Alnylam could be in position for the most likely additional gains, though. While anything can happen in the regulatory approval process, the results from Alnylam's late-stage study of patisiran were so positive that approval seems likely. Don't expect another 50% jump, expect Alnylam to remain a winner for a while.
10 stocks we like better than Alnylam Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Alnylam Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
Keith Speights owns shares of Pfizer. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Three such winners over the past five days are Madrigal Pharmaceuticals (NASDAQ: MDGL) , Alnylam Pharmaceuticals (NASDAQ: ALNY) , and Arbutus Biopharma (NASDAQ: ABUS) . Madrigal announced good news on Tuesday from a pre-planned data safety monitoring board review of phase 2 studies of experimental drug MGL-3196 in treating heterozygous familial hypercholesterolemia (HeFH) and non-alcoholic steatohepatitis (NASH). Alnylam stock surged more than 50% this week, causing the biotech's market cap to now stand more than three times higher than its level at the beginning of the year. | Three such winners over the past five days are Madrigal Pharmaceuticals (NASDAQ: MDGL) , Alnylam Pharmaceuticals (NASDAQ: ALNY) , and Arbutus Biopharma (NASDAQ: ABUS) . Alnylam Pharmaceuticals It's been a great year for Alnylam Pharmaceuticals, with the biotech's market cap nearly doubling so far in 2017 as of last week. While anything can happen in the regulatory approval process, the results from Alnylam's late-stage study of patisiran were so positive that approval seems likely. | Three such winners over the past five days are Madrigal Pharmaceuticals (NASDAQ: MDGL) , Alnylam Pharmaceuticals (NASDAQ: ALNY) , and Arbutus Biopharma (NASDAQ: ABUS) . Alnylam Pharmaceuticals It's been a great year for Alnylam Pharmaceuticals, with the biotech's market cap nearly doubling so far in 2017 as of last week. Alnylam stock surged more than 50% this week, causing the biotech's market cap to now stand more than three times higher than its level at the beginning of the year. | Three such winners over the past five days are Madrigal Pharmaceuticals (NASDAQ: MDGL) , Alnylam Pharmaceuticals (NASDAQ: ALNY) , and Arbutus Biopharma (NASDAQ: ABUS) . Madrigal Pharmaceuticals For much of the last four years, Madrigal Pharmaceuticals stock had been anything but a winner. Alnylam Pharmaceuticals It's been a great year for Alnylam Pharmaceuticals, with the biotech's market cap nearly doubling so far in 2017 as of last week. |
34705.0 | 2017-09-20 00:00:00 UTC | Here's Why Arbutus Biopharma Corp. Stock Soared Today | ABUS | https://www.nasdaq.com/articles/heres-why-arbutus-biopharma-corp-stock-soared-today-2017-09-20 | nan | nan | What happened
Shares of Arbutus Biopharma Corp. (NASDAQ: ABUS) rode some mighty coattails today. This morning, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced highly positive data for a candidate that employs delivery technology it licensed from Arbutus. The surprisingly positive results raised hopes for future royalties and lifted the stock 20.7% higher to end Wednesday's session.
So what
Alnylam suffered some safety-related setbacks that forced it to shutter a program with a drug similar to the candidate that succeeded today , patisiran. The familial amyloid polyneuropathy candidate uses Arbutus' lipid nanoparticle delivery technology to enter cells. If approved, Arbutus will be entitled to a single-digit royalty percentage on sales of the drug.
While few doubted patisiran's ability to reduce nerve damage, its safety profile was concerning. When they lifted the lid off the results, there were more side effects in the placebo group.
Now what
Alnylam intends to file a new drug application for patisiran before the end of the year and could begin generating sales as early as next summer. Annual patisiran sales are expected to top out around $700 million if approved.
A single-digit royalty percentage probably isn't going to bring Arbutus to profitability, but it would go a long way to fund development of hepatitis B antiviral candidates currently in mid-stage clinical trials. In the first half of the year, the company recorded $1.3 million in revenue, while operations chewed through $39.1 million. At this pace, checks from Alnylam probably won't be able to close the gap before the company needs to raise more capital. The cash balance on the balance sheet at the end of June totaled $115.6 million.
10 stocks we like better than Arbutus Biopharma
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Arbutus Biopharma wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Arbutus Biopharma Corp. (NASDAQ: ABUS) rode some mighty coattails today. This morning, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced highly positive data for a candidate that employs delivery technology it licensed from Arbutus. So what Alnylam suffered some safety-related setbacks that forced it to shutter a program with a drug similar to the candidate that succeeded today , patisiran. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. What happened Shares of Arbutus Biopharma Corp. (NASDAQ: ABUS) rode some mighty coattails today. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market. | What happened Shares of Arbutus Biopharma Corp. (NASDAQ: ABUS) rode some mighty coattails today. This morning, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced highly positive data for a candidate that employs delivery technology it licensed from Arbutus. 10 stocks we like better than Arbutus Biopharma When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. | What happened Shares of Arbutus Biopharma Corp. (NASDAQ: ABUS) rode some mighty coattails today. If approved, Arbutus will be entitled to a single-digit royalty percentage on sales of the drug. *Stock Advisor returns as of September 5, 2017 Cory Renauer has no position in any of the stocks mentioned. |
34706.0 | 2017-09-13 00:00:00 UTC | Alexion to Restructure Operations, to Lower Headcount by 20% | ABUS | https://www.nasdaq.com/articles/alexion-to-restructure-operations-to-lower-headcount-by-20-2017-09-13 | nan | nan | Alexion Pharmaceuticals, Inc . ALXN announced that it will undertake a restructuring plan to re-align the organization with refocused corporate strategy.
Details of Restructuring
The company plans to focus on rare diseases businesses in core areas of hematology, nephrology, neurology and metabolic disorders to enhance productivity. Alexion will reduce spending and headcount associated with the previously announced de-prioritized pipeline programs as well as optimizing additional R&D expenses.
The three programs which have been deprioritized are - ALXN1101 (cPMP replacement therapy) and ALXN6000 (samalizumab) as well as partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma ABUS .
Alongside, the company will shut Alexion Rhode Island manufacturing facility and certain regional and country-based offices. The company will align investments with its core, high-growth markets, optimize the global operating structure to leverage synergies across regions and countries, reduce operating redundancies and focus on continuity of the field teams.
Meanwhile, the company is also right-sizing certain G&A functions, such as Human Resources, Finance and Information Technology (IT), including out-sourcing certain non-core Finance and IT roles to support the realigned business. Alexion will continue to invest in other G&A functions, such as Legal and Compliance, to support its global business.
Concurrently, the company plans to relocate its headquarters to Boston, MA by mid-2018 with approximately 400 positions.
As a result of the restructuring plan, the company will reduce its global workforce by approximately 20%. The company expects that the increased financial flexibility will allow it to reinvest approximately $100 million annually into R&D.
Financial Impact
Alexion expects pre-tax savings of approximately $250 million by 2019 while the total pre-tax restructuring and related expenses associated with the plan will be in the range of $340- $440 million. The company targets non-GAAP operating margin of 50% by 2019. Approximately 50% of the restructuring and related expenses will result in cash outlays and restructuring (pre-tax) and related expenses of approximately $240 million to $300 million are expected to be recorded in 2017.
However, the company does not expect any changes to its annual revenue guidance due to the restructuring initiative.
Our Take
Alexion has been facing challenging conditions in recent times and the company is looking to turn around things. In June, Alexion named Paul J. Clancy as its Chief Financial Officer effective July 31, 2017.
Alexion's stock price has increased 18.1%, outperforming the industry 's gain of 16.5%
Earlier, in 2017, the company shares were hit after a Bloomberg report stated that it is under investigation by the U.S. Department of Health and Human Services' (HHS) Office of Inspector General (OIG). The HHS has reportedly said it is conducting an "open and ongoing investigation" into the biotech, though it did not specify what it was about. The investigation is reportedly related to Alexion's support of charitable organizations that provide financial assistance to Medicare patients who take drugs sold by the company.
Alexion's lead drug, Soliris continues to perform well but the company relies heavily on the drug for growth. The company is expecting Soliris revenues to be lower in the second half of the year due to an accelerating impact from the ALXN1210 trials. In addition, pricing will impact sales by 1%. Alexion is working on expanding Soliris' label into additional indications.
Alexion has filed regulatory applications with the FDA as well as the European Medicines Agency for Soliris for the treatment of refractory gMG in patients who are anti-acetylcholine receptor antibody-positive. The FDA accepted the supplemental Biologics License Application and set a Prescription Drug User Fee Act date of Oct 23.
We expect the restructuring plan to boost savings and positively impact margins.
Zacks Rank & Other Stocks to Consider
Alexion currently sports a Zacks Rank #1 (Strong Buy).
Other top-ranked stocks in the healthcare sector are Regeneron Pharmaceuticals, Inc. REGN and Aduro Biotech, Inc. ADRO . While Regeneron carries a Zacks Rank #1, Aduro carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Regeneron's shares up 20.7% this year so far. Earnings estimates have risen 16.8% for 2017 while that for 2018 have gone up by 8.1% over the past 60 days.
Aduro Biotech's loss per share estimates narrowed from $1.46 to $1.32 for 2017 and from $1.55 to $1.24 over the last 60 days. The company delivered positive surprises in two of the trailing four quarters with an average beat of 2.53%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020. Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The three programs which have been deprioritized are - ALXN1101 (cPMP replacement therapy) and ALXN6000 (samalizumab) as well as partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma ABUS . Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Details of Restructuring The company plans to focus on rare diseases businesses in core areas of hematology, nephrology, neurology and metabolic disorders to enhance productivity. | Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. The three programs which have been deprioritized are - ALXN1101 (cPMP replacement therapy) and ALXN6000 (samalizumab) as well as partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma ABUS . Financial Impact Alexion expects pre-tax savings of approximately $250 million by 2019 while the total pre-tax restructuring and related expenses associated with the plan will be in the range of $340- $440 million. | Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. The three programs which have been deprioritized are - ALXN1101 (cPMP replacement therapy) and ALXN6000 (samalizumab) as well as partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma ABUS . Financial Impact Alexion expects pre-tax savings of approximately $250 million by 2019 while the total pre-tax restructuring and related expenses associated with the plan will be in the range of $340- $440 million. | The three programs which have been deprioritized are - ALXN1101 (cPMP replacement therapy) and ALXN6000 (samalizumab) as well as partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma ABUS . Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. As a result of the restructuring plan, the company will reduce its global workforce by approximately 20%. |
34707.0 | 2017-03-17 00:00:00 UTC | Midday Update: Market Indices Flat But Set to Close The Week Higher | ABUS | https://www.nasdaq.com/articles/midday-update-market-indices-flat-set-close-week-higher-2017-03-17 | nan | nan | The benchmark averages were anchored to the flatline on Friday as steep losses in the healthcare and financial sectors were offset by strength in industrials, utilities and material stocks. Data on production and confidence of the U.S. consumer were briefly supportive, but failed to generate a sustained bid for equities as an eventful week winds down.
All three major indices were set to close the week higher with the Nasdaq Composite up for a third consecutive week.
To recap Friday's economic data: Industrial production was flat in Feb., but revised slightly higher in Jan. from negative 0.3% to negative 0.1%. The market expected a 0.2% gain in Feb.
Industrial production was slightly lower last month to 75.4% from an upwardly revised 75.5% in Jan.
Also, leading economic indicators jumped 0.6% in Feb, to its highest level in 10 years, beating +0.4% estimates.
And finally, consumer sentiment hit a 17-year high of 97.6 according to a monthly survey from the University of Michigan. This compares to 96.3 in Feb., and tops Wall Street estimates of 97.2.
European bourses were only marginally higher at the close ahead of this weekend's meeting of G20 finance ministers in Germany. Polls showing anti-EU French presidential candidate Marine Le Pen taking the lead over her opponent, Emmanuel Macron, compromised some of the Euro-Stoxx gains this morning, but the index ended up slightly above Thursday's close on gains in mining and financial stocks.
Crude oil was down $0.01 to $48.74 per barrel. Natural gas was down $0.03 to $2.99 per 1 million BTU. Gold was up $2.30 to $1,229.50 an ounce, while silver was down $0.03 to $17.36 an ounce. Copper was down $0.01 to $2.69 per pound.
Among energy ETFs, the United States Oil Fund was down 0.10% to $10.35 with the United States Natural Gas Fund was up 1.14% to $7.12. Amongst precious-metal funds, the Market Vectors Gold Miners ETF was down 0.40% to 22.68 while SPDR Gold Shares were up 0.27% to $117.05. The iShares Silver Trust was up 0.15% to $16.42.
Here's where the markets stand at mid-day:
US MARKETS
NYSE Composite Index was down 9.17 points (-0.08%) to 11,591.64
Dow Jones Industrial Index was down 4.44 points (-0.02%) to 20,930.84
S&P 500 was down 0.25 points (-0.01%) to 2,381.11
Nasdaq Composite Index was up 0.23 points (+0.01%) to 5,901.27
GLOBAL SENTIMENT
FTSE 100 was up 3.46 points (+0.04%) to 7,419.22
DAX was up 4.69 points (+0.04%) to 12,087.65
CAC 40 was up 4.42 points (+0.09%) to 5,017.47
Nikkei 225 was down 68.55 points (-0.35%) to 19,521.59
Hang Seng Index was up 21.65 points (+0.09%) to 23,309.93
Shanghai China Composite Index was down 31.49 points (-0.96%) to 3,237.45
NYSE SECTOR INDICES
NYSE Energy Sector Index was up 24.18 points (+0.22%) to 10,779.72
NYSE Financial Sector Index was down 49.07 points (-0.67%) to 7,337.70
NYSE Healthcare Sector Index was down 8.21 points (-0.07%) to 12,890.11
UPSIDE MOVERS
(+) ABUS (+17.72%) Licensed its LNP delivery technology to Alexion Pharmaceuticals ( ALXN )
(+) CLBS (+16.61%) Reported narrower-than-expected loss
(+) VIVE (+8.59%) Prices 7.5 million share offering at 6% discount
DOWNSIDE MOVERS
(-) INNL (-24.60%) Q4 earnings beat estimates on below-consensus revenue, downgraded at Stifel Nicolaus to hold from buy
(-) CRMD (-17.39%) Has not generated enough revenue to be profitable, needs additional funding to continue hemodialysis clinical trial in U.S.
(-) MDCO (-14.38%) Reacts negatively to President Trump's 20% budget cut for National Institutes of Health
(-) STML (-7.14%) Post wider-than-expected loss on above consensus revenue
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) ABUS (+17.72%) Licensed its LNP delivery technology to Alexion Pharmaceuticals ( ALXN ) (+) CLBS (+16.61%) Reported narrower-than-expected loss (+) VIVE (+8.59%) Prices 7.5 million share offering at 6% discount The benchmark averages were anchored to the flatline on Friday as steep losses in the healthcare and financial sectors were offset by strength in industrials, utilities and material stocks. The market expected a 0.2% gain in Feb. Industrial production was slightly lower last month to 75.4% from an upwardly revised 75.5% in Jan. Also, leading economic indicators jumped 0.6% in Feb, to its highest level in 10 years, beating +0.4% estimates. | (+) ABUS (+17.72%) Licensed its LNP delivery technology to Alexion Pharmaceuticals ( ALXN ) (+) CLBS (+16.61%) Reported narrower-than-expected loss (+) VIVE (+8.59%) Prices 7.5 million share offering at 6% discount To recap Friday's economic data: Industrial production was flat in Feb., but revised slightly higher in Jan. from negative 0.3% to negative 0.1%. Among energy ETFs, the United States Oil Fund was down 0.10% to $10.35 with the United States Natural Gas Fund was up 1.14% to $7.12. | (+) ABUS (+17.72%) Licensed its LNP delivery technology to Alexion Pharmaceuticals ( ALXN ) (+) CLBS (+16.61%) Reported narrower-than-expected loss (+) VIVE (+8.59%) Prices 7.5 million share offering at 6% discount NYSE Composite Index was down 9.17 points (-0.08%) to 11,591.64 Dow Jones Industrial Index was down 4.44 points (-0.02%) to 20,930.84 S&P 500 was down 0.25 points (-0.01%) to 2,381.11 Nasdaq Composite Index was up 0.23 points (+0.01%) to 5,901.27 FTSE 100 was up 3.46 points (+0.04%) to 7,419.22 DAX was up 4.69 points (+0.04%) to 12,087.65 CAC 40 was up 4.42 points (+0.09%) to 5,017.47 Nikkei 225 was down 68.55 points (-0.35%) to 19,521.59 Hang Seng Index was up 21.65 points (+0.09%) to 23,309.93 Shanghai China Composite Index was down 31.49 points (-0.96%) to 3,237.45 | (+) ABUS (+17.72%) Licensed its LNP delivery technology to Alexion Pharmaceuticals ( ALXN ) (+) CLBS (+16.61%) Reported narrower-than-expected loss (+) VIVE (+8.59%) Prices 7.5 million share offering at 6% discount All three major indices were set to close the week higher with the Nasdaq Composite up for a third consecutive week. Among energy ETFs, the United States Oil Fund was down 0.10% to $10.35 with the United States Natural Gas Fund was up 1.14% to $7.12. |
34708.0 | 2017-03-17 00:00:00 UTC | Futures Cautiously Higher Ahead of Production Data | ABUS | https://www.nasdaq.com/articles/futures-cautiously-higher-ahead-production-data-2017-03-17 | nan | nan | Stock futures are marginally higher ahead of Friday's open with Wall Street waiting for cues from this morning's series of economic data, as well as the impact the day's expiration of stock index futures and options, and stock futures and options will have on trading. Gains in the energy sector thanks to slightly firmer oil futures is being offset by modest pressure on industrial stocks.
At 9:15 a.m. ET, industrial production is expected to show a 0.2% gain in February with capacity utilization inching up to 75.4% from 75.3%.
Also the University of Michigan preliminary March consumer sentiment index should improve to 97.2 from 96.3, previously. The index will be announced at 10 a.m. ET.
Finally, leading economic indicators are projected to show a 0.4% gain from January.
Overseas markets were mixed as investors digested the outcome to the Federal Open Market Committee, Bank of England and Bank of Japan meetings this week, as well as statements made by a member of the European Central Bank surrounding the possibility for the ECB to raise rates before the end of the year. The Euro-Stoxx is holding up near its 15-month high from Thursday while China's Shanghai fell nearly 1% after the People's Bank of China conducted a net weekly drain of CNY120 billion.
-Dow Jones Industrial up 0.13%
-S&P 500 futures up 0.02%
-Nasdaq 100 futures up 0.15%
SENTIMENT
Nikkei down 0.35%
Hang Seng up 0.09%
Shanghai Composite down 0.97%
FTSE-100 up 0.25%
DAX-30 up 0.10%
PRE-MARKET SECTOR WATCH
(+/-) Large cap tech: Mixed
(+/-) Chip stocks: Mixed
(-) Software stocks: Lower
(+) Hardware stocks: Higher
(-) Internet stocks: Lower
(+) Oil stocks: Higher
(-) Biotech stocks: Lower
(+) Drug stocks: Higher
(+) Financial stocks: Higher
(+) Retail stocks: Higher
(-) Industrial stocks: Lower
(+/-) Airlines: Mixed
(-) Autos: Lower
UPSIDE MOVERS:
(+) CLBS (+53.33%) Reported narrower-than-expected loss
(+) ABUS (+10.53%) Licensed its LNP delivery technology to Alexion Pharmaceuticals ( ALXN )
(+) ADBE (+5.11%) Beat Q1 revenue expectations, issues bullish outlook for 2017
(+) GOOS (+5.04%) Shares rally after Thursday's IPO
(+) TIF (+4.75%) Beat Q4 profit expectations, issued upbeat guidance
DOWNSIDE MOVERS:
(-) VRTV (-8.58%) Priced 1.8 million share offering at $54.85 per share
(-) VUZI (-8.33%) Q4 sales miss estimates, net loss widens over year ago
(-) EDIT (-6.50%) Priced 4 million shares at $22.50 per share
(-) AXTI (-1.52%) Downgraded at B. Riley to neutral from buy
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) CLBS (+53.33%) Reported narrower-than-expected loss (+) ABUS (+10.53%) Licensed its LNP delivery technology to Alexion Pharmaceuticals ( ALXN ) (+) ADBE (+5.11%) Beat Q1 revenue expectations, issues bullish outlook for 2017 (+) GOOS (+5.04%) Shares rally after Thursday's IPO (+) TIF (+4.75%) Beat Q4 profit expectations, issued upbeat guidance Gains in the energy sector thanks to slightly firmer oil futures is being offset by modest pressure on industrial stocks. ET, industrial production is expected to show a 0.2% gain in February with capacity utilization inching up to 75.4% from 75.3%. | (+) CLBS (+53.33%) Reported narrower-than-expected loss (+) ABUS (+10.53%) Licensed its LNP delivery technology to Alexion Pharmaceuticals ( ALXN ) (+) ADBE (+5.11%) Beat Q1 revenue expectations, issues bullish outlook for 2017 (+) GOOS (+5.04%) Shares rally after Thursday's IPO (+) TIF (+4.75%) Beat Q4 profit expectations, issued upbeat guidance Stock futures are marginally higher ahead of Friday's open with Wall Street waiting for cues from this morning's series of economic data, as well as the impact the day's expiration of stock index futures and options, and stock futures and options will have on trading. (+/-) Large cap tech: Mixed (+/-) Chip stocks: Mixed (-) Software stocks: Lower (+) Hardware stocks: Higher (-) Internet stocks: Lower (+) Oil stocks: Higher (-) Biotech stocks: Lower (+) Drug stocks: Higher (+) Financial stocks: Higher (+) Retail stocks: Higher (-) Industrial stocks: Lower (+/-) Airlines: Mixed (-) Autos: Lower | (+) CLBS (+53.33%) Reported narrower-than-expected loss (+) ABUS (+10.53%) Licensed its LNP delivery technology to Alexion Pharmaceuticals ( ALXN ) (+) ADBE (+5.11%) Beat Q1 revenue expectations, issues bullish outlook for 2017 (+) GOOS (+5.04%) Shares rally after Thursday's IPO (+) TIF (+4.75%) Beat Q4 profit expectations, issued upbeat guidance Stock futures are marginally higher ahead of Friday's open with Wall Street waiting for cues from this morning's series of economic data, as well as the impact the day's expiration of stock index futures and options, and stock futures and options will have on trading. (+/-) Large cap tech: Mixed (+/-) Chip stocks: Mixed (-) Software stocks: Lower (+) Hardware stocks: Higher (-) Internet stocks: Lower (+) Oil stocks: Higher (-) Biotech stocks: Lower (+) Drug stocks: Higher (+) Financial stocks: Higher (+) Retail stocks: Higher (-) Industrial stocks: Lower (+/-) Airlines: Mixed (-) Autos: Lower | (+) CLBS (+53.33%) Reported narrower-than-expected loss (+) ABUS (+10.53%) Licensed its LNP delivery technology to Alexion Pharmaceuticals ( ALXN ) (+) ADBE (+5.11%) Beat Q1 revenue expectations, issues bullish outlook for 2017 (+) GOOS (+5.04%) Shares rally after Thursday's IPO (+) TIF (+4.75%) Beat Q4 profit expectations, issued upbeat guidance Stock futures are marginally higher ahead of Friday's open with Wall Street waiting for cues from this morning's series of economic data, as well as the impact the day's expiration of stock index futures and options, and stock futures and options will have on trading. Gains in the energy sector thanks to slightly firmer oil futures is being offset by modest pressure on industrial stocks. |
34709.0 | 2017-01-10 00:00:00 UTC | Celgene Issues Preliminary 2016 Results, Lifts 2017 View | ABUS | https://www.nasdaq.com/articles/celgene-issues-preliminary-2016-results-lifts-2017-view-2017-01-10 | nan | nan | Celgene CorporationCELG announced preliminary 2016 results and upped the guidance for 2017, while maintaining its outlook for 2020, at the J.P. Morgan Healthcare Conference. The company also provided a business update at the conference.
Celgene's share price movement shows that the stock has outperformed the Zacks classified Medical-Biomedical and Genetics industry in the past one year. Specifically, the stock has gained 16.7% during this period, compared with a decline of 12.8% for the industry.
Celgene expects adjusted earnings for 2016 to be approximately $5.94 per share, reflecting a year-over-year increase of 26%. Net product sales for 2016 are expected to be approximately $11.2 billion, up 22% year over year. The Zacks Consensus Estimate for earnings is pegged at $5.27 on revenues of $11.3 billion.
Sales of Revlimid, the key growth driver at Celgene, are projected to be approximately $7 billion, reflecting a year-over-year increase of 20%. While Pomalyst/Imnovid sales are expected to barely exceed $1.3 billion (up 33%), sales of Otezla, which is in the second year in the market, is anticipated to cross the $1 billion mark (up a substantial 116%). Abraxane sales are expected to inch up 1% to $973 million.
Adjusted operating margin is expected to be about 55% for 2016, reflecting an increase of 290 basis points (bps) from the year-ago period.
Celgene is scheduled to announce fourth-quarter 2016 and full-year results on Jan 26.
2017 Outlook Upped
Celgene raised the outlook for 2017. For 2017, Celgene now expects earnings in the range of $7.10-$7.25 per share, reflecting a 21% year-over-year increase. Previously (at the time of announcing third-quarter 2016 results), the company had guided earnings at the high end of the $6.75-$7.00 per share range.
Total revenue is now projected to be approximately $13.0 billion to $13.4 billion, representing an 18% increase. Earlier, the company had anticipated revenues at the high end of the $12.7-$13 billion range. Unfavorable foreign exchange is expected to impact revenues by about $170 million in 2017.
The Zacks Consensus Estimate for earnings stands at $6.52 on revenues of $13.2 billion.
Revlimid sales are now expected in the range of $8.0 billion to $8.3 billion, compared with the previous expectations of greater than $8 billion. Abraxane sales are still estimated to be around $1 billion.
While Pomalyst/Imnovid sales are anticipated to be approximately $1.6 billion, Otezla sales are projected in the range of approximately $1.5 billion to $1.7 billion.
Adjusted operating margin will continue to improve to about 56.4% in 2017.
2020 Outlook Maintained
Celgene has maintained its outlook for 2020. It continues to project net product sales in excess of $21 billion. Moreover, adjusted earnings are expected to cross $13 per share.
Celgene said of the 14 candidates that are currently in development, 10 have billion-dollar potential while four have multi-billion-dollar opportunities. Celgene expects to seek FDA approval for ozanimod for relapsing multiple sclerosis by the end of 2017.
The company expects 2017 through 2018 to be dominated by news related to its pipeline and label expansion efforts.
Celgene Corporation Price and Consensus
Celgene Corporation Price and Consensus | Celgene Corporation Quote
Zacks Rank & Stocks to Consider
Celgene currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in this industry include Kite Pharma, Inc. (KITE), Epizyme, Inc. (EPZM) and Intra-Cellular Therapies, Inc. (ITCI). All the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Kite's loss estimates narrowed 2.1% and 0.2% for 2016 and 2017, respectively, over the last 60 days. The company posted a positive surprise twice in the four trailing quarters with an average beat of 7.89%.
Epizyme's loss estimates narrowed 3% and 2.4% for 2016 and 2017, respectively, over the last 60 days. The company posted a positive surprise in each of the four trailing quarters, with an average beat of 14.03%. Its share price gained approximately 17% in the past one year.
Intra-Cellular Therapies' loss estimates narrowed 6.6% for 2016, over the last 60 days. The company posted a positive surprise in each of the four trailing quarters, with an average beat of 15.43%.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Orexigen Therapeutics, Inc. (OREX): Free Stock Analysis Report
Celgene Corporation (CELG): Free Stock Analysis Report
Epizyme, Inc. (EPZM): Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report Orexigen Therapeutics, Inc. (OREX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Epizyme, Inc. (EPZM): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Celgene CorporationCELG announced preliminary 2016 results and upped the guidance for 2017, while maintaining its outlook for 2020, at the J.P. Morgan Healthcare Conference. Celgene's share price movement shows that the stock has outperformed the Zacks classified Medical-Biomedical and Genetics industry in the past one year. | Click to get this free report Orexigen Therapeutics, Inc. (OREX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Epizyme, Inc. (EPZM): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. While Pomalyst/Imnovid sales are anticipated to be approximately $1.6 billion, Otezla sales are projected in the range of approximately $1.5 billion to $1.7 billion. Celgene Corporation Price and Consensus Celgene Corporation Price and Consensus | Celgene Corporation Quote Zacks Rank & Stocks to Consider Celgene currently carries a Zacks Rank #4 (Sell). | Click to get this free report Orexigen Therapeutics, Inc. (OREX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Epizyme, Inc. (EPZM): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Revlimid sales are now expected in the range of $8.0 billion to $8.3 billion, compared with the previous expectations of greater than $8 billion. Celgene Corporation Price and Consensus Celgene Corporation Price and Consensus | Celgene Corporation Quote Zacks Rank & Stocks to Consider Celgene currently carries a Zacks Rank #4 (Sell). | Click to get this free report Orexigen Therapeutics, Inc. (OREX): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Epizyme, Inc. (EPZM): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Celgene CorporationCELG announced preliminary 2016 results and upped the guidance for 2017, while maintaining its outlook for 2020, at the J.P. Morgan Healthcare Conference. The Zacks Consensus Estimate for earnings is pegged at $5.27 on revenues of $11.3 billion. |
34710.0 | 2017-01-09 00:00:00 UTC | Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments | ABUS | https://www.nasdaq.com/articles/ionis-novartis-ink-deal-to-focus-on-cardiovascular-treatments-2017-01-09 | nan | nan | Ionis Pharmaceuticals, Inc.IONS , along with its subsidiary Akcea Therapeutics, announced that the company has entered into an exclusive, worldwide collaboration agreement with Novartis AG NVS for the development and commercialization of two novel treatments, AKCEA-APO(a)-L and AKCEA-APOCIII-L, with the potential to treat cardiovascular disease.
Ionis' share price movement in the past one year shows that the company has outperformed the Zacks classified Medical Drugs industry. Specifically, the stock lost 4.7% during this period, compared to the industry's plunge of 8.5%.
Share of Novartis, on the other hand, have underperformed the Zacks classified Large Cap Pharma industry during this period, with the stock losing 10% while the industry's gained 1.7%.
Terms of the Agreement
Ionis and Akcea will receive an upfront payment of $75 million and an equity investment of $100 million, which equates to 1,631,435 shares at $61.30 per share.
Also, the companies will receive up to $315 million and $265 million in development and regulatory milestone payments, for AKCEA-APO(a)-L and AKCEA-APOCIII-L, respectively, as well as up to $285 million and $265 million in commercialization milestone payments. Moreover, the companies are eligible to receive tiered royalties in the mid teens to low twenties on net sales of each product.
As per the agreement terms, Novartis will exercise its option to license and commercialize each product following the successful completion of each phase II dose-ranging study. Ionis and Akcea believe that if both the drugs are licensed and successfully commercialized, the deal would be valued at significantly over $1 billion.
2016 Financial Guidance Updated
In a separate press release, Ionis provided an update on its 2016 financial guidance. Backed by the recent approval of Spinraza for the treatment of spinal muscular atrophy in both pediatric and adult patients, Ionis expects to end 2016 with net operating income in the low- to mid-$20 million range and with over $650 million in cash.
The company said that it has generated more than $340 million in revenues, including more than $150 million in the fourth quarter of 2016. The company also received $280 million from its partners up to the end of 2016.
The company expects its financial position to support the execution of its corporate goals throughout 2017.
Ionis currently carries a Zacks Rank #3 (Hold).
Key Picks in the Sector
A couple of better-ranked stocks in the health care sector are Arbutus Biopharma Corporation ABUS and Anika Therapeutics, Inc. ANIK . While Arbutus carries a Zacks Rank #1 (Strong Buy), Anika is a Zacks Rank #2 (Buy) stock. You can see the complete list of today's Zacks #1 Rank stocks here .
Arbutus' loss estimates narrowed from $1.76 to $1.71 for 2016 and from $1.53 to $1.52 for 2017 in the last 60 days. The company posted a positive surprise thrice in the four trailing quarters with an average beat of 59.31%.
Anika's earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively, over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price was up 35.8% in the past one year.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report
Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Key Picks in the Sector A couple of better-ranked stocks in the health care sector are Arbutus Biopharma Corporation ABUS and Anika Therapeutics, Inc. ANIK . Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Ionis Pharmaceuticals, Inc.IONS , along with its subsidiary Akcea Therapeutics, announced that the company has entered into an exclusive, worldwide collaboration agreement with Novartis AG NVS for the development and commercialization of two novel treatments, AKCEA-APO(a)-L and AKCEA-APOCIII-L, with the potential to treat cardiovascular disease. | Key Picks in the Sector A couple of better-ranked stocks in the health care sector are Arbutus Biopharma Corporation ABUS and Anika Therapeutics, Inc. ANIK . Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. While Arbutus carries a Zacks Rank #1 (Strong Buy), Anika is a Zacks Rank #2 (Buy) stock. | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks in the Sector A couple of better-ranked stocks in the health care sector are Arbutus Biopharma Corporation ABUS and Anika Therapeutics, Inc. ANIK . Terms of the Agreement Ionis and Akcea will receive an upfront payment of $75 million and an equity investment of $100 million, which equates to 1,631,435 shares at $61.30 per share. | Key Picks in the Sector A couple of better-ranked stocks in the health care sector are Arbutus Biopharma Corporation ABUS and Anika Therapeutics, Inc. ANIK . Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Terms of the Agreement Ionis and Akcea will receive an upfront payment of $75 million and an equity investment of $100 million, which equates to 1,631,435 shares at $61.30 per share. |
34711.0 | 2017-01-09 00:00:00 UTC | Alexion Blood Disorder Drug Gets Orphan Designation in U.S. | ABUS | https://www.nasdaq.com/articles/alexion-blood-disorder-drug-gets-orphan-designation-in-u.s.-2017-01-09 | nan | nan | Alexion Pharmaceuticals, Inc.ALXN announced that the FDA has granted orphan drug designation (ODD) to ALXN1210, a longer-acting anti-C5 antibody that inhibits terminal complement, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare, life-threatening blood disorder.
Shares of Alexion have outperformed the Zacks classified Medical-Biomedical and Genetics industry in the last one year. Specifically, the stock has lost 11.1% in the past one year, while the industry witnessed a decline of 12.7%.
Alexion is currently evaluating ALXN1210 in phase III studies for PNH as well as for atypical hemolytic uremic syndrome (aHUS), another ultra-rare and life-threatening disease. Additionally, the company is conducting a phase I study on a new formulation of ALXN1210 when administered subcutaneously in healthy volunteers.
Meanwhile, Alexion has completed enrollment in two ongoing studies on ALXN1210 in patients with PNH - a phase I/II dose-escalating study and an open-label, multi-dose phase II study on longer dosing intervals beyond 8 weeks.
We are encouraged by the FDA granting ODD to ALXN1210. The candidate also received ODD in the EU last June for the treatment of PNH.
We note that Alexion's key growth driver, Soliris, is approved for the treatment of both PNH and aHUS. The company is also developing Soliris for additional indications including refractory generalized myasthenia gravis and neuromyelitis optica spectrum disorder.
Alexion Pharmaceuticals, Inc. Price and Consensus
Alexion Pharmaceuticals, Inc. Price and Consensus | Alexion Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Alexion currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in this industry include Arbutus Biopharma Corporation ABUS , Epizyme, Inc. EPZM and Orexigen Therapeutics, Inc. OREX . All the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Arbutus' loss estimates narrowed 2.8% and 0.7% for 2016 and 2017, respectively, over the last 60 days. The company posted a positive surprise thrice in the four trailing quarters with an average beat of 59.31%.
Epizyme's loss estimates narrowed 3% and 2.4% for 2016 and 2017, respectively, over the last 60 days. The company posted a positive surprise in each of the four trailing quarters, with an average beat of 14.03%. Its share price gained approximately 13% in the past one year.
Orexigen's loss estimates for 2016 and 2017 have narrowed 8.5% and 52.4%, respectively, over the last 60 days.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report
Orexigen Therapeutics, Inc. (OREX): Free Stock Analysis Report
Epizyme, Inc. (EPZM): Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in this industry include Arbutus Biopharma Corporation ABUS , Epizyme, Inc. EPZM and Orexigen Therapeutics, Inc. OREX . Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Orexigen Therapeutics, Inc. (OREX): Free Stock Analysis Report Epizyme, Inc. (EPZM): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Alexion Pharmaceuticals, Inc.ALXN announced that the FDA has granted orphan drug designation (ODD) to ALXN1210, a longer-acting anti-C5 antibody that inhibits terminal complement, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare, life-threatening blood disorder. | Some better-ranked stocks in this industry include Arbutus Biopharma Corporation ABUS , Epizyme, Inc. EPZM and Orexigen Therapeutics, Inc. OREX . Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Orexigen Therapeutics, Inc. (OREX): Free Stock Analysis Report Epizyme, Inc. (EPZM): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Alexion Pharmaceuticals, Inc. Price and Consensus Alexion Pharmaceuticals, Inc. Price and Consensus | Alexion Pharmaceuticals, Inc. Quote Zacks Rank & Stocks to Consider Alexion currently carries a Zacks Rank #3 (Hold). | Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Orexigen Therapeutics, Inc. (OREX): Free Stock Analysis Report Epizyme, Inc. (EPZM): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in this industry include Arbutus Biopharma Corporation ABUS , Epizyme, Inc. EPZM and Orexigen Therapeutics, Inc. OREX . Meanwhile, Alexion has completed enrollment in two ongoing studies on ALXN1210 in patients with PNH - a phase I/II dose-escalating study and an open-label, multi-dose phase II study on longer dosing intervals beyond 8 weeks. | Some better-ranked stocks in this industry include Arbutus Biopharma Corporation ABUS , Epizyme, Inc. EPZM and Orexigen Therapeutics, Inc. OREX . Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Orexigen Therapeutics, Inc. (OREX): Free Stock Analysis Report Epizyme, Inc. (EPZM): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Alexion is currently evaluating ALXN1210 in phase III studies for PNH as well as for atypical hemolytic uremic syndrome (aHUS), another ultra-rare and life-threatening disease. |
34712.0 | 2017-01-09 00:00:00 UTC | The Medicines Co LDL-Lowering Drug Positive in Phase II | ABUS | https://www.nasdaq.com/articles/the-medicines-co-ldl-lowering-drug-positive-in-phase-ii-2017-01-09 | nan | nan | The Medicines CompanyMDCO announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran (formerly PCSK9si), for the treatment of hypercholesterolemia.
The Medicines Company is developing Inclisiran under a collaboration agreement with Alnylam Pharmaceuticals, Inc. ALNY , which was inked in early 2013. The Medicines Company is solely responsible for the development and commercialization of the candidate.
The Medicines Company's three-month share price movement shows that the stock has outperformed the Zacks classified Medical - Biomedical and Genetics industry. Specifically, the company lost 1.7%, while the industry lost 3.7%. | The Medicines CompanyMDCO announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran (formerly PCSK9si), for the treatment of hypercholesterolemia. The Medicines Company is developing Inclisiran under a collaboration agreement with Alnylam Pharmaceuticals, Inc. ALNY , which was inked in early 2013. The Medicines Company's three-month share price movement shows that the stock has outperformed the Zacks classified Medical - Biomedical and Genetics industry. | The Medicines CompanyMDCO announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran (formerly PCSK9si), for the treatment of hypercholesterolemia. The Medicines Company is developing Inclisiran under a collaboration agreement with Alnylam Pharmaceuticals, Inc. ALNY , which was inked in early 2013. Specifically, the company lost 1.7%, while the industry lost 3.7%. | The Medicines CompanyMDCO announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran (formerly PCSK9si), for the treatment of hypercholesterolemia. The Medicines Company is developing Inclisiran under a collaboration agreement with Alnylam Pharmaceuticals, Inc. ALNY , which was inked in early 2013. The Medicines Company's three-month share price movement shows that the stock has outperformed the Zacks classified Medical - Biomedical and Genetics industry. | The Medicines CompanyMDCO announced positive top-line results from a Day 180 interim analysis of the ongoing ORION-1 phase II study on its pipeline candidate, Inclisiran (formerly PCSK9si), for the treatment of hypercholesterolemia. The Medicines Company is developing Inclisiran under a collaboration agreement with Alnylam Pharmaceuticals, Inc. ALNY , which was inked in early 2013. The Medicines Company is solely responsible for the development and commercialization of the candidate. |
34713.0 | 2017-01-06 00:00:00 UTC | Ultragenyx's (RARE) KRN23 Accepted for Review in the EU | ABUS | https://www.nasdaq.com/articles/ultragenyxs-rare-krn23-accepted-for-review-in-the-eu-2017-01-06 | nan | nan | Ultragenyx Pharmaceutical Inc.RARE announced that the European Medicines Agency (EMA) has accepted to review the company's Marketing Authorization Application (MAA) for KRN23 for the treatment of X-linked hypophosphatemia (XLH).
KRN23, an antibody targeting fibroblast growth factor 23 (FGF23), is being developed in collaboration with Kyowa Hakko Kirin Co., Ltd.
Note that Ultragenyx's share price movement in 2016 shows that the company has outperformed the Zacks classified Medical-Biomedical/Genetics industry. Specifically, the stock lost 18.7% during this period, compared to the industry's plunge of 20.5%.
Coming back to the latest news, the company expects an opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) in the second half of 2017.
Meanwhile, a biologics license application (BLA) for KRN23 is expected to be filed in the U.S. in the second half of 2017. The companies are in discussions with the FDA for the details of the planned submission.
We remind investors that in Jun 2016, the FDA had granted breakthrough therapy designation to KRN23 for the treatment of XLH in pediatric patients aged one year and above.
Currently, KRN23 is being evaluated in a phase III study in adults with XLH. Data from the study are expected to be out in the first half of 2017. KRN23 is also in a phase II and phase III study for the treatment of pediatric patients.
Apart from XLH, KRN23 is also being developed in a phase II study for the treatment of tumor-induced osteomalacia (TIO).
We note that Ultragenyx is making impressive progress with its pipeline candidates. The company expects to submit regulatory filings for rhGUS (UX003) for the treatment of mucopolysaccharidosis 7 (MPS 7) in both the U.S. and the EU in the first half of 2017.
Going forward, we expect investors to focus on the CHMP's opinion on KRN23 and the company's regulatory filing for rhGUS.
ULTRAGENYX PHAR Price and Consensus
ULTRAGENYX PHAR Price and Consensus | ULTRAGENYX PHAR Quote
Ultragenyx currently carries a Zacks Rank #4 (Sell).
Key Picks in the Sector
Some better-ranked stocks in the health care sector are Cambrex Corporation CBM , Arbutus Biopharma Corporation ABUS and Anika Therapeutics, Inc. ANIK . All three sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here
Cambrex's earnings estimates increased 3.7% for 2016 and 5.2% for 2017 in the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 19.78%. Its share price was up 26.7% in the past one year.
Arbutus' loss estimates narrowed from $2.15 to $1.71 for 2016 and from $1.96 to $1.52 for 2017 in the last 60 days. The company posted a positive surprise thrice in the four trailing quarters with an average beat of 59.31%.
Anika's earnings estimates for 2016 and 2017 were up 3.9% and 0.5% respectively for the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 33.14%. Its share price was up 35.8% in the past one year.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks - absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report
Cambrex Corporation (CBM): Free Stock Analysis Report
Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report
Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Key Picks in the Sector Some better-ranked stocks in the health care sector are Cambrex Corporation CBM , Arbutus Biopharma Corporation ABUS and Anika Therapeutics, Inc. ANIK . Click to get this free report Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report Cambrex Corporation (CBM): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report To read this article on Zacks.com click here. Ultragenyx Pharmaceutical Inc.RARE announced that the European Medicines Agency (EMA) has accepted to review the company's Marketing Authorization Application (MAA) for KRN23 for the treatment of X-linked hypophosphatemia (XLH). | Key Picks in the Sector Some better-ranked stocks in the health care sector are Cambrex Corporation CBM , Arbutus Biopharma Corporation ABUS and Anika Therapeutics, Inc. ANIK . Click to get this free report Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report Cambrex Corporation (CBM): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report To read this article on Zacks.com click here. ULTRAGENYX PHAR Price and Consensus ULTRAGENYX PHAR Price and Consensus | ULTRAGENYX PHAR Quote Ultragenyx currently carries a Zacks Rank #4 (Sell). | Click to get this free report Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report Cambrex Corporation (CBM): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks in the Sector Some better-ranked stocks in the health care sector are Cambrex Corporation CBM , Arbutus Biopharma Corporation ABUS and Anika Therapeutics, Inc. ANIK . ULTRAGENYX PHAR Price and Consensus ULTRAGENYX PHAR Price and Consensus | ULTRAGENYX PHAR Quote Ultragenyx currently carries a Zacks Rank #4 (Sell). | Key Picks in the Sector Some better-ranked stocks in the health care sector are Cambrex Corporation CBM , Arbutus Biopharma Corporation ABUS and Anika Therapeutics, Inc. ANIK . Click to get this free report Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report Cambrex Corporation (CBM): Free Stock Analysis Report Arbutus Biopharma Corporation (ABUS): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report To read this article on Zacks.com click here. Note that Ultragenyx's share price movement in 2016 shows that the company has outperformed the Zacks classified Medical-Biomedical/Genetics industry. |
34714.0 | 2017-01-05 00:00:00 UTC | Bayer's sNDA for Stivarga Granted Priority Review in the U.S. | ABUS | https://www.nasdaq.com/articles/bayers-snda-for-stivarga-granted-priority-review-in-the-u.s.-2017-01-05 | nan | nan | Bayer AGBAYRY announced that the FDA has granted priority review designation to the company's supplemental New Drug Application (sNDA) for its cancer drug, Stivarga, for the second-line treatment of patients with unresectable hepatocellular carcinoma (uHCC).
Bayer's share price movement in 2016 shows that the company has underperformed the Zacks classified Large Cap Pharma industry. Specifically, the stock lost 8.8% during this period, compared to the industry's 2.9% dip.
The FDA has granted priority review to the sNDA and intends to provide an update on the approval status of Stivarga within six months (compared to 10 months under standard review).
We remind investors that the sNDA was submitted in Nov 2016 and was based on data from the phase III RESORCE ( RE gorafenib after SOR afenib in patients with hepato CE llular carcinoma) study on patients whose disease had progressed during treatment with Nexavar. Results demonstrated that Stivarga significantly improved overall survival (OS) compared to placebo, thereby representing a 37% reduction in the risk of death for patients who received Stivarga plus best supportive care (BSC), compared to patients who received placebo plus BSC.
Note that Stivarga is currently approved in both the U.S. and the EU for the treatment of metastatic colorectal cancer (mCRC) and metastatic gastrointestinal stromal tumors (GIST).
In the EU, Stivarga is also indicated for the treatment of adults with mCRC who have been previously treated with, or are not considered for, available therapies including fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy; and for the treatment of adult patients with unresectable or metastatic GIST who progressed on or are intolerant to prior treatment with imatinib and Pfizer Inc.'s PFE Sutent (sunitinib).
We note that Stivarga has been witnessing sluggish sales due to intense competition in the U.S. In the first nine months of 2016, Stivarga generated sales of $198 million, down 16.1%.
However, the situation should improve with a potential label expansion of the drug. Going forward, we expect investors to focus on the approval status of the drug.
Bayer currently carries a Zacks Rank #4 (Sell).
BAYER A G -ADR Price and Consensus
BAYER A G -ADR Price and Consensus | BAYER A G -ADR Quote
Key Picks in the Sector
A couple of better-ranked stocks in the health care sector are Cambrex Corporation CBM and Arbutus Biopharma Corporation ABUS . Both sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Cambrex's earnings estimates increased 3.7% for 2016 and 5.2% for 2017 in the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 19.78%. Its share price was up 26.7% in the past one year.
Arbutus' loss estimates narrowed from $2.15 to $1.71 for 2016 and from $1.96 to $1.52 for 2017 in the last 60 days. The company posted a positive surprise thrice in the four trailing quarters with an average beat of 59.31%.
Zacks' Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PFIZER INC (PFE): Free Stock Analysis Report
BAYER A G -ADR (BAYRY): Free Stock Analysis Report
CAMBREX CORP (CBM): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | BAYER A G -ADR Price and Consensus BAYER A G -ADR Price and Consensus | BAYER A G -ADR Quote Key Picks in the Sector A couple of better-ranked stocks in the health care sector are Cambrex Corporation CBM and Arbutus Biopharma Corporation ABUS . Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Bayer's share price movement in 2016 shows that the company has underperformed the Zacks classified Large Cap Pharma industry. | Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. BAYER A G -ADR Price and Consensus BAYER A G -ADR Price and Consensus | BAYER A G -ADR Quote Key Picks in the Sector A couple of better-ranked stocks in the health care sector are Cambrex Corporation CBM and Arbutus Biopharma Corporation ABUS . Bayer AGBAYRY announced that the FDA has granted priority review designation to the company's supplemental New Drug Application (sNDA) for its cancer drug, Stivarga, for the second-line treatment of patients with unresectable hepatocellular carcinoma (uHCC). | BAYER A G -ADR Price and Consensus BAYER A G -ADR Price and Consensus | BAYER A G -ADR Quote Key Picks in the Sector A couple of better-ranked stocks in the health care sector are Cambrex Corporation CBM and Arbutus Biopharma Corporation ABUS . Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Bayer AGBAYRY announced that the FDA has granted priority review designation to the company's supplemental New Drug Application (sNDA) for its cancer drug, Stivarga, for the second-line treatment of patients with unresectable hepatocellular carcinoma (uHCC). | BAYER A G -ADR Price and Consensus BAYER A G -ADR Price and Consensus | BAYER A G -ADR Quote Key Picks in the Sector A couple of better-ranked stocks in the health care sector are Cambrex Corporation CBM and Arbutus Biopharma Corporation ABUS . Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Bayer AGBAYRY announced that the FDA has granted priority review designation to the company's supplemental New Drug Application (sNDA) for its cancer drug, Stivarga, for the second-line treatment of patients with unresectable hepatocellular carcinoma (uHCC). |
34715.0 | 2017-01-05 00:00:00 UTC | Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data | ABUS | https://www.nasdaq.com/articles/ionis-ions-stock-up-on-positive-type-ii-diabetes-drug-data-2017-01-05 | nan | nan | Shares of Ionis Pharmaceuticals, Inc.IONS were up 4.2% after the company announced encouraging data from a phase II study on IONIS-GCGR for the treatment type II diabetes.
Ionis' share price movement in 2016 shows that the company has outperformed the Zacks classified Medical Drugs industry. Specifically, the stock lost 16% during this period, compared to the industry's plunge of 20.2%.
IONIS-GCGRrx, a next-generation antisense drug, is designed to reduce the production glucagon receptor (GCGR).
Results from the study revealed that IONIS-GCGRrx demonstrated statistically significant improvements in hemoglobin A1c (HbA1c) and other measures of glucose control at 26 weeks. Patients receiving a once weekly dose of IONIS-GCGRrx (50 mg and 75 mg) achieved reductions from baseline in HbA1c of 0.7% and 1.4%, respectively, compared to placebo (0.1%).
Moreover, patients dosed with 50mg of the candidate showed robust HbA1c reductions without the unwanted side effects of liver enzyme elevations, increases in low-density lipoprotein (LDL)-cholesterol or blood pressure, thereby meeting the primary goal of the study.
Note that the diabetes space is highly crowded with drugs like Tradjenta, Victoza, Tresiba and Jardiance among others.
Meanwhile, Ionis is actively using its proprietary antisense technology to create a large pipeline of first-in-class or best-in-class drugs, with over a dozen drugs in mid- to late-stage development. Drugs currently in phase III development include volanesorsen (chylomicronemia syndrome or familial partial lipodystrophy) and IONIS-TTRRx (transthyretin/TTR amyloidosis).
Last month, the company's spinal muscular atrophy's drug, Spinraza, was approved in the U.S. under priority review. The company has a collaboration agreement with Biogen Inc. BIIB for Spinraza.
Going forward, we expect investors to remain focused on further updates on the company's pipeline candidates and an initial update on Spinraza.
Ionis currently carries a Zacks Rank #3 (Hold).
IONIS PHARMACT Price and Consensus
IONIS PHARMACT Price and Consensus | IONIS PHARMACT Quote
Key Picks in the Sector
A couple of better-ranked stocks in the health care sector are Cambrex Corporation CBM and Arbutus Biopharma Corporation ABUS . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Cambrex's earnings estimates increased 3.7% for 2016 and 5.2% for 2017 in the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters, with an average beat of 19.78%. Its share price was up 23.5% in the past one year.
Arbutus' loss estimates narrowed from $2.15 to $1.71 for 2016 and from $1.53 to $1.52 for 2017 in the last 60 days. The company posted a positive surprise thrice in the four trailing quarters with an average beat of 59.31%.
Zacks' Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BIOGEN INC (BIIB): Free Stock Analysis Report
CAMBREX CORP (CBM): Free Stock Analysis Report
IONIS PHARMACT (IONS): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | IONIS PHARMACT Price and Consensus IONIS PHARMACT Price and Consensus | IONIS PHARMACT Quote Key Picks in the Sector A couple of better-ranked stocks in the health care sector are Cambrex Corporation CBM and Arbutus Biopharma Corporation ABUS . Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Results from the study revealed that IONIS-GCGRrx demonstrated statistically significant improvements in hemoglobin A1c (HbA1c) and other measures of glucose control at 26 weeks. | IONIS PHARMACT Price and Consensus IONIS PHARMACT Price and Consensus | IONIS PHARMACT Quote Key Picks in the Sector A couple of better-ranked stocks in the health care sector are Cambrex Corporation CBM and Arbutus Biopharma Corporation ABUS . Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | IONIS PHARMACT Price and Consensus IONIS PHARMACT Price and Consensus | IONIS PHARMACT Quote Key Picks in the Sector A couple of better-ranked stocks in the health care sector are Cambrex Corporation CBM and Arbutus Biopharma Corporation ABUS . Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Ionis' share price movement in 2016 shows that the company has outperformed the Zacks classified Medical Drugs industry. | IONIS PHARMACT Price and Consensus IONIS PHARMACT Price and Consensus | IONIS PHARMACT Quote Key Picks in the Sector A couple of better-ranked stocks in the health care sector are Cambrex Corporation CBM and Arbutus Biopharma Corporation ABUS . Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Ionis' share price movement in 2016 shows that the company has outperformed the Zacks classified Medical Drugs industry. |
34716.0 | 2016-12-30 00:00:00 UTC | Fortress Biotech (FBIO) in Focus: Stock Moves 20.9% Higher | ABUS | https://www.nasdaq.com/articles/fortress-biotech-fbio-in-focus%3A-stock-moves-20.9-higher-2016-12-30 | nan | nan | Fortress Biotech, Inc.FBIO was a big mover last session, as its shares rose almost 21% on the day. The move came after the company reported breakthrough with CAR-T cancer approach. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $1.95 to $2.43 in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Fortress Biotech currently carries a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
FORTRESS BIOTEC Price
FORTRESS BIOTEC Price | FORTRESS BIOTEC Quote
A better-ranked stock in the medical-biomedical and genetics space is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
FORTRESS BIOTEC (FBIO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | FORTRESS BIOTEC Price FORTRESS BIOTEC Price | FORTRESS BIOTEC Quote A better-ranked stock in the medical-biomedical and genetics space is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report FORTRESS BIOTEC (FBIO): Free Stock Analysis Report To read this article on Zacks.com click here. Fortress Biotech, Inc.FBIO was a big mover last session, as its shares rose almost 21% on the day. | FORTRESS BIOTEC Price FORTRESS BIOTEC Price | FORTRESS BIOTEC Quote A better-ranked stock in the medical-biomedical and genetics space is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report FORTRESS BIOTEC (FBIO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | FORTRESS BIOTEC Price FORTRESS BIOTEC Price | FORTRESS BIOTEC Quote A better-ranked stock in the medical-biomedical and genetics space is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report FORTRESS BIOTEC (FBIO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report FORTRESS BIOTEC (FBIO): Free Stock Analysis Report To read this article on Zacks.com click here. FORTRESS BIOTEC Price FORTRESS BIOTEC Price | FORTRESS BIOTEC Quote A better-ranked stock in the medical-biomedical and genetics space is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Fortress Biotech, Inc.FBIO was a big mover last session, as its shares rose almost 21% on the day. |
34717.0 | 2016-12-29 00:00:00 UTC | Galena Biopharma Reveals Regulatory Pathway for GALE-401 | ABUS | https://www.nasdaq.com/articles/galena-biopharma-reveals-regulatory-pathway-for-gale-401-2016-12-29 | nan | nan | Galena Biopharma, Inc. 's GALE shares surged 21.4% after the company confirmed the regulatory pathway to advance GALE-401 (anagrelide CR) into a pivotal phase III study.
Galena's year-to-date share price movement shows that the company has underperformed the Zacks classified Medical-Biomedical/Genetics industry. Specifically, the stock plunged almost 92% during this period, while the industry declined 25.4%.
Note that GALE-401 is being developed for the treatment of patients with essential thrombocythemia (ET). Following a meeting with the FDA, the company said that the proposed study is appropriate for filing a New Drug Application (NDA) using the 505(b)(2) regulatory pathway.
The study will evaluate GALE-401, in comparison to the best available therapy (BAT), in patients with ET who have either failed or are intolerant to hydroxyurea, including a sizable subpopulation of patients treated with anagrelide immediate release.
Galena expects to finalize the phase III protocol and initiate the study in the second quarter of 2017.
We note that GALE-401 is a controlled release (CR) version of Agrylin (an immediate release formulation of anagrelide). Currently, Agrylin is the only FDA approved drug for the treatment of ET. This indicates significant market opportunity for GALE-401, if approved.
Successful development and commercialization of the controlled release version of Agrylin will significantly boost the company's top line.
According to information provided by the company in its press release, ET affects 135,000-175,000 individuals in the U.S. of which approximately 75% receive treatment.
GALENA BIOPHARM Price and Consensus
GALENA BIOPHARM Price and Consensus | GALENA BIOPHARM Quote
Galena currently carries a Zacks Rank #3 (Hold).
Key Picks in the Sector
Some better-ranked stocks in the health care sector include Vanda Pharmaceuticals Inc. VNDA , MannKind Corporation MNKD and Arbutus Biopharma Corporation ABUS . Each of them sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Vanda's loss estimates for 2016 narrowed from 62 cents to 45 cents over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%.
MannKind's estimates narrowed from loss of 24 cents to earnings of 12 cents for 2016 over the last 60 days. For 2017, its loss estimates narrowed from 14 cents to 9 cents over this period. The company posted a positive surprise in two of the four trailing quarters with an average beat of 103.33%.
Arbutus' loss estimates narrowed from $2.15 to $1.71 for 2016 and from $1.96 to $1.52 for 2017 over the last 60 days. The company posted a positive surprise thrice in the four trailing quarters with an average beat of 59.31%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks - absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MANNKIND CORP (MNKD): Free Stock Analysis Report
VANDA PHARMACT (VNDA): Free Stock Analysis Report
GALENA BIOPHARM (GALE): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Key Picks in the Sector Some better-ranked stocks in the health care sector include Vanda Pharmaceuticals Inc. VNDA , MannKind Corporation MNKD and Arbutus Biopharma Corporation ABUS . Click to get this free report MANNKIND CORP (MNKD): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report GALENA BIOPHARM (GALE): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Galena Biopharma, Inc. 's GALE shares surged 21.4% after the company confirmed the regulatory pathway to advance GALE-401 (anagrelide CR) into a pivotal phase III study. | Key Picks in the Sector Some better-ranked stocks in the health care sector include Vanda Pharmaceuticals Inc. VNDA , MannKind Corporation MNKD and Arbutus Biopharma Corporation ABUS . Click to get this free report MANNKIND CORP (MNKD): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report GALENA BIOPHARM (GALE): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. GALENA BIOPHARM Price and Consensus GALENA BIOPHARM Price and Consensus | GALENA BIOPHARM Quote Galena currently carries a Zacks Rank #3 (Hold). | Click to get this free report MANNKIND CORP (MNKD): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report GALENA BIOPHARM (GALE): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks in the Sector Some better-ranked stocks in the health care sector include Vanda Pharmaceuticals Inc. VNDA , MannKind Corporation MNKD and Arbutus Biopharma Corporation ABUS . GALENA BIOPHARM Price and Consensus GALENA BIOPHARM Price and Consensus | GALENA BIOPHARM Quote Galena currently carries a Zacks Rank #3 (Hold). | Key Picks in the Sector Some better-ranked stocks in the health care sector include Vanda Pharmaceuticals Inc. VNDA , MannKind Corporation MNKD and Arbutus Biopharma Corporation ABUS . Click to get this free report MANNKIND CORP (MNKD): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report GALENA BIOPHARM (GALE): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. We note that GALE-401 is a controlled release (CR) version of Agrylin (an immediate release formulation of anagrelide). |
34718.0 | 2016-12-29 00:00:00 UTC | Intercept Pharmaceuticals (ICPT) Jumps: Stock Rises 9.3% | ABUS | https://www.nasdaq.com/articles/intercept-pharmaceuticals-icpt-jumps%3A-stock-rises-9.3-2016-12-29 | nan | nan | Intercept Pharmaceuticals, Inc.ICPT was a big mover last session, as the company saw its shares rise over 9% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $99.70 to $109.89 in the past one-month time frame.
None of the estimates for this stock were revised in the last 30 days, while the Zacks Consensus Estimate also remained unchanged. Yesterday's action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Intercept Pharmaceuticals carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
INTERCEPT PHARM Price
INTERCEPT PHARM Price | INTERCEPT PHARM Quote
A better-ranked stock in the same industry is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Is ICPT going up? Or down? Predict to see what others think: Up or Down
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017? Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
INTERCEPT PHARM (ICPT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | INTERCEPT PHARM Price INTERCEPT PHARM Price | INTERCEPT PHARM Quote A better-ranked stock in the same industry is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report INTERCEPT PHARM (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Intercept Pharmaceuticals, Inc.ICPT was a big mover last session, as the company saw its shares rise over 9% on the day. | INTERCEPT PHARM Price INTERCEPT PHARM Price | INTERCEPT PHARM Quote A better-ranked stock in the same industry is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report INTERCEPT PHARM (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. You can see the complete list of today's Zacks #1 Rank stocks here . | INTERCEPT PHARM Price INTERCEPT PHARM Price | INTERCEPT PHARM Quote A better-ranked stock in the same industry is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report INTERCEPT PHARM (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Predict to see what others think: Up or Down Zacks' Top 10 Stocks for 2017 In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017? | INTERCEPT PHARM Price INTERCEPT PHARM Price | INTERCEPT PHARM Quote A better-ranked stock in the same industry is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report INTERCEPT PHARM (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Intercept Pharmaceuticals, Inc.ICPT was a big mover last session, as the company saw its shares rise over 9% on the day. |
34719.0 | 2016-12-28 00:00:00 UTC | Anthera (ANTH) Stock Falls on Poor Phase III Sollpura Data | ABUS | https://www.nasdaq.com/articles/anthera-anth-stock-falls-on-poor-phase-iii-sollpura-data-2016-12-28 | nan | nan | Anthera Pharmaceuticals, Inc.ANTH announced disappointing top-line data from a phase III study - SOLUTION - on one of its pipeline candidates, Sollpura (liprotamase), in cystic fibrosis patients with exocrine pancreatic insufficiency (EPI). Shares of the company plunged 58.2% on Dec 27, during the after-hours trading session. Moreover, the company's shares were down 57.8% on Dec 28, during the pre-market trading session.
Anthera's year-to-date share price movement shows that the stock has underperformed the Zacks classified Medical - Biomedical and Genetics industry. Specifically, Anthera has tumbled 57.6% during this period, while the industry lost 24.5%.
The study was conducted to evaluate non-inferiority of Sollpura in comparison to Johnson & Johnson JNJ Janssen Pharmaceuticals, Inc.'s porcine-derived, enterically coated pancreatic enzyme replacement therapy, Pancreaze, when administered to patients with EPI due to cystic fibrosis.
According to information provided by Anthera in its press release, the study barely missed the primary endpoint of a change in the Coefficient of Fat Absorption (CFA) non-inferiority margin. However, Sollpura achieved the statistical criterion for nitrogen absorption. On the safety front, Sollpura was found to be well tolerated in comparison to Pancreaze, though symptoms associated with malabsorption were modestly more recurrent in the Sollpura arm.
Considering the robust activity demonstrated by Sollpura in the study, the company believes that the deficiency in fat absorption may be addressed by small changes in study design, including more liberal dose adjustment. Therefore, Anthera plans to initiate an additional study on Sollpura in patients with EPI due to cystic fibrosis.
The study is expected to begin in the first quarter of 2017. The company further noted that alterations in the study will help patients achieve optimal level of fat absorption as measured by CFA and provide necessary flexibility to adjust Sollpura dose, based on malabsorption symptoms at any time during the study.
Anthera anticipates a slight delay in the filing of a regulatory application in the U.S. to around the first quarter of 2018, as the new study, and the required chemistry, manufacturing, and control activities will complete simultaneously.
Anthera also anticipates reporting data from the extension phase of the SOLUTION study in the first quarter of 2017. The company further intends to continue the SIMPLICITY study in younger pediatric patients and the open-label EASY study.
The recent development is concerning given that company doesn't have any approved product in its portfolio. We note that the latest pipeline setback comes over a month after the company announced the failure of another phase III study, CHABLIS-SC1, on blisibimod for the treatment of systemic lupus erythematosus, to meet the primary endpoint.
ANTHERA PHARMA Price and Consensus
ANTHERA PHARMA Price and Consensus | ANTHERA PHARMA Quote
Zacks Rank & Key Picks
Anthera carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in this industry include Arbutus Biopharma Corporation ABUS and MannKind Corporation MNKD . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Arbutus' loss estimates narrowed from $2.15 to $1.71 for 2016 and from $1.96 to $1.52 for 2017 over the last 60 days. The company posted a positive surprise thrice in the four trailing quarters with an average beat of 59.31%.
MannKind's estimates narrowed from loss of 24 cents to earnings of 12 cents for 2016 over the last 60 days. For 2017, its loss estimates narrowed from 14 cents to 9 cents over this period. The company posted a positive surprise in two of the four trailing quarters with an average beat of 103.33%.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
MANNKIND CORP (MNKD): Free Stock Analysis Report
ANTHERA PHARMA (ANTH): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A couple of better-ranked stocks in this industry include Arbutus Biopharma Corporation ABUS and MannKind Corporation MNKD . Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MANNKIND CORP (MNKD): Free Stock Analysis Report ANTHERA PHARMA (ANTH): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Anthera Pharmaceuticals, Inc.ANTH announced disappointing top-line data from a phase III study - SOLUTION - on one of its pipeline candidates, Sollpura (liprotamase), in cystic fibrosis patients with exocrine pancreatic insufficiency (EPI). | Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MANNKIND CORP (MNKD): Free Stock Analysis Report ANTHERA PHARMA (ANTH): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in this industry include Arbutus Biopharma Corporation ABUS and MannKind Corporation MNKD . The study was conducted to evaluate non-inferiority of Sollpura in comparison to Johnson & Johnson JNJ Janssen Pharmaceuticals, Inc.'s porcine-derived, enterically coated pancreatic enzyme replacement therapy, Pancreaze, when administered to patients with EPI due to cystic fibrosis. | Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MANNKIND CORP (MNKD): Free Stock Analysis Report ANTHERA PHARMA (ANTH): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in this industry include Arbutus Biopharma Corporation ABUS and MannKind Corporation MNKD . The company further noted that alterations in the study will help patients achieve optimal level of fat absorption as measured by CFA and provide necessary flexibility to adjust Sollpura dose, based on malabsorption symptoms at any time during the study. | A couple of better-ranked stocks in this industry include Arbutus Biopharma Corporation ABUS and MannKind Corporation MNKD . Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MANNKIND CORP (MNKD): Free Stock Analysis Report ANTHERA PHARMA (ANTH): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. The company further noted that alterations in the study will help patients achieve optimal level of fat absorption as measured by CFA and provide necessary flexibility to adjust Sollpura dose, based on malabsorption symptoms at any time during the study. |
34720.0 | 2016-12-27 00:00:00 UTC | NewLink Genetics (NLNK) Jumps: Stock Adds 10% in Session | ABUS | https://www.nasdaq.com/articles/newlink-genetics-nlnk-jumps%3A-stock-adds-10-in-session-2016-12-27 | nan | nan | NewLink Genetics CorporationNLNK was a big mover last session, as the company saw its shares rise almost 10% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This reverses the recent trend of the company, as the stock is now down 15% in the past one-month time frame.
None of the estimates for this stock were revised in the last 30 days, while the Zacks Consensus Estimate also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
NewLink Genetics carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
NEWLINK GENETIC Price
NEWLINK GENETIC Price | NEWLINK GENETIC Quote
A better-ranked stock in the same industry is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Is NLNK going up? Or down? Predict to see what others think: Up or Down
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
NEWLINK GENETIC (NLNK): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | NEWLINK GENETIC Price NEWLINK GENETIC Price | NEWLINK GENETIC Quote A better-ranked stock in the same industry is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report NEWLINK GENETIC (NLNK): Free Stock Analysis Report To read this article on Zacks.com click here. NewLink Genetics CorporationNLNK was a big mover last session, as the company saw its shares rise almost 10% on the day. | NEWLINK GENETIC Price NEWLINK GENETIC Price | NEWLINK GENETIC Quote A better-ranked stock in the same industry is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report NEWLINK GENETIC (NLNK): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | NEWLINK GENETIC Price NEWLINK GENETIC Price | NEWLINK GENETIC Quote A better-ranked stock in the same industry is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report NEWLINK GENETIC (NLNK): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | NEWLINK GENETIC Price NEWLINK GENETIC Price | NEWLINK GENETIC Quote A better-ranked stock in the same industry is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report NEWLINK GENETIC (NLNK): Free Stock Analysis Report To read this article on Zacks.com click here. NewLink Genetics CorporationNLNK was a big mover last session, as the company saw its shares rise almost 10% on the day. |
34721.0 | 2016-12-22 00:00:00 UTC | Alexion Soliris Fails in Phase II/III Delayed Graft Function Study | ABUS | https://www.nasdaq.com/articles/alexion-soliris-fails-in-phase-ii-iii-delayed-graft-function-study-2016-12-22 | nan | nan | Alexion Pharmaceuticals, Inc.ALXN announced that Soliris has failed to meet the primary endpoint in a randomized, parallel-group, double-blind, placebo-controlled, multi-center phase II/III study (PROTECT).
We expect investors to react negatively to the news. Alexion's year-to-date share price movement shows that the stock has underperformed the Zacks classified Medical - Biomedical and Genetics industry. Specifically, Alexion has plunged 37.6% during this period, while the industry lost 25.3%.
Shares of Alexion have been under pressure of late, given the sudden departure of its key executives in the middle of an ongoing internal investigation into the sales practices related to Soliris. This sales probe led to a delay in the filing of the company's Form 10-Q for the period ended Sep 30, 2016. It now expects to file the 10-Q in Jan 2017 or earlier. Naturally, the recent label expansion setback related to Soliris isn't helping matters in any way.
Coming back to the news, Soliris was administered in an acute setting in the study for the prevention of delayed graft function (DGF) in adult recipients of a deceased-donor kidney transplant who are at increased risk of the disease.
Data revealed that the primary endpoint of incidence of DGF with a two-dose regimen of Soliris in comparison to placebo failed to attain statistical significance. The primary endpoint also included the incidence of death, graft loss and loss to follow-up including discontinuation, which was 35.9% for patients receiving a two-dose regimen of Soliris in comparison to 41.7% for patients in the placebo arm. However, Soliris demonstrated a favorable safety profile.
Alexion stated in the press release that it will continue to analyze the data to facilitate understanding of the findings for patients undergoing kidney transplant. The company anticipates publication of the study data at a later date.
Nevertheless, the study results are far from impressive. Per the company's press release, DGF is an early and serious complication of organ transplantation, affecting around 25-50% of deceased-donor kidney transplant cases, in which the transplanted organ fails to function normally following transplantation.
Note that Alexion was looking to increase the commercial potential of Soliris by expanding the drug's label to include this indication. Considering that there is no approved treatment for this serious and life-threatening complication, successful development of Soliris would have added to the drug's sales.
Soliris had been granted Orphan Drug designation for the prevention of DGF in renal transplant patients in the U.S., and for the prevention of DGF after solid organ transplantation in the EU.
We note that Soliris is a key growth driver at Alexion and is approved for the treatment of two life-threatening ultra-rare disorders - paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. The drug raked in sales of $2.1 billion in the first nine months of 2016.
Alexion is also developing Soliris for the treatment of patients with refractory generalized myasthenia gravis and relapsing neuromyelitis optica spectrum disorder.
ALEXION PHARMA Price and Consensus
ALEXION PHARMA Price and Consensus | ALEXION PHARMA Quote
Zacks Rank & Key Picks
Alexion currently carries a Zacks Rank #5 (Strong Sell). Some better-ranked stocks in this industry include Arbutus Biopharma Corporation ABUS , Athersys, Inc. ATHX and MannKind Corporation MNKD . All the three stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Athersys' loss estimates narrowed from 23 cents to 18 cents for 2016 while that for 2017 remained unchanged over the last 60 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 110.52%. Its share price has gained 53.4% year to date.
Arbutus' loss estimates narrowed from $2.15 to $1.71 for 2016 and from $1.96 to $1.46 for 2017 over the last 60 days. The company posted positive surprises thrice in the four trailing quarters with an average beat of 59.31%.
MannKind's estimates narrowed from loss of 24 cents to earnings of 12 cents for 2016 over the last 60 days. For 2017, loss estimates narrowed from 14 cents to 9 cents over this period. The company posted a positive surprise in two of the four trailing quarters with an average beat of 103.33%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks - absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MANNKIND CORP (MNKD): Free Stock Analysis Report
ALEXION PHARMA (ALXN): Free Stock Analysis Report
ATHERSYS INC (ATHX): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in this industry include Arbutus Biopharma Corporation ABUS , Athersys, Inc. ATHX and MannKind Corporation MNKD . Click to get this free report MANNKIND CORP (MNKD): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Alexion have been under pressure of late, given the sudden departure of its key executives in the middle of an ongoing internal investigation into the sales practices related to Soliris. | Some better-ranked stocks in this industry include Arbutus Biopharma Corporation ABUS , Athersys, Inc. ATHX and MannKind Corporation MNKD . Click to get this free report MANNKIND CORP (MNKD): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. ALEXION PHARMA Price and Consensus ALEXION PHARMA Price and Consensus | ALEXION PHARMA Quote Zacks Rank & Key Picks Alexion currently carries a Zacks Rank #5 (Strong Sell). | Click to get this free report MANNKIND CORP (MNKD): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in this industry include Arbutus Biopharma Corporation ABUS , Athersys, Inc. ATHX and MannKind Corporation MNKD . Per the company's press release, DGF is an early and serious complication of organ transplantation, affecting around 25-50% of deceased-donor kidney transplant cases, in which the transplanted organ fails to function normally following transplantation. | Some better-ranked stocks in this industry include Arbutus Biopharma Corporation ABUS , Athersys, Inc. ATHX and MannKind Corporation MNKD . Click to get this free report MANNKIND CORP (MNKD): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Considering that there is no approved treatment for this serious and life-threatening complication, successful development of Soliris would have added to the drug's sales. |
34722.0 | 2016-12-21 00:00:00 UTC | Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy | ABUS | https://www.nasdaq.com/articles/bristol-myers-psioxus-ink-deal-for-oncolytic-virus-therapy-2016-12-21 | nan | nan | Bristol-Myers Squibb CompanyBMY announced that it has entered into an agreement with PsiOxus Therapeutics, Ltd., under which it will gain exclusive worldwide rights to the latter's "armed" oncolytic virus candidate NG-348, currently in pre-clinical development, for the treatment of solid tumors.
Bristol-Myers' year-to-date share price movement shows that the stock has underperformed the Zacks classified Large Cap Pharmaceuticals industry. Specifically, the stock has lost 14% during this period, compared with a drop of 5.4% for the industry.
We note that this marks the second collaboration between the two companies. This June, Bristol-Myers and PsiOxus entered into an exclusive clinical collaboration agreement to study the latter's systemically administered "unarmed" oncolytic adenovirus therapeutic, enadenotucirev, in combination with Bristol-Myers' immuno-oncology drug Opdivo, for the treatment of a range of tumor types in late-stage cancer patients.
We are positive on the latest deal. The goal is to study the role of oncolytic viruses in enhancing checkpoint blockade across multiple types of cancer in the tumor microenvironment, thereby creating new treatment options for cancer patients.
We note that in Oct 2015, Amgen Inc. AMGN had gained FDA approval for the first oncolytic virus therapy, Imlygic (talimogene laherparepvec), for the treatment of melanoma lesions in the skin and lymph nodes.
Note that Bristol-Myers has been quite active on the deal-making and acquisitions fronts, particularly in the immuno-oncology space. The company is looking to expedite the development of its pipeline, which will help bring transformational immunotherapies to market.
BRISTOL-MYERS Price and Consensus
BRISTOL-MYERS Price and Consensus | BRISTOL-MYERS Quote
Zacks Rank & Key Picks
Bristol-Myers carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the health care sector include Arbutus Biopharma Corporation ABUS and Athersys, Inc. ATHX . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Athersys' loss estimates narrowed from 23 cents to 18 cents for 2016 while that for 2017 remained unchanged over the last 60 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 110.52%. Its share price has gained 58% year to date.
Arbutus' loss estimates narrowed from $2.15 to $1.71 for 2016 and from $1.96 to $1.46 for 2017 over the last 60 days. The company posted positive surprises thrice in the four trailing quarters with an average beat of 59.31%.
Zacks' Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BRISTOL-MYERS (BMY): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
ATHERSYS INC (ATHX): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A couple of better-ranked stocks in the health care sector include Arbutus Biopharma Corporation ABUS and Athersys, Inc. ATHX . Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb CompanyBMY announced that it has entered into an agreement with PsiOxus Therapeutics, Ltd., under which it will gain exclusive worldwide rights to the latter's "armed" oncolytic virus candidate NG-348, currently in pre-clinical development, for the treatment of solid tumors. | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the health care sector include Arbutus Biopharma Corporation ABUS and Athersys, Inc. ATHX . BRISTOL-MYERS Price and Consensus BRISTOL-MYERS Price and Consensus | BRISTOL-MYERS Quote Zacks Rank & Key Picks Bristol-Myers carries a Zacks Rank #3 (Hold). | Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the health care sector include Arbutus Biopharma Corporation ABUS and Athersys, Inc. ATHX . This June, Bristol-Myers and PsiOxus entered into an exclusive clinical collaboration agreement to study the latter's systemically administered "unarmed" oncolytic adenovirus therapeutic, enadenotucirev, in combination with Bristol-Myers' immuno-oncology drug Opdivo, for the treatment of a range of tumor types in late-stage cancer patients. | A couple of better-ranked stocks in the health care sector include Arbutus Biopharma Corporation ABUS and Athersys, Inc. ATHX . Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. BRISTOL-MYERS Price and Consensus BRISTOL-MYERS Price and Consensus | BRISTOL-MYERS Quote Zacks Rank & Key Picks Bristol-Myers carries a Zacks Rank #3 (Hold). |
34723.0 | 2016-12-15 00:00:00 UTC | Syndax Pharmaceuticals (SNDX) Looks Good: Stock Up 14.3% | ABUS | https://www.nasdaq.com/articles/syndax-pharmaceuticals-sndx-looks-good%3A-stock-up-14.3-2016-12-15 | nan | nan | Syndax Pharmaceuticals, Inc.SNDX was a big mover last session, as the company saw its shares rise over 14% on the day. The upside was driven after the company announced entering into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). The news also led to far more shares changing hands than in a normal session, resulting in solid volume. This reverses the recent trend of the company, as the stock is now down 14.8% since Dec 7.
None of the estimates for this stock were revised over the last 30 days, while the Zacks Consensus Estimate also remained unchanged. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Syndax Pharmaceuticals carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
SYNDAX PHARMA Price
SYNDAX PHARMA Price | SYNDAX PHARMA Quote
A better-ranked stock in the same industry is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Is SNDX going up? Or down? Predict to see what others think: Up or Down
The Best Place to Start Your Stock Search
Today, you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks - absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
SYNDAX PHARMA (SNDX): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | SYNDAX PHARMA Price SYNDAX PHARMA Price | SYNDAX PHARMA Quote A better-ranked stock in the same industry is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report SYNDAX PHARMA (SNDX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Syndax Pharmaceuticals, Inc.SNDX was a big mover last session, as the company saw its shares rise over 14% on the day. | SYNDAX PHARMA Price SYNDAX PHARMA Price | SYNDAX PHARMA Quote A better-ranked stock in the same industry is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report SYNDAX PHARMA (SNDX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | SYNDAX PHARMA Price SYNDAX PHARMA Price | SYNDAX PHARMA Quote A better-ranked stock in the same industry is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report SYNDAX PHARMA (SNDX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Predict to see what others think: Up or Down The Best Place to Start Your Stock Search Today, you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks - absolutely free of charge. | SYNDAX PHARMA Price SYNDAX PHARMA Price | SYNDAX PHARMA Quote A better-ranked stock in the same industry is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report SYNDAX PHARMA (SNDX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. You can see the complete list of today's Zacks #1 Rank stocks here . |
34724.0 | 2016-12-09 00:00:00 UTC | Should You Get Rid of Emergent BioSolutions (EBS) Now? | ABUS | https://www.nasdaq.com/articles/should-you-get-rid-of-emergent-biosolutions-ebs-now-2016-12-09 | nan | nan | Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is Emergent BioSolutions Inc.EBS , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #5 (Strong Sell) further confirms weakness in EBS.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 1 estimate moving down in the past 30 days, compared with no upward revision. This trend has caused the consensus estimate to trend lower, going from $1.23 a share a month ago to its current level of $1.08.
Also, for the current quarter, Emergent BioSolutionshas seen 1 downward estimate revision versus no revision in the opposite direction, dragging the consensus estimate down to 60 cents a share from 98 cents over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 8.2% in the past month.
EMERGENT BIOSOL Price and Consensus
EMERGENT BIOSOL Price and Consensus | EMERGENT BIOSOL Quote
So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait.
If you are still interested in the Medical - Biomedical and Genetics industry, you may instead consider a better-ranked stock - Arbutus Biopharma Corporation ABUS . The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
The Best Place to Start Your Stock Search
Today, you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks - absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
EMERGENT BIOSOL (EBS): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | If you are still interested in the Medical - Biomedical and Genetics industry, you may instead consider a better-ranked stock - Arbutus Biopharma Corporation ABUS . Click to get this free report EMERGENT BIOSOL (EBS): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. | Click to get this free report EMERGENT BIOSOL (EBS): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. If you are still interested in the Medical - Biomedical and Genetics industry, you may instead consider a better-ranked stock - Arbutus Biopharma Corporation ABUS . EMERGENT BIOSOL Price and Consensus EMERGENT BIOSOL Price and Consensus | EMERGENT BIOSOL Quote So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait. | Click to get this free report EMERGENT BIOSOL (EBS): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. If you are still interested in the Medical - Biomedical and Genetics industry, you may instead consider a better-ranked stock - Arbutus Biopharma Corporation ABUS . EMERGENT BIOSOL Price and Consensus EMERGENT BIOSOL Price and Consensus | EMERGENT BIOSOL Quote So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait. | If you are still interested in the Medical - Biomedical and Genetics industry, you may instead consider a better-ranked stock - Arbutus Biopharma Corporation ABUS . Click to get this free report EMERGENT BIOSOL (EBS): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. EMERGENT BIOSOL Price and Consensus EMERGENT BIOSOL Price and Consensus | EMERGENT BIOSOL Quote So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait. |
34725.0 | 2016-12-06 00:00:00 UTC | Pfizer Leukemia Drug Meets Primary Endpoint in Phase III | ABUS | https://www.nasdaq.com/articles/pfizer-leukemia-drug-meets-primary-endpoint-in-phase-iii-2016-12-06 | nan | nan | Pfizer Inc.PFE and partner Avillion LLP announced that a phase III study (BFORE) evaluating its marketed drug Bosulif in the first-line setting met the primary endpoint.
Results from the BFORE study demonstrated superiority of Bosulif (bosutinib) over Glivec for the first-line treatment of patients suffering from chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML).
Bosulif is already approved for the treatment of Ph+ CML in adults who are resistant or intolerant to prior therapy.
Note that post Trump's victory in the Presidential race, Pfizer's shares gained 5.3%, comparing favorably to a decline of 1.5% for the Zacks classified Large Cap Pharma industry
The study met the primary endpoint of major molecular response at 12 months and no new or unexpected safety issue was identified.
This marks an important milestone for Pfizer's emerging hematology portfolio given that the company is focused on developing new treatments for acute and chronic hematologic malignancies.
Based on the latest results, Pfizer is working with the FDA and other regulatory authorities for an approval of Bosulif for Ph+ CML patients in the first-line setting.
We note that Pfizer and Avillion entered into an exclusive collaborative development agreement in 2014 for the BFORE trial. Under the terms of the agreement, Avillion was responsible for funding and conducting the trial. If approved for this indication, Avillion will be eligible to receive milestone payments from Pfizer, while Pfizer retains all rights to commercialize the product globally.
Pfizer currently carries a Zacks Rank #3 (Hold).
PFIZER INC Price and Consensus
PFIZER INC Price and Consensus | PFIZER INC Quote
Stocks to Consider
Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Anika and Athersys sport a Zacks Rank #1 (Strong Buy), while Arbutus carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Anika's earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company posted a positive surprise in the four trailing quarters with an average beat of 33.14%. Its share price has gained 24% year to date.
Athersys' loss estimates narrowed from 23 cents to 18 cents in 2016 while that for 2017 remained unchanged over the last 60 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 110.52%. Its share price has gained 56.3% year to date.
Arbutus' loss estimates narrowed from $2.15 to $1.74 for 2016 and from $1.96 to $1.51 for 2017 over the last 60 days. The company posted positive surprises thrice in the four trailing quarters with an average beat of 59.31%.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PFIZER INC (PFE): Free Stock Analysis Report
ATHERSYS INC (ATHX): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PFIZER INC Price and Consensus PFIZER INC Price and Consensus | PFIZER INC Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Pfizer Inc.PFE and partner Avillion LLP announced that a phase III study (BFORE) evaluating its marketed drug Bosulif in the first-line setting met the primary endpoint. | Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. PFIZER INC Price and Consensus PFIZER INC Price and Consensus | PFIZER INC Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Anika and Athersys sport a Zacks Rank #1 (Strong Buy), while Arbutus carries a Zacks Rank #2 (Buy). | PFIZER INC Price and Consensus PFIZER INC Price and Consensus | PFIZER INC Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Note that post Trump's victory in the Presidential race, Pfizer's shares gained 5.3%, comparing favorably to a decline of 1.5% for the Zacks classified Large Cap Pharma industry The study met the primary endpoint of major molecular response at 12 months and no new or unexpected safety issue was identified. | PFIZER INC Price and Consensus PFIZER INC Price and Consensus | PFIZER INC Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Results from the BFORE study demonstrated superiority of Bosulif (bosutinib) over Glivec for the first-line treatment of patients suffering from chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). |
34726.0 | 2016-12-06 00:00:00 UTC | Roche Presents Positive Follicular Lymphoma Data on Gazvya | ABUS | https://www.nasdaq.com/articles/roche-presents-positive-follicular-lymphoma-data-on-gazvya-2016-12-06 | nan | nan | Roche Holding AGRHHBY announced encouraging data from the pivotal phase III study, GALLIUM, which compared Gazyva plus chemotherapy, followed by Gazyva alone head-to-head against MabThera plus chemotherapy followed by MabThera alone in patients with previously untreated follicular lymphoma. Note that Gazyva is marketed as Gazyvaro in the EU and Switzerland.
Note that the year-to-date share price movement of Roche shows that the stock has underperformed the Zacks classified Large Cap Pharma industry. The stock has lost 19.7% so far this year, compared to the industry's decline of 8.4%.
Reported results showed that treatment with Gazyva reduced the risk of disease worsening or death (progression-free survival) by 34% in comparison to MabThera. Data were presented at the annual meeting of the American Society of Hematology and the National Cancer Research Institute.
We note that GALLIUM is the third phase III study on Gazyva. The company plans to submit this data and seek regulatory approval.
We note that Gazyva is currently approved in combination with chlorambucil in previously untreated chronic lymphocytic leukemia patients. In Feb 2016, Gazyva gained FDA approval in combination with bendamustine, followed by Gazyva alone, for the treatment of follicular lymphoma in patients who did not respond to a Rituxan-containing regimen.
Additional studies evaluating Gazyva, in combination with other approved or investigational treatments, including cancer immunotherapies and small molecule inhibitors, are currently underway across a range of blood cancers.
Roche currently carries a Zacks Rank #4 (Sell).
ROCHE HLDG LTD Price and Consensus
ROCHE HLDG LTD Price and Consensus | ROCHE HLDG LTD Quote
Stocks to Consider
Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corp. ABUS . Anika and Athersys sport a Zacks Rank #1 (Strong Buy), while Arbutus carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Anika's earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company posted a positive surprise in the four trailing quarters with an average beat of 33.14%. Its share price has gained 24% year to date.
Athersys' loss estimates narrowed from 23 cents to 18 cents in 2016 while that for 2017 remained unchanged over the last 60 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 110.52%. Its share price has gained 56% year to date.
Arbutus' loss estimates narrowed from $2.15 to $1.74 for 2016 and from $1.96 to $1.51 for 2017 over the last 60 days. The company posted positive surprises thrice in the four trailing quarters with an average beat of 59.31%.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
ATHERSYS INC (ATHX): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ROCHE HLDG LTD Price and Consensus ROCHE HLDG LTD Price and Consensus | ROCHE HLDG LTD Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corp. ABUS . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Note that the year-to-date share price movement of Roche shows that the stock has underperformed the Zacks classified Large Cap Pharma industry. | ROCHE HLDG LTD Price and Consensus ROCHE HLDG LTD Price and Consensus | ROCHE HLDG LTD Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corp. ABUS . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Roche Holding AGRHHBY announced encouraging data from the pivotal phase III study, GALLIUM, which compared Gazyva plus chemotherapy, followed by Gazyva alone head-to-head against MabThera plus chemotherapy followed by MabThera alone in patients with previously untreated follicular lymphoma. | ROCHE HLDG LTD Price and Consensus ROCHE HLDG LTD Price and Consensus | ROCHE HLDG LTD Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corp. ABUS . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Roche Holding AGRHHBY announced encouraging data from the pivotal phase III study, GALLIUM, which compared Gazyva plus chemotherapy, followed by Gazyva alone head-to-head against MabThera plus chemotherapy followed by MabThera alone in patients with previously untreated follicular lymphoma. | ROCHE HLDG LTD Price and Consensus ROCHE HLDG LTD Price and Consensus | ROCHE HLDG LTD Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corp. ABUS . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Gazyva is currently approved in combination with chlorambucil in previously untreated chronic lymphocytic leukemia patients. |
34727.0 | 2016-11-30 00:00:00 UTC | Aimmune Closes Enrolment in Phase III Peanut Allergy Study | ABUS | https://www.nasdaq.com/articles/aimmune-closes-enrolment-in-phase-iii-peanut-allergy-study-2016-11-30 | nan | nan | Aimmune Therapeutics, Inc.AIMT announced that it has completed global enrollment in the phase III PALISADE study on AR101 for the desensitization of patients with peanut allergy.
Aimmune anticipates top-line data from the study in the fourth quarter of 2017. Positive data would allow the company to file regulatory applications for the candidate in both the U.S. and Europe in 2018. Notably, the company has completed North American enrollment in the PALISADE study this September.
Meanwhile, another study, RAMSES, which is scheduled to begin in the U.S. in early 2017, will evaluate AR101 in 'real life' clinical setting. Aimmune expects to submit a biologics license application (BLA) on the successful completion of the PALISADE and RAMSES studies.
Aimmune also announced the initiation of a randomized, double-blind, placebo-controlled, European study - ARTEMIS - evaluating AR101 in children and adolescents aged 4-17 years suffering from peanut allergy. Aimmune intends to enroll 120 to 160 patients in the study at multiple sites across Europe, beginning mid 2017. It expects to include data from the ARTEMIS study in its initial regulatory application in Europe.
We note that AR101 has received Breakthrough Therapy status from the FDA for the desensitization of patients aged 4-17 years with peanut allergy.
Note that post Trump's victory in the Presidential race, shares of Aimmune have surged 15.7%, compared to a drop of 17.9% for the Zacks categorized Medical-Biomed/Genetics industry.
Aimmune currently carries a Zacks Rank #3 (Hold).
AIMMUNE THERAPT Price
AIMMUNE THERAPT Price | AIMMUNE THERAPT Quote
Stocks to Consider
Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Athersys sports a Zacks Rank #1 (Strong Buy), while both Anika and Arbutus carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Anika's earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company posted a positive surprise in the four trailing quarters with an average beat of 33.14%. Its share price has gained 21.4% year to date.
Athersys' loss estimates narrowed from 24 cents to 18 cents in 2016 and from 38 cents to 28 cents for 2017 over the last 60 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 110.52%. Its share price has gained 61% year to date.
Arbutus' loss estimates narrowed from $2.15 to $1.74 for 2016 and from $1.96 to $1.51 for 2017 over the last 60 days. The company posted positive surprises thrice in the four trailing quarters with an average beat of 59.31%.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ATHERSYS INC (ATHX): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
AIMMUNE THERAPT (AIMT): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AIMMUNE THERAPT Price AIMMUNE THERAPT Price | AIMMUNE THERAPT Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Click to get this free report ATHERSYS INC (ATHX): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report AIMMUNE THERAPT (AIMT): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Aimmune Therapeutics, Inc.AIMT announced that it has completed global enrollment in the phase III PALISADE study on AR101 for the desensitization of patients with peanut allergy. | AIMMUNE THERAPT Price AIMMUNE THERAPT Price | AIMMUNE THERAPT Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Click to get this free report ATHERSYS INC (ATHX): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report AIMMUNE THERAPT (AIMT): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Athersys sports a Zacks Rank #1 (Strong Buy), while both Anika and Arbutus carry a Zacks Rank #2 (Buy). | AIMMUNE THERAPT Price AIMMUNE THERAPT Price | AIMMUNE THERAPT Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Click to get this free report ATHERSYS INC (ATHX): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report AIMMUNE THERAPT (AIMT): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Aimmune Therapeutics, Inc.AIMT announced that it has completed global enrollment in the phase III PALISADE study on AR101 for the desensitization of patients with peanut allergy. | AIMMUNE THERAPT Price AIMMUNE THERAPT Price | AIMMUNE THERAPT Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Click to get this free report ATHERSYS INC (ATHX): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report AIMMUNE THERAPT (AIMT): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Aimmune Therapeutics, Inc.AIMT announced that it has completed global enrollment in the phase III PALISADE study on AR101 for the desensitization of patients with peanut allergy. |
34728.0 | 2016-11-30 00:00:00 UTC | Foamix Completes Enrolment in Phase III Acne Drug Studies | ABUS | https://www.nasdaq.com/articles/foamix-completes-enrolment-in-phase-iii-acne-drug-studies-2016-11-30 | nan | nan | Foamix Pharmaceuticals Ltd.FOMX announced that it has completed patient enrollment in two phase III studies that will evaluate the efficacy and safety of one of its pipeline candidates, FMX101 (topical 4% minocycline foam), for the treatment of moderate-to-severe acne.
In the study, patients will be randomized in a 12-week double-blind phase, when they will be treated topically once daily with either FMX101 or the respective foam vehicle. The two co-primary efficacy endpoints of both the studies include the absolute change from baseline in inflammatory lesion counts in each treatment group at week 12, the proportion of patients achieving success at week 12, and at least a 2-grade improvement (decrease) from baseline at week 12.
Patients who complete the entire 12 weeks of the double-blind portion will have the option to continue in a long-term open-label safety extension, which will evaluate the safety of intermittent use of FMX101 for up to nine more months.
The two studies are being conducted simultaneously and the company expects to report top-line data in the first half of 2017. Foamix intends to file for FMX101 approval under the 505(b)(2) regulatory pathway.
We are encouraged by the company's progress with the candidate. Upon approved, FMX101 will be the first FDA-approved topical antibiotic treatment for moderate-to-severe acne, a skin disorder that affects millions of people every year with potentially significant psychological and social implications.
Note that post Trump's victory in the presidential race, shares of Foamix have gained a significant 72% compared to the Zacks categorized Medical-Drugs industry's 21.8% drop.
Foamix currently carries a Zacks Rank #3 (Hold).
FOAMIX PHARMA Price
FOAMIX PHARMA Price | FOAMIX PHARMA Quote
Stocks to Consider
Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Athersys sports a Zacks Rank #1 (Strong Buy), while both Anika and Arbutus carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Anika's earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company posted a positive surprise in the four trailing quarters with an average beat of 33.14%. Its share price has gained 21% year to date.
Athersys' loss estimates narrowed from 24 cents to 18 cents in 2016 and from 38 cents to 28 cents for 2017 over the last 60 days. The company posted positive surprises in all the four trailing quarters with an average beat of 110.52%. Its share price has gained 61% year to date.
Arbutus' loss estimates narrowed from $2.15 to $1.74 for 2016 and from $1.96 to $1.51 for 2017 over the last 60 days. The company posted a positive surprise thrice in the four trailing quarters with an average beat of 59.31%.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ATHERSYS INC (ATHX): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
FOAMIX PHARMA (FOMX): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | FOAMIX PHARMA Price FOAMIX PHARMA Price | FOAMIX PHARMA Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Click to get this free report ATHERSYS INC (ATHX): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report FOAMIX PHARMA (FOMX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Foamix Pharmaceuticals Ltd.FOMX announced that it has completed patient enrollment in two phase III studies that will evaluate the efficacy and safety of one of its pipeline candidates, FMX101 (topical 4% minocycline foam), for the treatment of moderate-to-severe acne. | FOAMIX PHARMA Price FOAMIX PHARMA Price | FOAMIX PHARMA Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Click to get this free report ATHERSYS INC (ATHX): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report FOAMIX PHARMA (FOMX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Athersys sports a Zacks Rank #1 (Strong Buy), while both Anika and Arbutus carry a Zacks Rank #2 (Buy). | FOAMIX PHARMA Price FOAMIX PHARMA Price | FOAMIX PHARMA Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Click to get this free report ATHERSYS INC (ATHX): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report FOAMIX PHARMA (FOMX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Foamix Pharmaceuticals Ltd.FOMX announced that it has completed patient enrollment in two phase III studies that will evaluate the efficacy and safety of one of its pipeline candidates, FMX101 (topical 4% minocycline foam), for the treatment of moderate-to-severe acne. | FOAMIX PHARMA Price FOAMIX PHARMA Price | FOAMIX PHARMA Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Anika Therapeutics ANIK , Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Click to get this free report ATHERSYS INC (ATHX): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report FOAMIX PHARMA (FOMX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Foamix Pharmaceuticals Ltd.FOMX announced that it has completed patient enrollment in two phase III studies that will evaluate the efficacy and safety of one of its pipeline candidates, FMX101 (topical 4% minocycline foam), for the treatment of moderate-to-severe acne. |
34729.0 | 2016-11-30 00:00:00 UTC | Valeant (VRX) Ups Sales Force to Support Xifaxan/Relistor | ABUS | https://www.nasdaq.com/articles/valeant-vrx-ups-sales-force-to-support-xifaxan-relistor-2016-11-30 | nan | nan | Valeant Pharmaceuticals International, Inc.VRX announced that it is expanding its sales force to reach primary care physicians. The new sales force team is going to promote the company's two products, Xifaxan for irritable bowel syndrome with diarrhea (IBS-D) and Relistor for opioid induced constipation (OIC).
Valeant Pharmaceuticals and partner Progenics Pharmaceuticals, Inc. PGNX commercially launched their constipation tablets, Relistor (methylnaltrexone bromide) in the U.S. in September this year. Relistor Tablets (450 mg once daily) were approved to treat OIC in adults with chronic non-cancer pain in July. Progenics has exclusively licensed the development and commercialization rights for Relistor to Valeant.
Valeant Pharmaceuticals and its wholly owned subsidiary, Salix Pharmaceuticals, Inc. received FDA approval for Xifaxan (rifaximin) 550 mg for the treatment of irritable bowel syndrome (IBS-D) in adults in May 2015. However, the drug has performed below expectations due to higher managed care rebates. The sales force expansion strategy is aimed at getting at better patient access for the drug.
The company's share price is down 3.81%, though the Zacks Classified Drugs industry has seen growth of 7.55% in the past one month.
VALEANT PHARMA Price
VALEANT PHARMA Price | VALEANT PHARMA Quote
Valeant is a Zacks Rank #5 (Strong Sell) stock. It has been in the spotlight for all the wrong reasons in recent times like a price hike of specialty drugs, erroneous financial reporting, and termination of contracts with Philidor Rx Services. The company has also been the subject of a pricing controversy over the last few months with politicians and media focusing on the high pricing of drugs. Adding to its woes, mutual fund investor T. Rowe Price filed a lawsuit against the company. However, Valeant has been quite aggressive on the acquisition front, which has been driving growth. The share price of the company is down more than 80% year to date.
A couple of better-ranked stocks in the healthcare sector include Heska Corporation HSKA , Arbutus Biopharma Corporation ABUS . Heska sports a Zacks Rank #1 (Strong Buy) while Arbutus carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Heska's earnings estimates increased from $1.13 per share to $1.35 for 2016 and from $1.38 per share to $1.53 for 2017, over the last 60 days. The company posted positive surprises in each of the four trailing quarters, with an average beat of 301.64%. Share price has increased 93.31% year to date for the company.
Arbutus' loss estimates narrowed from $2.15 to $1.74 per share for 2016 and from $1.96 to $1.51 per share for 2017 over the last 60 days. The company posted positive surprises in three of the trailing four quarters, with an average beat of 59.31%.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PROGENICS PHARM (PGNX): Free Stock Analysis Report
HESKA CORP (HSKA): Free Stock Analysis Report
VALEANT PHARMA (VRX): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A couple of better-ranked stocks in the healthcare sector include Heska Corporation HSKA , Arbutus Biopharma Corporation ABUS . Click to get this free report PROGENICS PHARM (PGNX): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. The new sales force team is going to promote the company's two products, Xifaxan for irritable bowel syndrome with diarrhea (IBS-D) and Relistor for opioid induced constipation (OIC). | Click to get this free report PROGENICS PHARM (PGNX): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the healthcare sector include Heska Corporation HSKA , Arbutus Biopharma Corporation ABUS . Valeant Pharmaceuticals and partner Progenics Pharmaceuticals, Inc. PGNX commercially launched their constipation tablets, Relistor (methylnaltrexone bromide) in the U.S. in September this year. | Click to get this free report PROGENICS PHARM (PGNX): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the healthcare sector include Heska Corporation HSKA , Arbutus Biopharma Corporation ABUS . The company's share price is down 3.81%, though the Zacks Classified Drugs industry has seen growth of 7.55% in the past one month. | Click to get this free report PROGENICS PHARM (PGNX): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the healthcare sector include Heska Corporation HSKA , Arbutus Biopharma Corporation ABUS . VALEANT PHARMA Price VALEANT PHARMA Price | VALEANT PHARMA Quote Valeant is a Zacks Rank #5 (Strong Sell) stock. |
34730.0 | 2016-11-29 00:00:00 UTC | Epizyme Tazemetostat Gets Fast Track Designation in U.S. | ABUS | https://www.nasdaq.com/articles/epizyme-tazemetostat-gets-fast-track-designation-in-u.s.-2016-11-29 | nan | nan | Epizyme, Inc. 's EPZM lead pipeline candidate, tazemetostat (an EZH2 inhibitor), has received Fast Track designation in the U.S. for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DCBL) whose tumors carry an EZH2 activating mutation.
This designation is intended to facilitate the development of important new drugs and provide quick patient access to these drugs. It enables early and frequent communication between the FDA and a product sponsor throughout the drug development and review process. With this designation, a product may be eligible for priority review at the time of a new drug application (NDA) filing and may submit completed sections of the NDA on a rolling basis before the complete application is submitted, thereby reducing development time and costs associated with bringing a drug to the market.
Additionally, following review by an independent data monitoring committee, Epizyme decided to expand the epithelioid sarcoma cohort of its ongoing phase II study in adult patients with INI1-negative solid tumors, based on encouraging early activity, including confirmed objective responses. The company will now enroll an additional 30 epithelioid sarcoma patients, bringing the total number of patients in the cohort to 60.
Meanwhile, the synovial sarcoma arm of the phase II study has been fully enrolled. Epizyme has concluded that the activity of tazemetostat in this cohort is insufficient to continue further evaluation of the candidate as monotherapy.
Therefore, Epizyme is focusing on four cohorts of INI1-negative tumors in the study, including the epithelioid sarcoma. While enrollment continues in these cohorts, data from the phase II study is expected to be presented in the first half of 2017.
We note that tazemetostat is being evaluated in phase II studies as monotherapy for the treatment of non-Hodgkin lymphoma and mesothelioma characterized by BAP1 loss-of-function. Moreover, a phase Ib study evaluating tazemetostat, in combination with Tecentriq (an anti-PD-L1 cancer immunotherapy), is being conducted as part of a collaboration with Roche Holding AG's RHHBY Genentech for the treatment of relapsed and refractory DLBCL.
Epizyme carries a Zacks Rank #2 (Buy)
EPIZYME INC Price
EPIZYME INC Price | EPIZYME INC Quote
Stocks to Consider
A couple of favorably ranked stocks in the healthcare sector include Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Athersys sports a Zacks Rank #1 (Strong Buy), while Arbutus carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
Athersys' loss estimates narrowed from 24 cents to 18 cents in 2016 and from 38 cents to 28 cents for 2017 over the last 60 days. The company posted positive surprises in all the four trailing quarters with an average beat of 110.52%. Its share price has gained 63% year to date.
Arbutus' loss estimates narrowed from $2.15 to $1.74 for 2016 and from $1.96 to $1.51 for 2017 over the last 60 days. The company posted positive surprises thrice in the four trailing quarters with an average beat of 59.31%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks - absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
ATHERSYS INC (ATHX): Free Stock Analysis Report
EPIZYME INC (EPZM): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Epizyme carries a Zacks Rank #2 (Buy) EPIZYME INC Price EPIZYME INC Price | EPIZYME INC Quote Stocks to Consider A couple of favorably ranked stocks in the healthcare sector include Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report EPIZYME INC (EPZM): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Epizyme, Inc. 's EPZM lead pipeline candidate, tazemetostat (an EZH2 inhibitor), has received Fast Track designation in the U.S. for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DCBL) whose tumors carry an EZH2 activating mutation. | Epizyme carries a Zacks Rank #2 (Buy) EPIZYME INC Price EPIZYME INC Price | EPIZYME INC Quote Stocks to Consider A couple of favorably ranked stocks in the healthcare sector include Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report EPIZYME INC (EPZM): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Athersys sports a Zacks Rank #1 (Strong Buy), while Arbutus carries a Zacks Rank #2. | Epizyme carries a Zacks Rank #2 (Buy) EPIZYME INC Price EPIZYME INC Price | EPIZYME INC Quote Stocks to Consider A couple of favorably ranked stocks in the healthcare sector include Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report EPIZYME INC (EPZM): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Additionally, following review by an independent data monitoring committee, Epizyme decided to expand the epithelioid sarcoma cohort of its ongoing phase II study in adult patients with INI1-negative solid tumors, based on encouraging early activity, including confirmed objective responses. | Epizyme carries a Zacks Rank #2 (Buy) EPIZYME INC Price EPIZYME INC Price | EPIZYME INC Quote Stocks to Consider A couple of favorably ranked stocks in the healthcare sector include Athersys, Inc. ATHX and Arbutus Biopharma Corporation ABUS . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report EPIZYME INC (EPZM): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. You can see the complete list of today's Zacks #1 Rank stocks here . |
34731.0 | 2016-11-29 00:00:00 UTC | Jazz Completes Patient Enrollment in JZP-110 Narcolepsy Trial | ABUS | https://www.nasdaq.com/articles/jazz-completes-patient-enrollment-in-jzp-110-narcolepsy-trial-2016-11-29 | nan | nan | Jazz Pharmaceuticals Public Limited CompanyJAZZ announced that its phase III study, evaluating JZP-110 has completed patient enrollment. The study is evaluating JZP-110 for the treatment of excessive sleepiness (ES) associated with narcolepsy.
The phase III narcolepsy study is a double-blind, placebo-controlled, multiple-center study, which enrolled 240 patients. The Maintenance of Wakefulness Test and the Epworth Sleepiness Scale were the co-primary endpoints. These measure the patient's ability to stay awake and the severity of ES in them.
JZP-110 is also being evaluated in two phase III studies for the treatment of ES associated with obstructive sleep apnea (OSA).
The company expects to report positive results from the OSA studies in the first quarter of 2017 and from the narcolepsy study in the second quarter of 2017. Positive data from these studies would allow the company to file for approval in late 2017.
JZP-110, which enjoys Orphan Drug designation in the U.S. for narcolepsy, complements Jazz's existing sleep disorder portfolio. According to the company, there is significant unmet need in narcolepsy and OSA with about 175-300K patients having an inadequate response to current wake-promoting therapies. More than 50% of patients fail one or more stimulants or wake-promoting agents. Data generated on JZP-110 looks good so far.
In Sep 2016, Jazz announced the completion of patient enrollment in the two OSA phase III studies.
JAZZ PHARMACEUT Price
JAZZ PHARMACEUT Price | JAZZ PHARMACEUT Quote
Jazz is a Zacks Rank #3 (Hold) stock. The company's share price is down almost 1.5%, while the medical drugs market is up at 8.74% in the last one month. Some better-ranked stocks in the healthcare sector include Heska Corporation HSKA , Arbutus Biopharma Corporation ABUS and Anika Therapeutics Inc. ANIK . Heska sports a Zacks Rank #1 (Strong Buy) while Arbutus and Anika carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Heska's earnings estimates increased from $1.13 per share to $1.35 for 2016 and from $1.38 per share to $1.53 for 2017, over the last 60 days. The company posted positive surprises in each of the four trailing quarters, with an average beat of 301.64%. Share price has increased 69.60% year to date for the company.
Arbutus' loss estimates narrowed from $2.15 to $1.74 per share for 2016 and from $1.96 to $1.51 per share for 2017 over the last 60 days. The company posted positive surprises in three of the trailing four quarters, with an average beat of 59.31%.
Anika's earnings estimates increased from $1.96 per share to $2.06 for 2016 and from $2.03 per share to $2.09 for 2017, over the last 60 days. The company posted positive surprises in each of the four trailing quarters, with an average beat of 33.14%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks - absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
HESKA CORP (HSKA): Free Stock Analysis Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the healthcare sector include Heska Corporation HSKA , Arbutus Biopharma Corporation ABUS and Anika Therapeutics Inc. ANIK . Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Jazz Pharmaceuticals Public Limited CompanyJAZZ announced that its phase III study, evaluating JZP-110 has completed patient enrollment. | Some better-ranked stocks in the healthcare sector include Heska Corporation HSKA , Arbutus Biopharma Corporation ABUS and Anika Therapeutics Inc. ANIK . Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. JAZZ PHARMACEUT Price JAZZ PHARMACEUT Price | JAZZ PHARMACEUT Quote Jazz is a Zacks Rank #3 (Hold) stock. | Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector include Heska Corporation HSKA , Arbutus Biopharma Corporation ABUS and Anika Therapeutics Inc. ANIK . The company expects to report positive results from the OSA studies in the first quarter of 2017 and from the narcolepsy study in the second quarter of 2017. | Some better-ranked stocks in the healthcare sector include Heska Corporation HSKA , Arbutus Biopharma Corporation ABUS and Anika Therapeutics Inc. ANIK . Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. The study is evaluating JZP-110 for the treatment of excessive sleepiness (ES) associated with narcolepsy. |
34732.0 | 2016-11-29 00:00:00 UTC | After Hours Most Active for Nov 29, 2016 : YHOO, GE, CHK, MDRX, CSCO, XLNX, SWNC, ABUS, TMUSP, ABBV, TSM, FCAM | ABUS | https://www.nasdaq.com/articles/after-hours-most-active-nov-29-2016-yhoo-ge-chk-mdrx-csco-xlnx-swnc-abus-tmusp-abbv-tsm | nan | nan | The NASDAQ 100 After Hours Indicator is up .68 to 4,873.89. The total After hours volume is currently 42,152,437 shares traded.
The following are the most active stocks for the after hours session :
Yahoo! Inc. ( YHOO ) is unchanged at $41.60, with 5,253,824 shares traded. YHOO's current last sale is 94.55% of the target price of $44.
General Electric Company ( GE ) is unchanged at $31.05, with 3,483,058 shares traded. GE's current last sale is 91.32% of the target price of $34.
Chesapeake Energy Corporation ( CHK ) is -0.02 at $6.35, with 2,246,426 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2016. The consensus EPS forecast is $0.08. CHK's current last sale is 105.83% of the target price of $6.
Allscripts Healthcare Solutions, Inc. ( MDRX ) is +0.1584 at $11.11, with 2,136,187 shares traded. MDRX's current last sale is 74.06% of the target price of $15.
Cisco Systems, Inc. ( CSCO ) is unchanged at $29.83, with 2,063,425 shares traded. As reported by Zacks, the current mean recommendation for CSCO is in the "buy range".
Xilinx, Inc. ( XLNX ) is unchanged at $54.01, with 1,967,694 shares traded. XLNX's current last sale is 108.02% of the target price of $50.
Southwestern Energy Company ( SWNC ) is unchanged at $28.02, with 1,786,200 shares traded.
Arbutus Biopharma Corporation ( ABUS ) is unchanged at $2.65, with 1,712,000 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2016. The consensus EPS forecast is $-0.35. As reported in the last short interest update the days to cover for ABUS is 9.08212; this calculation is based on the average trading volume of the stock.
T-Mobile US, Inc. ( TMUSP ) is unchanged at $91.11, with 1,500,000 shares traded.TMUSP has a $2.75000000cash dividend with an Ex/Eff Date of11/29/2016
AbbVie Inc. ( ABBV ) is unchanged at $61.59, with 1,381,118 shares traded. ABBV's current last sale is 87.99% of the target price of $70.
Taiwan Semiconductor Manufacturing Company Ltd. ( TSM ) is unchanged at $29.55, with 722,199 shares traded. TSM's current last sale is 96.24% of the target price of $30.705.
Fiat Chrysler Automobiles N.V. ( FCAM ) is +0.083 at $64.54, with 712,810 shares traded.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As reported in the last short interest update the days to cover for ABUS is 9.08212; this calculation is based on the average trading volume of the stock. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2016. Arbutus Biopharma Corporation ( ABUS ) is unchanged at $2.65, with 1,712,000 shares traded. | Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2016. Arbutus Biopharma Corporation ( ABUS ) is unchanged at $2.65, with 1,712,000 shares traded. As reported in the last short interest update the days to cover for ABUS is 9.08212; this calculation is based on the average trading volume of the stock. | Arbutus Biopharma Corporation ( ABUS ) is unchanged at $2.65, with 1,712,000 shares traded. As reported in the last short interest update the days to cover for ABUS is 9.08212; this calculation is based on the average trading volume of the stock. Inc. ( YHOO ) is unchanged at $41.60, with 5,253,824 shares traded. | Arbutus Biopharma Corporation ( ABUS ) is unchanged at $2.65, with 1,712,000 shares traded. As reported in the last short interest update the days to cover for ABUS is 9.08212; this calculation is based on the average trading volume of the stock. The NASDAQ 100 After Hours Indicator is up .68 to 4,873.89. |
34733.0 | 2016-11-28 00:00:00 UTC | Intellipharmaceutics Submits NDA for Pain Treatment Rexista | ABUS | https://www.nasdaq.com/articles/intellipharmaceutics-submits-nda-for-pain-treatment-rexista-2016-11-28 | nan | nan | Intellipharmaceutics International Inc.IPCI announced that it has filed a new drug application (NDA) with the FDA for Rexista (abuse-deterrent oxycodone hydrochloride extended release tablets) in the 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg and 80 mg strengths.
The company is looking to get Rexista approved for the management of pain, severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
We note that Rexista is a bioequivalent of Purdue Pharma's OxyContin (oxycodone hydrochloride extended release).
Notably, this marks Intellipharmaceutics' first regulatory submission in the U.S. Upon approval, Rexista could be the first abuse-deterrent oxycodone product that not only resists common forms of abuse but also provides a preventive tool that flags early signs of abuse.
The company has identified potential manufacturing partners and is currently evaluating various manufacturing options for Rexista in the U.S.
Meanwhile, in Oct 2016, Intellipharmaceutics entered into a license and commercial supply agreement with Mallinckrodt Public Limited Company MNK , granting the latter an exclusive license to market, sell and distribute generic Seroquel XR, Pristiq and Lamictal XR in the U.S., for which Intellipharmaceutics has filed abbreviated NDAs. While generic version of Seroquel XR has been tentatively approved by the FDA, generic versions of Pristiq and Lamictal are currently under review.
Intellipharmaceutics currently carries a Zacks Rank #3 (Hold).
INTELLIPHARMACT Price
INTELLIPHARMACT Price | INTELLIPHARMACT Quote
Stocks to Consider
A couple of better-ranked stocks in the healthcare sector include Incyte Corporation INCY and Arbutus Biopharma Corporation ABUS . Arbutus sports a Zacks Rank #1 (Strong Buy), while Incyte carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Incyte's earnings estimates increased from 23 cents to 64 cents for 2016 and from $1.46 to $1.68 for 2017 over the last 30 days. The company posted a positive average beat of 431.43% over the last four quarters.
Arbutus' loss estimates narrowed from $2.15 to $1.74 for 2016 and from $1.96 to $1.51 for 2017 over the last 30 days. The company posted positive surprises thrice in the four trailing quarters with an average beat of 59.31%.
Zacks' Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
INCYTE CORP (INCY): Free Stock Analysis Report
INTELLIPHARMACT (IPCI): Free Stock Analysis Report
MALLINCKRODT PL (MNK): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Intellipharmaceutics International Inc.IPCI announced that it has filed a new drug application (NDA) with the FDA for Rexista (abuse-deterrent oxycodone hydrochloride extended release tablets) in the 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg and 80 mg strengths. Upon approval, Rexista could be the first abuse-deterrent oxycodone product that not only resists common forms of abuse but also provides a preventive tool that flags early signs of abuse. INTELLIPHARMACT Price INTELLIPHARMACT Price | INTELLIPHARMACT Quote Stocks to Consider A couple of better-ranked stocks in the healthcare sector include Incyte Corporation INCY and Arbutus Biopharma Corporation ABUS . | Intellipharmaceutics International Inc.IPCI announced that it has filed a new drug application (NDA) with the FDA for Rexista (abuse-deterrent oxycodone hydrochloride extended release tablets) in the 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg and 80 mg strengths. Click to get this free report INCYTE CORP (INCY): Free Stock Analysis Report INTELLIPHARMACT (IPCI): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Upon approval, Rexista could be the first abuse-deterrent oxycodone product that not only resists common forms of abuse but also provides a preventive tool that flags early signs of abuse. | Intellipharmaceutics International Inc.IPCI announced that it has filed a new drug application (NDA) with the FDA for Rexista (abuse-deterrent oxycodone hydrochloride extended release tablets) in the 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg and 80 mg strengths. Click to get this free report INCYTE CORP (INCY): Free Stock Analysis Report INTELLIPHARMACT (IPCI): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Upon approval, Rexista could be the first abuse-deterrent oxycodone product that not only resists common forms of abuse but also provides a preventive tool that flags early signs of abuse. | Intellipharmaceutics International Inc.IPCI announced that it has filed a new drug application (NDA) with the FDA for Rexista (abuse-deterrent oxycodone hydrochloride extended release tablets) in the 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg and 80 mg strengths. Upon approval, Rexista could be the first abuse-deterrent oxycodone product that not only resists common forms of abuse but also provides a preventive tool that flags early signs of abuse. INTELLIPHARMACT Price INTELLIPHARMACT Price | INTELLIPHARMACT Quote Stocks to Consider A couple of better-ranked stocks in the healthcare sector include Incyte Corporation INCY and Arbutus Biopharma Corporation ABUS . |
34734.0 | 2016-11-28 00:00:00 UTC | New Strong Buy Stocks for November 28th | ABUS | https://www.nasdaq.com/articles/new-strong-buy-stocks-november-28th-2016-11-28 | nan | nan | Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Arbutus Biopharma Corporation (ABUS): This biopharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings surging 19.3% over the last 30 days.
ARBUTUS BIOPH Price and Consensus
ARBUTUS BIOPH Price and Consensus | ARBUTUS BIOPH Quote
Daktronics, Inc. (DAKT): This supplier of electronic scoreboards, electronic display systems, digital messaging solutions has seen the Zacks Consensus Estimate for its current year earnings climbing 45.5% over the last 30 days.
DAKTRONICS INC Price and Consensus
DAKTRONICS INC Price and Consensus | DAKTRONICS INC Quote
Edgewell Personal Care Company (EPC): This manufactures and markets personal care products has witnessed the Zacks Consensus Estimate for its current year earnings gaining 6.2% over the last 30 days.
EDGEWELL PERSNL Price and Consensus
EDGEWELL PERSNL Price and Consensus | EDGEWELL PERSNL Quote
Employers Holdings, Inc. (EIG): This company that operates in the commercial property and casualty insurance industry has seen the Zacks Consensus Estimate for its current year earnings increasing 3% over the last 30 days.
EMPLOYERS HLDGS Price and Consensus
EMPLOYERS HLDGS Price and Consensus | EMPLOYERS HLDGS Quote
Marin Software Incorporated (MRIN): This company that operates a cloud-based digital advertising management platform has witnessed the Zacks Consensus Estimate for its current year earnings surging 11.8% over the last 30 days.
MARIN SOFTWARE Price and Consensus
MARIN SOFTWARE Price and Consensus | MARIN SOFTWARE Quote
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Now See All Our Private Trades
While today's Zacks Rank #1 new additions are being shared with the public, other trades are hidden from everyone but selected members. Would you like to peek behind the curtain and view them? Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for all Zacks trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MARIN SOFTWARE (MRIN): Free Stock Analysis Report
EDGEWELL PERSNL (EPC): Free Stock Analysis Report
EMPLOYERS HLDGS (EIG): Free Stock Analysis Report
DAKTRONICS INC (DAKT): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Arbutus Biopharma Corporation (ABUS): This biopharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings surging 19.3% over the last 30 days. Click to get this free report MARIN SOFTWARE (MRIN): Free Stock Analysis Report EDGEWELL PERSNL (EPC): Free Stock Analysis Report EMPLOYERS HLDGS (EIG): Free Stock Analysis Report DAKTRONICS INC (DAKT): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Starting today, for the next month, you can follow all Zacks' private buys and sells in real time from value to momentum . | Click to get this free report MARIN SOFTWARE (MRIN): Free Stock Analysis Report EDGEWELL PERSNL (EPC): Free Stock Analysis Report EMPLOYERS HLDGS (EIG): Free Stock Analysis Report DAKTRONICS INC (DAKT): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Arbutus Biopharma Corporation (ABUS): This biopharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings surging 19.3% over the last 30 days. EDGEWELL PERSNL Price and Consensus EDGEWELL PERSNL Price and Consensus | EDGEWELL PERSNL Quote Employers Holdings, Inc. (EIG): This company that operates in the commercial property and casualty insurance industry has seen the Zacks Consensus Estimate for its current year earnings increasing 3% over the last 30 days. | Click to get this free report MARIN SOFTWARE (MRIN): Free Stock Analysis Report EDGEWELL PERSNL (EPC): Free Stock Analysis Report EMPLOYERS HLDGS (EIG): Free Stock Analysis Report DAKTRONICS INC (DAKT): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Arbutus Biopharma Corporation (ABUS): This biopharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings surging 19.3% over the last 30 days. EDGEWELL PERSNL Price and Consensus EDGEWELL PERSNL Price and Consensus | EDGEWELL PERSNL Quote Employers Holdings, Inc. (EIG): This company that operates in the commercial property and casualty insurance industry has seen the Zacks Consensus Estimate for its current year earnings increasing 3% over the last 30 days. | Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Arbutus Biopharma Corporation (ABUS): This biopharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings surging 19.3% over the last 30 days. Click to get this free report MARIN SOFTWARE (MRIN): Free Stock Analysis Report EDGEWELL PERSNL (EPC): Free Stock Analysis Report EMPLOYERS HLDGS (EIG): Free Stock Analysis Report DAKTRONICS INC (DAKT): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. MARIN SOFTWARE Price and Consensus MARIN SOFTWARE Price and Consensus | MARIN SOFTWARE Quote You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . |
34735.0 | 2016-11-25 00:00:00 UTC | OPKO Health (OPK) Launches Kidney Drug Rayaldee in U.S. | ABUS | https://www.nasdaq.com/articles/opko-health-opk-launches-kidney-drug-rayaldee-in-u.s.-2016-11-25 | nan | nan | OPKO Health, Inc.OPK announced the launch of its kidney drug Rayaldee (calcifediol). The company said it will begin shipping of the drug to distributors in the United States on Nov 29, 2016. Rayaldee extended release capsules were approved by the FDA in June this year for treating secondary hyperparathyroidism (SHPT) in patients above 18 years with stage III or IV chronic kidney disease (CKD). The product will be available nationwide at retail pharmacies from Nov 30.
Rayaldee was introduced to nephrologists at the American Society of Nephrology (ASN) Kidney Week Meeting held last week in Chicago. Rayaldee is the first product developed by OPKO Health. The product has side effects like anemia, nasopharyngitis, increased blood creatinine, dyspnea, cough, congestive heart failure and constipation. However, this launch is expected to immensely help patients with CKD.
OPKO HEALTH INC Price
OPKO HEALTH INC Price | OPKO HEALTH INC Quote
OPKO Health is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the healthcare sector include Heska Corporation HSKA , Arbutus Biopharma Corporation ABUS and Anika Therapeutics Inc. ANIK . Heska sports a Zacks Rank #1 (Strong Buy) while Arbutus and Anika carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Heska's earnings estimates increased from $1.13 per share to $1.35 for 2016 and from $1.38 per share to $1.53 for 2017, over the last 60 days. The company posted positive surprises in each of the four trailing quarters, with an average beat of 301.64%. Share price has increased 93.31% year to date for the company.
Arbutus' loss estimates narrowed from $2.15 to $1.74 per share for 2016 and from $1.96 to $1.51 per share for 2017 over the last 60 days. The company posted positive surprises in three of the trailing four quarters, with an average beat of 59.31%.
Anika's earnings estimates increased from $1.96 per share to $2.06 for 2016 and from $2.03 per share to $2.09 for 2017, over the last 60 days. The company posted positive surprises in each of the four trailing quarters, with an average beat of 33.14%. Share price has increased 13.42% year to date for the company.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
OPKO HEALTH INC (OPK): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
HESKA CORP (HSKA): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the healthcare sector include Heska Corporation HSKA , Arbutus Biopharma Corporation ABUS and Anika Therapeutics Inc. ANIK . Click to get this free report OPKO HEALTH INC (OPK): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Rayaldee extended release capsules were approved by the FDA in June this year for treating secondary hyperparathyroidism (SHPT) in patients above 18 years with stage III or IV chronic kidney disease (CKD). | Some better-ranked stocks in the healthcare sector include Heska Corporation HSKA , Arbutus Biopharma Corporation ABUS and Anika Therapeutics Inc. ANIK . Click to get this free report OPKO HEALTH INC (OPK): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. OPKO HEALTH INC Price OPKO HEALTH INC Price | OPKO HEALTH INC Quote OPKO Health is a Zacks Rank #3 (Hold) stock. | Click to get this free report OPKO HEALTH INC (OPK): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector include Heska Corporation HSKA , Arbutus Biopharma Corporation ABUS and Anika Therapeutics Inc. ANIK . OPKO HEALTH INC Price OPKO HEALTH INC Price | OPKO HEALTH INC Quote OPKO Health is a Zacks Rank #3 (Hold) stock. | Some better-ranked stocks in the healthcare sector include Heska Corporation HSKA , Arbutus Biopharma Corporation ABUS and Anika Therapeutics Inc. ANIK . Click to get this free report OPKO HEALTH INC (OPK): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. OPKO Health, Inc.OPK announced the launch of its kidney drug Rayaldee (calcifediol). |
34736.0 | 2016-11-24 00:00:00 UTC | Merck (MRK) Announces 2.2% Increase in Quarterly Dividend | ABUS | https://www.nasdaq.com/articles/merck-mrk-announces-2.2-increase-in-quarterly-dividend-2016-11-24 | nan | nan | Merck & Co., Inc,MRK recently announced a 2.2% hike in its quarterly dividend. The company will now pay shareholders a quarterly dividend of 47 cents compared with the previous payout of 46 cents. Based on the closing price of $61.64 on Nov 23, the increased payout translates to a yield of 3%.
The new dividend will be paid on Jan 9, 2017, to stockholders on record at the close of business on Dec 15, 2016.
The last time the company had raised its dividend (from $0.45 to $0.46 per common share) was in Nov 2015 by a similar percentage.
Meanwhile, Merck announced this month that its hepatitis C virus (HCV) treatment Zepatier will be launched in the European markets in late Nov 2016. It also revealed positive data from three phase II studies on its pipeline candidate, MK-3682, in combination with grazoprevir and ruzasvir1, for the treatment of chronic HCV infection.
Merck currently carries a Zacks Rank #3 (Hold).
MERCK & CO INC Price
MERCK & CO INC Price | MERCK & CO INC Quote
Stocks to Consider
Some better-ranked stocks in the healthcare sector include Incyte Corporation INCY , Anika Therapeutics ANIK and Arbutus Biopharma Corporation ABUS . Anika sports a Zacks Rank #1 (Strong Buy), while both Incyte and Arbutus carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Incyte's earnings estimates increased from 22 cents to 68 cents for 2016 and from $1.46 to $1.68 for 2017 over the last 30 days. The company posted a positive average beat of 431.43% over the last four quarters.
Anika's earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 30 days. The company posted a positive surprise in the four trailing quarters with an average beat of 33.14%. Its share price has gained 22.5% year to date.
Arbutus's loss estimates narrowed from $2.15 to $1.74 for 2016 and from $1.96 to $1.51 for 2017 over the last 30 days. The company posted positive surprises thrice in the four trailing quarters with an average beat of 59.31%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MERCK & CO INC (MRK): Free Stock Analysis Report
INCYTE CORP (INCY): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MERCK & CO INC Price MERCK & CO INC Price | MERCK & CO INC Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Incyte Corporation INCY , Anika Therapeutics ANIK and Arbutus Biopharma Corporation ABUS . Click to get this free report MERCK & CO INC (MRK): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, Merck announced this month that its hepatitis C virus (HCV) treatment Zepatier will be launched in the European markets in late Nov 2016. | MERCK & CO INC Price MERCK & CO INC Price | MERCK & CO INC Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Incyte Corporation INCY , Anika Therapeutics ANIK and Arbutus Biopharma Corporation ABUS . Click to get this free report MERCK & CO INC (MRK): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Anika sports a Zacks Rank #1 (Strong Buy), while both Incyte and Arbutus carry a Zacks Rank #2 (Buy). | MERCK & CO INC Price MERCK & CO INC Price | MERCK & CO INC Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Incyte Corporation INCY , Anika Therapeutics ANIK and Arbutus Biopharma Corporation ABUS . Click to get this free report MERCK & CO INC (MRK): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Anika sports a Zacks Rank #1 (Strong Buy), while both Incyte and Arbutus carry a Zacks Rank #2 (Buy). | MERCK & CO INC Price MERCK & CO INC Price | MERCK & CO INC Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Incyte Corporation INCY , Anika Therapeutics ANIK and Arbutus Biopharma Corporation ABUS . Click to get this free report MERCK & CO INC (MRK): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. The company will now pay shareholders a quarterly dividend of 47 cents compared with the previous payout of 46 cents. |
34737.0 | 2016-11-23 00:00:00 UTC | Novo Nordisk's Diabetes Combination Drug Gets FDA's Nod | ABUS | https://www.nasdaq.com/articles/novo-nordisks-diabetes-combination-drug-gets-fdas-nod-2016-11-23 | nan | nan | Novo Nordisk A/SNVO received favorable news with the FDA approving its new drug application for Xultophy 100/3.6. Xultophy 100/3.6 is approved as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus who have inadequately controlled their disease on basal insulin (less than 50 units daily) or Victoza (liraglutide; less than or equal to 1.8 mg daily).
Xultophy 100/3.6 is a once-daily, single injection, fixed combination of Tresiba (insulin degludec) and Victoza and can be taken at the same time each day with or without food. It will be available in a prefilled pen.
Novo Nordisk is looking forward to launch it in the U.S. in the first half of 2017.
We remind investors that the FDA had extended the review period of the company's NDA for Xultophy 100/3.6 by three months in Sep 2016.
We note that Novo Nordisk is going through a rough patch as several drugs in its portfolio are losing patent protection. It is also facing a risk from biosimilars in the human growth hormone market and pricing pressure for some of its drugs. The company anticipates continually strong performance of modern insulins, Tresiba and Victoza, as well as higher contributions from Saxenda and Xultophy.
Novo Nordisk currently carries a Zacks Rank #4 (Sell).
NOVO-NORDISK AS Price
NOVO-NORDISK AS Price | NOVO-NORDISK AS Quote
Stocks to Consider
Some better-ranked stocks in the healthcare sector include Incyte Corporation INCY , Anika Therapeutics ANIK and Arbutus Biopharma Corporation ABUS . Arbutus sports a Zacks Rank #1 (Strong Buy), while Incyte and Anika carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Incyte's earnings estimates increased from 20 cents to 68 cents for 2016 and from $1.42 to $1.68 for 2017 over the last 60 days. The company posted a positive average beat of 431.43% over the last four quarters.
Anika's earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company has posted positive surprises in the four trailing quarters with an average beat of 33.14%. Its share price has gained 21% year to date.
Arbutus's loss estimates narrowed from $2.15 to $1.74 for 2016 and from $1.96 to $1.51 for 2017 over the last 60 days. The company posted positive surprises thrice in the four trailing quarters with an average beat of 59.31%.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
INCYTE CORP (INCY): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | NOVO-NORDISK AS Price NOVO-NORDISK AS Price | NOVO-NORDISK AS Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Incyte Corporation INCY , Anika Therapeutics ANIK and Arbutus Biopharma Corporation ABUS . Click to get this free report NOVO-NORDISK AS (NVO): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Xultophy 100/3.6 is a once-daily, single injection, fixed combination of Tresiba (insulin degludec) and Victoza and can be taken at the same time each day with or without food. | NOVO-NORDISK AS Price NOVO-NORDISK AS Price | NOVO-NORDISK AS Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Incyte Corporation INCY , Anika Therapeutics ANIK and Arbutus Biopharma Corporation ABUS . Click to get this free report NOVO-NORDISK AS (NVO): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Arbutus sports a Zacks Rank #1 (Strong Buy), while Incyte and Anika carry a Zacks Rank #2 (Buy). | NOVO-NORDISK AS Price NOVO-NORDISK AS Price | NOVO-NORDISK AS Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Incyte Corporation INCY , Anika Therapeutics ANIK and Arbutus Biopharma Corporation ABUS . Click to get this free report NOVO-NORDISK AS (NVO): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Arbutus sports a Zacks Rank #1 (Strong Buy), while Incyte and Anika carry a Zacks Rank #2 (Buy). | NOVO-NORDISK AS Price NOVO-NORDISK AS Price | NOVO-NORDISK AS Quote Stocks to Consider Some better-ranked stocks in the healthcare sector include Incyte Corporation INCY , Anika Therapeutics ANIK and Arbutus Biopharma Corporation ABUS . Click to get this free report NOVO-NORDISK AS (NVO): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Novo Nordisk A/SNVO received favorable news with the FDA approving its new drug application for Xultophy 100/3.6. |
34738.0 | 2016-11-21 00:00:00 UTC | Novartis (NVS) Reports Favorable Data on Enbrel Biosimilar | ABUS | https://www.nasdaq.com/articles/novartis-nvs-reports-favorable-data-on-enbrel-biosimilar-2016-11-21 | nan | nan | Novartis AG 's NVS generic arm, Sandoz announced the publication of results from EGALITY study in the British Journal of Dermatology. The study showed that its biosimilar version of Amgen Inc.'s AMGN blockbuster drug, Enbrel, Erelzi, is equivalent to the originator product in more than 500 adult patients over 52 weeks.
Erelzi was approved by the FDA in August this year for the treatment of various inflammatory conditions including rheumatoid arthritis, plaque psoriasis and psoriatic arthritis. The biosimilar candidate is under review in the EU where the submission was accepted last year. Notably, Erelzi is still to be launched in the U.S.
EGALITY included both the switched and continuous treatment arms. Patients were treated with Erelzi and Enbrel alternatively and it was seen that no clinically meaningful difference in safety and efficacy were observed between Erelzi and the originator product over the duration of the study. In addition the three treatment switches had no impact on the safety and efficacy of the biosimilar candidate.
Sandoz currently markets Zarxio in the U.S. a biosimilar version of Amgen Inc.'s (AMGN) Neupogen. In addition, it has a strong pipeline of biosimilars including that of Roche Holding AG's RHHBY Rituxan. The company plans to launch five biosimilars for major oncology and immunology biologics across key geographies by 2020. Sandoz is well positioned in the biosimilars space based on its experience and capabilities in development, manufacturing and commercialization.
Novartis currently carries a Zacks Rank #3 (Hold).
A Stock to Consider
A better-ranked stock in the healthcare sector is Arbutus Biopharma Corporation ABUS , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Arbutus's loss estimates narrowed from $2.15 to $1.74 for 2016 and from $1.96 to $1.51 for 2017 over the last 60 days. The company posted a positive surprise thrice in the four trailing quarters with an average beat of 59.31%.
NOVARTIS AG-ADR Price
NOVARTIS AG-ADR Price | NOVARTIS AG-ADR Quote
Zacks' Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A Stock to Consider A better-ranked stock in the healthcare sector is Arbutus Biopharma Corporation ABUS , which sports a Zacks Rank #1 (Strong Buy). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis AG 's NVS generic arm, Sandoz announced the publication of results from EGALITY study in the British Journal of Dermatology. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. A Stock to Consider A better-ranked stock in the healthcare sector is Arbutus Biopharma Corporation ABUS , which sports a Zacks Rank #1 (Strong Buy). NOVARTIS AG-ADR Price NOVARTIS AG-ADR Price | NOVARTIS AG-ADR Quote Zacks' Best Private Investment Ideas In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time? | A Stock to Consider A better-ranked stock in the healthcare sector is Arbutus Biopharma Corporation ABUS , which sports a Zacks Rank #1 (Strong Buy). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. NOVARTIS AG-ADR Price NOVARTIS AG-ADR Price | NOVARTIS AG-ADR Quote Zacks' Best Private Investment Ideas In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time? | A Stock to Consider A better-ranked stock in the healthcare sector is Arbutus Biopharma Corporation ABUS , which sports a Zacks Rank #1 (Strong Buy). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. In addition the three treatment switches had no impact on the safety and efficacy of the biosimilar candidate. |
34739.0 | 2016-11-21 00:00:00 UTC | Agios Presents Data from Dose Expansion Study of AG-120 | ABUS | https://www.nasdaq.com/articles/agios-presents-data-from-dose-expansion-study-of-ag-120-2016-11-21 | nan | nan | Agios Pharmaceuticals, Inc.AGIO announced first data from a phase I study on AG-120, an oral, first-in-class IDH1 mutant inhibitor which is being evaluated as a single agent, for the treatment of isocitrate dehydrogenase-1 (IDH1) mutant positive glioma and chondrosarcoma.
The study is part of dose expansion for AG-120, and the data was presented at the Society for Neuro-Oncology (SNO) Annual Meeting in Scottsdale in the state of Arizona. Further, the chondrosarcoma data was also presented last week at the annual meeting of the Connective Tissue Oncology Society (CTOS) in Lisbon, Portugal.
The phase I study is assessing the safety and tolerability of AG-120 in advanced solid tumors, including glioma, intrahepatic cholangiocarcinoma (IHCC) and chondrosarcomas that harbor an IDH1 mutation.
Data from the study demonstrated a well-tolerated safety profile for AG-120 at a fixed daily dose of 500 mg. Both patient populations experienced prolonged stable disease.
In May 2016, Agios announced an agreement with Celgene Corporation CELG in the field of metabolic immuno-oncology. The companies also agreed to amend certain rights under their 2010 collaboration, with Agios gaining full global development and commercialization rights to AG-120. Previously, Agios had only U.S. rights to AG-120.
Agios plans to initiate a phase III study evaluating AG-120 in front-line AML patients with an IDH1 mutation in the first half of 2017. The company plans to explore a similar regulatory path for AG-120, which could lead to an NDA submission in the U.S. in 2017.
AGIOS PHARMACT Price
AGIOS PHARMACT Price | AGIOS PHARMACT Quote
Agios currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the healthcare sector include Arbutus Biopharma Corporation ABUS and Heska Corporation HSKA , both sporting a Zacks Rank #1(Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Arbutus' loss estimates narrowed from $2.15 to $1.74 for 2016 and from $1.96 to $1.51 for 2017 over the last 60 days. The company posted positive surprises in three of the trailing four quarters, with an average beat of 59.31%.
Heska's earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 over the last 60 days. The company posted positive surprises in each of the four trailing quarters, with an average beat of 301.64%. Share price surged 73.66% year to date.
Zacks' Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CELGENE CORP (CELG): Free Stock Analysis Report
HESKA CORP (HSKA): Free Stock Analysis Report
AGIOS PHARMACT (AGIO): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | A couple of better-ranked stocks in the healthcare sector include Arbutus Biopharma Corporation ABUS and Heska Corporation HSKA , both sporting a Zacks Rank #1(Strong Buy). Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report AGIOS PHARMACT (AGIO): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. The study is part of dose expansion for AG-120, and the data was presented at the Society for Neuro-Oncology (SNO) Annual Meeting in Scottsdale in the state of Arizona. | A couple of better-ranked stocks in the healthcare sector include Arbutus Biopharma Corporation ABUS and Heska Corporation HSKA , both sporting a Zacks Rank #1(Strong Buy). Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report AGIOS PHARMACT (AGIO): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. AGIOS PHARMACT Price AGIOS PHARMACT Price | AGIOS PHARMACT Quote Agios currently carries a Zacks Rank #3 (Hold). | Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report AGIOS PHARMACT (AGIO): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. A couple of better-ranked stocks in the healthcare sector include Arbutus Biopharma Corporation ABUS and Heska Corporation HSKA , both sporting a Zacks Rank #1(Strong Buy). Agios Pharmaceuticals, Inc.AGIO announced first data from a phase I study on AG-120, an oral, first-in-class IDH1 mutant inhibitor which is being evaluated as a single agent, for the treatment of isocitrate dehydrogenase-1 (IDH1) mutant positive glioma and chondrosarcoma. | A couple of better-ranked stocks in the healthcare sector include Arbutus Biopharma Corporation ABUS and Heska Corporation HSKA , both sporting a Zacks Rank #1(Strong Buy). Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report AGIOS PHARMACT (AGIO): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. AGIOS PHARMACT Price AGIOS PHARMACT Price | AGIOS PHARMACT Quote Agios currently carries a Zacks Rank #3 (Hold). |
34740.0 | 2016-11-21 00:00:00 UTC | New Strong Buy Stocks for November 21st | ABUS | https://www.nasdaq.com/articles/new-strong-buy-stocks-november-21st-2016-11-21 | nan | nan | Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Best Buy Co., Inc. (BBY): This technology products retailer has witnessed the Zacks Consensus Estimate for its current year earnings surging 7.1% over the last 30 days.
BEST BUY Price and Consensus
BEST BUY Price and Consensus | BEST BUY Quote
The Charles Schwab Corporation (SCHW): This full-service investing solution provider has seen the Zacks Consensus Estimate for its current year earnings increasing 0.4% over the last 30 days.
SCHWAB(CHAS) Price and Consensus
SCHWAB(CHAS) Price and Consensus | SCHWAB(CHAS) Quote
LHC Group, Inc. (LHCG): This post-acute continuum of care provider has witnessed the Zacks Consensus Estimate for its current year earnings improving 3.9% over the last 30 days.
LHC GROUP LLC Price and Consensus
LHC GROUP LLC Price and Consensus | LHC GROUP LLC Quote
Ocwen Financial Corp. (OCN): This financial services holding company has seen the Zacks Consensus Estimate for its current year earnings soaring 28.7% over the last 30 days.
OCWEN FINL CORP Price and Consensus
OCWEN FINL CORP Price and Consensus | OCWEN FINL CORP Quote
Arbutus Biopharma Corporation (ABUS): This biopharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings climbing 19.3% over the last 30 days.
ARBUTUS BIOPH Price and Consensus
ARBUTUS BIOPH Price and Consensus | ARBUTUS BIOPH Quote
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Confidential from Zacks
Would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to access these private picks >> .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
SCHWAB(CHAS) (SCHW): Free Stock Analysis Report
OCWEN FINL CORP (OCN): Free Stock Analysis Report
LHC GROUP LLC (LHCG): Free Stock Analysis Report
BEST BUY (BBY): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | OCWEN FINL CORP Price and Consensus OCWEN FINL CORP Price and Consensus | OCWEN FINL CORP Quote Arbutus Biopharma Corporation (ABUS): This biopharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings climbing 19.3% over the last 30 days. Click to get this free report SCHWAB(CHAS) (SCHW): Free Stock Analysis Report OCWEN FINL CORP (OCN): Free Stock Analysis Report LHC GROUP LLC (LHCG): Free Stock Analysis Report BEST BUY (BBY): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Best Buy Co., Inc. (BBY): This technology products retailer has witnessed the Zacks Consensus Estimate for its current year earnings surging 7.1% over the last 30 days. | OCWEN FINL CORP Price and Consensus OCWEN FINL CORP Price and Consensus | OCWEN FINL CORP Quote Arbutus Biopharma Corporation (ABUS): This biopharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings climbing 19.3% over the last 30 days. Click to get this free report SCHWAB(CHAS) (SCHW): Free Stock Analysis Report OCWEN FINL CORP (OCN): Free Stock Analysis Report LHC GROUP LLC (LHCG): Free Stock Analysis Report BEST BUY (BBY): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. LHC GROUP LLC Price and Consensus LHC GROUP LLC Price and Consensus | LHC GROUP LLC Quote Ocwen Financial Corp. (OCN): This financial services holding company has seen the Zacks Consensus Estimate for its current year earnings soaring 28.7% over the last 30 days. | OCWEN FINL CORP Price and Consensus OCWEN FINL CORP Price and Consensus | OCWEN FINL CORP Quote Arbutus Biopharma Corporation (ABUS): This biopharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings climbing 19.3% over the last 30 days. Click to get this free report SCHWAB(CHAS) (SCHW): Free Stock Analysis Report OCWEN FINL CORP (OCN): Free Stock Analysis Report LHC GROUP LLC (LHCG): Free Stock Analysis Report BEST BUY (BBY): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. LHC GROUP LLC Price and Consensus LHC GROUP LLC Price and Consensus | LHC GROUP LLC Quote Ocwen Financial Corp. (OCN): This financial services holding company has seen the Zacks Consensus Estimate for its current year earnings soaring 28.7% over the last 30 days. | OCWEN FINL CORP Price and Consensus OCWEN FINL CORP Price and Consensus | OCWEN FINL CORP Quote Arbutus Biopharma Corporation (ABUS): This biopharmaceutical company has witnessed the Zacks Consensus Estimate for its current year earnings climbing 19.3% over the last 30 days. Click to get this free report SCHWAB(CHAS) (SCHW): Free Stock Analysis Report OCWEN FINL CORP (OCN): Free Stock Analysis Report LHC GROUP LLC (LHCG): Free Stock Analysis Report BEST BUY (BBY): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. ARBUTUS BIOPH Price and Consensus ARBUTUS BIOPH Price and Consensus | ARBUTUS BIOPH Quote You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here . |
34741.0 | 2016-11-21 00:00:00 UTC | Apricus Biosciences Aims to Resubmit Vitaros NDA in 2017 | ABUS | https://www.nasdaq.com/articles/apricus-biosciences-aims-to-resubmit-vitaros-nda-in-2017-2016-11-21 | nan | nan | Apricus Biosciences, Inc.APRI announced that it intends to resubmit its new drug application (NDA) for its drug Vitaros in 2017.
Apricus had a Type B meeting with the FDA as previously announced to confirm its plans for addressing the deficiencies contained in the 2008 Complete Response Letter (CRL) for Vitaros.
Notably, Vitaros is already approved in Canada and certain countries in Europe, Latin America and the Middle East, and is marketed in several European countries.
The FDA suggested including additional analysis of existing clinical and non-clinical data in the re-submitted NDA and did not indicate that new clinical studies would be required for re-submission. The company intends to resubmit the NDA as soon as possible in 2017.
Importantly, according to the present regulations, the FDA determined that Vitaros should be considered a drug-device combination. Apricus was advised to meet with the Office of Product Quality to confirm the necessary compliance requirements for the NDA resubmission.
APPRICUS BIOSCI Price
APPRICUS BIOSCI Price | APPRICUS BIOSCI Quote
Apricus currently carries a Zacks Rank #2 (Buy). Some other favorably ranked stocks in the healthcare sector include Arbutus Biopharma Corporation ABUS , Heska Corporation HSKA and Anika Therapeutics Inc. ANIK . Arbutus and Heska sport a Zacks Rank #1 (Strong Buy), while Anika carries a Zacks Rank #2. You can see the complete list of today's Zacks #1 Rank stocks here .
Arbutus' loss estimates narrowed from $2.15 to $1.74 for 2016 and from $1.96 to $1.51 for 2017 over the last 60 days. The company posted positive surprises in three of the trailing four quarters, with an average beat of 59.31%.
Heska's earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 over the last 60 days. The company posted positive surprises in each of the four trailing quarters, with an average beat of 301.64%.
Anika's earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company posted positive surprises in each of the four trailing quarters, with an average beat of 33.14%.
Zacks' Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
HESKA CORP (HSKA): Free Stock Analysis Report
APPRICUS BIOSCI (APRI): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some other favorably ranked stocks in the healthcare sector include Arbutus Biopharma Corporation ABUS , Heska Corporation HSKA and Anika Therapeutics Inc. ANIK . Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report APPRICUS BIOSCI (APRI): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Apricus had a Type B meeting with the FDA as previously announced to confirm its plans for addressing the deficiencies contained in the 2008 Complete Response Letter (CRL) for Vitaros. | Some other favorably ranked stocks in the healthcare sector include Arbutus Biopharma Corporation ABUS , Heska Corporation HSKA and Anika Therapeutics Inc. ANIK . Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report APPRICUS BIOSCI (APRI): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. APPRICUS BIOSCI Price APPRICUS BIOSCI Price | APPRICUS BIOSCI Quote Apricus currently carries a Zacks Rank #2 (Buy). | Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report APPRICUS BIOSCI (APRI): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Some other favorably ranked stocks in the healthcare sector include Arbutus Biopharma Corporation ABUS , Heska Corporation HSKA and Anika Therapeutics Inc. ANIK . APPRICUS BIOSCI Price APPRICUS BIOSCI Price | APPRICUS BIOSCI Quote Apricus currently carries a Zacks Rank #2 (Buy). | Some other favorably ranked stocks in the healthcare sector include Arbutus Biopharma Corporation ABUS , Heska Corporation HSKA and Anika Therapeutics Inc. ANIK . Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report APPRICUS BIOSCI (APRI): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. You can see the complete list of today's Zacks #1 Rank stocks here . |
34742.0 | 2016-11-21 00:00:00 UTC | Arbutus Biopharma (ABUS) Enters Oversold Territory | ABUS | https://www.nasdaq.com/articles/arbutus-biopharma-abus-enters-oversold-territory-2016-11-21 | nan | nan | Arbutus Biopharma CorporationABUS has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at ABUS given that, according to its RSI reading of 25.75, it is now in oversold territory.
What is RSI?
RSI stands for 'Relative Strength Index' and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses in days that closed down; readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present.
Other Factors
Yet, ABUS's low RSI value isn't the only reason to have some optimism over a coming turnaround, as there has been plenty of positive earnings estimate revision activity as of late. This is especially true when investors take a deep dive into some of these estimate revision stats and recent changes to Arbutus Biopharma's earnings consensus.
Over the past two months, investors have seen 2 earnings estimate revisions move higher, compared with none lower, at least when looking at the key current year time frame. And the consensus estimate for ABUS has also been on an upward trend over the past 60 days, as estimates have risen from -$2.15/share two months ago to just -$1.74/share right now.
If this wasn't enough, Arbutus Biopharma also has a Zacks Rank #1 (Strong Buy)which puts it into rare company among its peers. So, given all of these factors, investors may want to consider getting in on this stock now (or holding on), as there are some favorable trends that could bubble up for this stock before long. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arbutus Biopharma CorporationABUS has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. Other Factors Yet, ABUS's low RSI value isn't the only reason to have some optimism over a coming turnaround, as there has been plenty of positive earnings estimate revision activity as of late. And for technical investors there is some hope when looking at ABUS given that, according to its RSI reading of 25.75, it is now in oversold territory. | Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Arbutus Biopharma CorporationABUS has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at ABUS given that, according to its RSI reading of 25.75, it is now in oversold territory. | Other Factors Yet, ABUS's low RSI value isn't the only reason to have some optimism over a coming turnaround, as there has been plenty of positive earnings estimate revision activity as of late. Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Arbutus Biopharma CorporationABUS has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. | Arbutus Biopharma CorporationABUS has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at ABUS given that, according to its RSI reading of 25.75, it is now in oversold territory. Other Factors Yet, ABUS's low RSI value isn't the only reason to have some optimism over a coming turnaround, as there has been plenty of positive earnings estimate revision activity as of late. |
34743.0 | 2016-11-21 00:00:00 UTC | VIVUS (VVUS) Shows Strength: Stock Adds 5.1% in Session | ABUS | https://www.nasdaq.com/articles/vivus-vvus-shows-strength%3A-stock-adds-5.1-in-session-2016-11-21 | nan | nan | VIVUS Inc.VVUS was a big mover last session, as its shares rose a little more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $1.04 to $1.17 in the past one-month time frame.
Over the last 30 days, the company witnessed one positive estimate revision and the Zacks Consensus Estimate also moved higher, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday's jump can turn into more strength down the road.
VIVUS currently carries a Zacks Rank #2 (Buy).
VIVUS INC Price
VIVUS INC Price | VIVUS INC Quote
A similarly ranked stock in the biotechnology space is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Is VVUS going up? Or down? Predict to see what others think: Up or Down
Zacks' Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
VIVUS INC (VVUS): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | VIVUS INC Price VIVUS INC Price | VIVUS INC Quote A similarly ranked stock in the biotechnology space is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report VIVUS INC (VVUS): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $1.04 to $1.17 in the past one-month time frame. | Click to get this free report VIVUS INC (VVUS): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. VIVUS INC Price VIVUS INC Price | VIVUS INC Quote A similarly ranked stock in the biotechnology space is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click here for Zacks' private trades >> Want the latest recommendations from Zacks Investment Research? | VIVUS INC Price VIVUS INC Price | VIVUS INC Quote A similarly ranked stock in the biotechnology space is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report VIVUS INC (VVUS): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | VIVUS INC Price VIVUS INC Price | VIVUS INC Quote A similarly ranked stock in the biotechnology space is Arbutus Biopharma Corporation ABUS , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report VIVUS INC (VVUS): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. |
34744.0 | 2016-11-14 00:00:00 UTC | Lily's Jardiance Effective in Lowering Cardiovascular Death | ABUS | https://www.nasdaq.com/articles/lilys-jardiance-effective-in-lowering-cardiovascular-death-2016-11-14 | nan | nan | Eli Lilly and CompanyLLY announced that new data presented at the American Heart Association Scientific Sessions 2016 from long-term cardiovascular (CV) outcomes study of its diabetes medicine Jardiance showed that the drug was effective in reducing the risk for cardiovascular death.
The results, which are part of the landmark EMPA-REG OUTCOME trial, showed that irrespective of the type of cardiovascular disease at baseline, Jardiance tablets reduced the risk of cardiovascular death in adults with type II diabetes and established cardiovascular disease compared to placebo when added to standard of care.
Cardiovascular disease is very common in adults with type II diabetes. Approximately two out of three deaths in people with type II diabetes in the U.S. are caused by cardiovascular diseases. These include a number of different vascular outcomes like heart attack, heart failure, peripheral vascular disease and stroke.
EMPA-REG OUTCOME trial was carried out on more than 7,000 patients, from 42 countries, with type II diabetes and cardiovascular disease. It is regarded as the first long-term trial of a diabetes medication to show a reduction in cardiovascular death in adults with type II diabetes and established cardiovascular disease. This study is supported by Boehringer Ingelheim, a leading research-driven pharmaceutical company and Lilly.
Lilly and partner Boehringer Ingelheim are currently seeking FDA approval for the addition of cardiovascular (CV) risk reduction data from the EMPA-REG OUTCOME study on Jardiance. In June. The FDA's Endocrinologic and Metabolic Drugs Advisory Committee met to review the data and voted 12-11 that enough evidence exists to establish that Jardiance reduces CV death in adults with type 2 diabetes and established CV disease. An FDA decision is expected in early December.
The addition of this data to Jardiance's label can lead to a major surge in sales.
Last month the company reported its third-quarter 2016 results wherein Jardiance sales were reported to be $47.5 million up from $15.4 reported in the year ago quarter.
Other than Jardiance, Lilly's diabetes portfolio includes other newly launched drugs like Tradjenta, Trulicity, Synjardy and Glyxambi which is a fixed dose combination of Jardiance/metformin. Lately, these drugs have been driving the company's topline growth.
LILLY ELI & CO Price
LILLY ELI & CO Price | LILLY ELI & CO Quote
Lilly currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Arbutus Biopharma Corp. ABUS , Heska Corp. HSKA and Anika Therapeutics Inc. ANIK . Anika and Heska sports a Zacks Rank #1 (Strong Buy) while Arbutus carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Arbutus' loss estimates narrowed from $2.15 to $1.80 for 2016 and from $1.96 to $1.53 for 2017 over the last 60 days. The company posted positive surprises in three of the trailing four quarters with an average beat of 59.31%.
Heska's earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 over the last 60 days. The company posted positive surprises in all of the four trailing quarters with an average beat of 301.64%.
Anika's earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company posted positive surprises in all of the four trailing quarters with an average beat of 33.14%.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
LILLY ELI & CO (LLY): Free Stock Analysis Report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
HESKA CORP (HSKA): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the healthcare sector include Arbutus Biopharma Corp. ABUS , Heska Corp. HSKA and Anika Therapeutics Inc. ANIK . Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Lilly and partner Boehringer Ingelheim are currently seeking FDA approval for the addition of cardiovascular (CV) risk reduction data from the EMPA-REG OUTCOME study on Jardiance. | Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector include Arbutus Biopharma Corp. ABUS , Heska Corp. HSKA and Anika Therapeutics Inc. ANIK . The results, which are part of the landmark EMPA-REG OUTCOME trial, showed that irrespective of the type of cardiovascular disease at baseline, Jardiance tablets reduced the risk of cardiovascular death in adults with type II diabetes and established cardiovascular disease compared to placebo when added to standard of care. | Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector include Arbutus Biopharma Corp. ABUS , Heska Corp. HSKA and Anika Therapeutics Inc. ANIK . Eli Lilly and CompanyLLY announced that new data presented at the American Heart Association Scientific Sessions 2016 from long-term cardiovascular (CV) outcomes study of its diabetes medicine Jardiance showed that the drug was effective in reducing the risk for cardiovascular death. | Some better-ranked stocks in the healthcare sector include Arbutus Biopharma Corp. ABUS , Heska Corp. HSKA and Anika Therapeutics Inc. ANIK . Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Eli Lilly and CompanyLLY announced that new data presented at the American Heart Association Scientific Sessions 2016 from long-term cardiovascular (CV) outcomes study of its diabetes medicine Jardiance showed that the drug was effective in reducing the risk for cardiovascular death. |
34745.0 | 2016-11-11 00:00:00 UTC | Intrexon (XON) Reports In-Line Loss in Q3, Revenues Miss | ABUS | https://www.nasdaq.com/articles/intrexon-xon-reports-in-line-loss-in-q3-revenues-miss-2016-11-11 | nan | nan | Shares of Intrexon CorporationXON have risen more than 4% since it announced its third quarter results.
Intrexon reported a loss of 24 cents per share in third-quarter 2016, which was in line with the Zacks Consensus Estimate.
However, adjusted loss per share was 17 cents compared to 4 cents in the prior year quarter. Adjusted loss excudes among other items, shares issued as compensation for services, bad debt expense and noncash research and development expenses related to the acquisition of Intrexon's license agreement with the University of Texas MD Anderson Cancer Center.
Total revenue came in at $48.9 million in the quarter, down 8.2% year over year. The decline was driven mostly by a drop in product and service sales from Trans Ova subsidiary. Reported revenues were, however, slightly below the Zacks Consensus Estimate of $50 million.
Quarter in Detail
Intrexon's revenues primarily consist of collaboration and licensing revenues as well as product revenues and service revenues.
Collaboration and licensing revenues declined 11.9% to $30.6 million.
Product revenues came in at $9.2 million, down 2% from the year-ago period. Service revenues came in at $8.7 million, down 2.8% year over year.
R&D expenses increased 34% to $29 million due to higher personnel costs, along with rise in lab supplies and consulting expenses. Selling, general and administrative expenses escalated 47% to $33.8 million.
Intrexon follows a business model under which it commercializes its technologies through exclusive channel collaborations (ECC), licensing agreements and joint ventures with collaborators that have market and product development expertise, as well as sales and marketing capabilities to bring new and improved products and processes to market. Such agreements provide the company with funds in the form of technology access fees, and milestones and other payments.
Moreover, Intrexon has been very active on striking new ECCs and expanding its partnership with the existing ones. In Sep 2016, the company entered into an ECC with two startup companies - Genten Therapeutics, Inc. and CRS Bio, Inc.
Intrexon is also developing several candidates in partnership with other companies.
Meanwhile, the company is working with both governmental and non-governmental organizations for the potential use of Oxitec's OX513A to reduce or eradicate populations of the Aedes aegypti mosquito, the primary vector for dengue, chikungunya and the Zika virus.
We expect investor focus to remain on further developmental updates by the company.
INTREXON CORP Price, Consensus and EPS Surprise
INTREXON CORP Price, Consensus and EPS Surprise | INTREXON CORP Quote
Intrexon is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the healthcare sector include Arbutus Biopharma Corp. ABUS , Heska Corp. HSKA and Anika Therapeutics Inc. ANIK . Each of the stocks sports a Zacks Rank #1(Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Arbutus' loss estimates narrowed from $2.15 to $1.80 for 2016 and from $1.96 to $1.53 for 2017 over the last 60 days. The company posted positive surprises in three of the trailing four quarters with an average beat of 59.31%.
Heska's earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 over the last 60 days. The company posted positive surprises in all of the four trailing quarters with an average beat of 301.64%.
Anika's earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company posted positive surprises in all of the four trailing quarters with an average beat of 33.14%.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
HESKA CORP (HSKA): Free Stock Analysis Report
INTREXON CORP (XON): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the healthcare sector include Arbutus Biopharma Corp. ABUS , Heska Corp. HSKA and Anika Therapeutics Inc. ANIK . Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report INTREXON CORP (XON): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Adjusted loss excudes among other items, shares issued as compensation for services, bad debt expense and noncash research and development expenses related to the acquisition of Intrexon's license agreement with the University of Texas MD Anderson Cancer Center. | Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report INTREXON CORP (XON): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector include Arbutus Biopharma Corp. ABUS , Heska Corp. HSKA and Anika Therapeutics Inc. ANIK . INTREXON CORP Price, Consensus and EPS Surprise INTREXON CORP Price, Consensus and EPS Surprise | INTREXON CORP Quote Intrexon is a Zacks Rank #3 (Hold) stock. | Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report INTREXON CORP (XON): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the healthcare sector include Arbutus Biopharma Corp. ABUS , Heska Corp. HSKA and Anika Therapeutics Inc. ANIK . Quarter in Detail Intrexon's revenues primarily consist of collaboration and licensing revenues as well as product revenues and service revenues. | Some better-ranked stocks in the healthcare sector include Arbutus Biopharma Corp. ABUS , Heska Corp. HSKA and Anika Therapeutics Inc. ANIK . Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report INTREXON CORP (XON): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Intrexon reported a loss of 24 cents per share in third-quarter 2016, which was in line with the Zacks Consensus Estimate. |
34746.0 | 2016-11-10 00:00:00 UTC | Puma (PBYI) Posts Wider Loss in Q3, Neratinib in Focus | ABUS | https://www.nasdaq.com/articles/puma-pbyi-posts-wider-loss-in-q3-neratinib-in-focus-2016-11-10 | nan | nan | Puma Biotechnology, Inc . PBYI reported a third-quarter 2016 loss of $2.02 per share (including the impact of stock-based compensation expense), wider than the Zacks Consensus Estimate of a loss of $2.00 and the year-ago loss of $1.87.
With no approved products in Puma Biotech's portfolio at the moment, the company does not generate revenues yet.
In the third quarter, research and development (R&D) expenses were $52 million, up 0.2% from the year-ago quarter. General and administrative expenses were up by 59.1% year over year to $14 million.
Focus on Neratinib
During the quarter, Puma Biotech made significant progress with its lead candidate, neratinib. While the European Medicines Agency's validated the company's marketing authorization application for neratinib for the extended adjuvant treatment of HER2-positive early stage breast cancer, the FDA accepted the new drug application for the candidate for the extended adjuvant treatment of patients with early-stage HER2-overexpressed/amplified breast cancer who have been previously treated with Herceptin-based adjuvant therapy.
Several phase II studies evaluating neratinib for the treatment of breast cancer are currently underway.
The company anticipates several milestones in the current quarter and in the first half of 2017. It plans to report additional data from the phase II study on neratinib as an extended adjuvant treatment of HER2-positive early-stage breast cancer using loperamide and budesonide prophylaxis in the current quarter.
Further, the company expects to report data from the phase III study on neratinib for the third-line HER2-positive metastatic breast cancer patients in the first half of 2017.
Given that Puma Biotech has no approved products in its portfolio at the moment and neratinib is its lead candidate, we expect investor focus to remain on updates pertaining to its development.
PUMA BIOTECHNLG Price, Consensus and EPS Surprise
PUMA BIOTECHNLG Price, Consensus and EPS Surprise | PUMA BIOTECHNLG Quote
Zacks Rank & Stocks to Consider
Puma Biotech is a Zacks Rank #2 (Buy) stock. Other favorably ranked stocks in the healthcare sector include Arbutus Biopharma Corporation ABUS , Heska Corporation HSKA and Anika Therapeutics Inc. ANIK . Each of the stocks sports a Zacks Rank #1(Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Arbutus' loss estimates narrowed from $2.15 to $1.80 for 2016 and from $1.96 to $1.53 for 2017 over the last 60 days. The company posted positive surprises in three of the trailing four quarters with an average beat of 59.31%.
Heska's earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 over the last 60 days. The company posted positive surprises in all of the four trailing quarters with an average beat of 301.64%.
Anika's earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company posted positive surprises in all of the four trailing quarters with an average beat of 33.14%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks - absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
HESKA CORP (HSKA): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
PUMA BIOTECHNLG (PBYI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Other favorably ranked stocks in the healthcare sector include Arbutus Biopharma Corporation ABUS , Heska Corporation HSKA and Anika Therapeutics Inc. ANIK . Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report PUMA BIOTECHNLG (PBYI): Free Stock Analysis Report To read this article on Zacks.com click here. It plans to report additional data from the phase II study on neratinib as an extended adjuvant treatment of HER2-positive early-stage breast cancer using loperamide and budesonide prophylaxis in the current quarter. | Other favorably ranked stocks in the healthcare sector include Arbutus Biopharma Corporation ABUS , Heska Corporation HSKA and Anika Therapeutics Inc. ANIK . Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report PUMA BIOTECHNLG (PBYI): Free Stock Analysis Report To read this article on Zacks.com click here. PUMA BIOTECHNLG Price, Consensus and EPS Surprise PUMA BIOTECHNLG Price, Consensus and EPS Surprise | PUMA BIOTECHNLG Quote Zacks Rank & Stocks to Consider Puma Biotech is a Zacks Rank #2 (Buy) stock. | Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report PUMA BIOTECHNLG (PBYI): Free Stock Analysis Report To read this article on Zacks.com click here. Other favorably ranked stocks in the healthcare sector include Arbutus Biopharma Corporation ABUS , Heska Corporation HSKA and Anika Therapeutics Inc. ANIK . While the European Medicines Agency's validated the company's marketing authorization application for neratinib for the extended adjuvant treatment of HER2-positive early stage breast cancer, the FDA accepted the new drug application for the candidate for the extended adjuvant treatment of patients with early-stage HER2-overexpressed/amplified breast cancer who have been previously treated with Herceptin-based adjuvant therapy. | Other favorably ranked stocks in the healthcare sector include Arbutus Biopharma Corporation ABUS , Heska Corporation HSKA and Anika Therapeutics Inc. ANIK . Click to get this free report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report PUMA BIOTECHNLG (PBYI): Free Stock Analysis Report To read this article on Zacks.com click here. In the third quarter, research and development (R&D) expenses were $52 million, up 0.2% from the year-ago quarter. |
34747.0 | 2016-11-09 00:00:00 UTC | Why Arbutus Biopharma (ABUS) Stock Might be a Great Pick | ABUS | https://www.nasdaq.com/articles/why-arbutus-biopharma-abus-stock-might-be-a-great-pick-2016-11-09 | nan | nan | One stock that might be an intriguing choice for investors right now is Arbutus Biopharma CorporationABUS . This is because this security in the Medical-Biomedical/Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical-Biomedical/Genetics space as it currently has a Zacks Industry Rank of 75 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.
Meanwhile, Arbutus Biopharma is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm's prospects in both the short and long term.
ARBUTUS BIOPH Price and Consensus
ARBUTUS BIOPH Price and Consensus | ARBUTUS BIOPH Quote
In fact, over the past month, current quarter estimates have narrowed from a loss of 50 cents per share to a loss of 36 cents per share, while current year estimates have narrowed from a loss of $2.15 per share to $1.80 per share. This has helped ABUS to earn a Zacks Rank #1 (Strong Buy), further underscoring the company's solid position.You can see the complete list of today's Zacks #1 Rank stocks here .
So, if you are looking for a decent pick in a strong industry, consider Arbutus Biopharma. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.
Zacks' Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One stock that might be an intriguing choice for investors right now is Arbutus Biopharma CorporationABUS . This has helped ABUS to earn a Zacks Rank #1 (Strong Buy), further underscoring the company's solid position.You can see the complete list of today's Zacks #1 Rank stocks here . Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. | Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. One stock that might be an intriguing choice for investors right now is Arbutus Biopharma CorporationABUS . This has helped ABUS to earn a Zacks Rank #1 (Strong Buy), further underscoring the company's solid position.You can see the complete list of today's Zacks #1 Rank stocks here . | This has helped ABUS to earn a Zacks Rank #1 (Strong Buy), further underscoring the company's solid position.You can see the complete list of today's Zacks #1 Rank stocks here . One stock that might be an intriguing choice for investors right now is Arbutus Biopharma CorporationABUS . Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. | This has helped ABUS to earn a Zacks Rank #1 (Strong Buy), further underscoring the company's solid position.You can see the complete list of today's Zacks #1 Rank stocks here . One stock that might be an intriguing choice for investors right now is Arbutus Biopharma CorporationABUS . Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. |
34748.0 | 2016-08-12 00:00:00 UTC | Should You Get Rid of Arbutus Biopharma (ABUS) Now? | ABUS | https://www.nasdaq.com/articles/should-you-get-rid-of-arbutus-biopharma-abus-now-2016-08-12 | nan | nan | Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is Arbutus Biopharma CorporationABUS , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in ABUS.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 1 estimate moving down in the past 30 days, compared with no upward revisions. This trend has caused the consensus estimate to trend lower, going from a loss of $1.46 a share a month ago to its current level of a loss of $1.86.
Also, for the current quarter, Arbutus Biopharma has seen 1 downward estimate revision versus no revisions in the opposite direction, dragging the consensus estimate down to a loss of 57 cents a share from a loss of 39 cents over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 10.8% in the past month.
ARBUTUS BIOPH Price and Consensus
ARBUTUS BIOPH Price and Consensus | ARBUTUS BIOPH Quote
So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don't have a long time horizon to wait.
If you are still interested in the Medical-Biomedical/Genetics industry, you may instead consider a better-ranked stock - Cambrex Corporation (CBM). The stock currently holds a Zacks Rank #1 (Strong Buy) and may be a better selection at this time.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One such stock that you may want to consider dropping is Arbutus Biopharma CorporationABUS , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in ABUS. Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. | One such stock that you may want to consider dropping is Arbutus Biopharma CorporationABUS , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. A Zacks Rank #4 (Sell) further confirms weakness in ABUS. | One such stock that you may want to consider dropping is Arbutus Biopharma CorporationABUS , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in ABUS. Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. | One such stock that you may want to consider dropping is Arbutus Biopharma CorporationABUS , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in ABUS. Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. |
34749.0 | 2016-07-17 00:00:00 UTC | Andreas Halvorsen's Largest 2nd Quarter Buys | ABUS | https://www.nasdaq.com/articles/andreas-halvorsens-largest-2nd-quarter-buys-2016-07-17 | nan | nan | Andreas Halvorsen ( Trades , Portfolio ) is a founding partner of Viking Global Investors LP and currently serves as its CIO. During the second quarter, he traded the following stocks according to GuruFocus Real-Time updates.
The guru bought 75,000,000 shares in Axovant Sciences Ltd . ( AXON ) with an impact of 4.14% on the portfolio.
The company is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders.
During the last quarter it reported successful completion of a drug-drug interaction study of intepirdine (formerly RVT-101) with memantine and strong balance sheet with $276.3 million of cash to support the company's current development plans.
GuruFocus gives the stock a profitability and growth rating of 2 out of 10. Financial strength has a rating of 4 out of 10 with no debt.
Another notable shareholder among the gurus is PRIMECAP Management ( Trades , Portfolio ) with 0.77% of outstanding shares.
Halvorsen bought 16,013,540 shares in Arbutus Biopharma Corp. ( ABUS ) with an impact of 0.27% on the portfolio.
The company is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.
The non-GAAP net loss for first quarter 2016 was $9.9 million (19 cent loss per common share) and net loss was $15.9 million (31 cents basic and diluted loss per common share).
GuruFocus gives the stock a profitability and growth rating of 2 out of 10. Financial strength has a rating of 6 out of 10 with no debt.
PRIMECAP Management ( Trades , Portfolio ) is another notable shareholder of the company among the gurus with 7.05% of outstanding shares, followed by Jim Simons ( Trades , Portfolio ) with 0.51%.
Halvorsen increased his stake in Calpine Corp . ( CPN ) by 95.75% with an impact of 0.62% on the portfolio.
The company is a wholesale power producer. The company owns and operates natural gas-fired and geothermal power plants in North America. It sells wholesale power, steam, capacity and ancillary services to utilities, independent electric system operators.
First quarter operating revenues decreased 1.9% from the same quarter of a year before and adjusted EBITDA grew 10.7%.
GuruFocus gives the stock a profitability and growth rating of 7 out of 10 with ROE of 1.54% and ROA of 0.26% that are underperforming 62% of the companies in the Global Utilities - Independent Power Producers industry. Financial strength has a rating of 3 out of 10, with cash to debt of 0.02 that is below industry median of 0.19.
The largest shareholder among the gurus is HOTCHKIS & WILEY with 10.8% of outstanding shares, followed by Andreas Halvorsen ( Trades , Portfolio ) with 5.72%, RS Investment Management ( Trades , Portfolio ) with 0.81%, Jim Simons ( Trades , Portfolio ) with 0.72%, Joel Greenblatt ( Trades , Portfolio ) with 0.2% and Robert Bruce ( Trades , Portfolio ) with 0.08%.
About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Halvorsen bought 16,013,540 shares in Arbutus Biopharma Corp. ( ABUS ) with an impact of 0.27% on the portfolio. During the last quarter it reported successful completion of a drug-drug interaction study of intepirdine (formerly RVT-101) with memantine and strong balance sheet with $276.3 million of cash to support the company's current development plans. The company is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection. | Halvorsen bought 16,013,540 shares in Arbutus Biopharma Corp. ( ABUS ) with an impact of 0.27% on the portfolio. The non-GAAP net loss for first quarter 2016 was $9.9 million (19 cent loss per common share) and net loss was $15.9 million (31 cents basic and diluted loss per common share). PRIMECAP Management ( Trades , Portfolio ) is another notable shareholder of the company among the gurus with 7.05% of outstanding shares, followed by Jim Simons ( Trades , Portfolio ) with 0.51%. | Halvorsen bought 16,013,540 shares in Arbutus Biopharma Corp. ( ABUS ) with an impact of 0.27% on the portfolio. PRIMECAP Management ( Trades , Portfolio ) is another notable shareholder of the company among the gurus with 7.05% of outstanding shares, followed by Jim Simons ( Trades , Portfolio ) with 0.51%. GuruFocus gives the stock a profitability and growth rating of 7 out of 10 with ROE of 1.54% and ROA of 0.26% that are underperforming 62% of the companies in the Global Utilities - Independent Power Producers industry. | Halvorsen bought 16,013,540 shares in Arbutus Biopharma Corp. ( ABUS ) with an impact of 0.27% on the portfolio. GuruFocus gives the stock a profitability and growth rating of 2 out of 10. |
34750.0 | 2016-07-15 00:00:00 UTC | Halvorsen Funds Company Buying Neglected Drugs, Gets Stakes in 2 Biotechs | ABUS | https://www.nasdaq.com/articles/halvorsen-funds-company-buying-neglected-drugs-gets-stakes-2-biotechs-2016-07-15 | nan | nan | Andreas Halvorsen ( Trades , Portfolio )AAAs Viking Global Investors said Wednesday it had invested in one of biotechAAAs hottest companies and in the process two of the companies it is involved in.
Roivant Sciences, a company dedicated to promoting forgotten or waylaid drugs, disclosed HalvorsenAAAs financial backing in an announcement that MIT Professor Andrew Lo, Ph.D., would join the board as an independent director. AAAThe appointment follows the closing of RoivantAAAs financing led by Viking Global Investors,AAA the release said.
Warning! GuruFocus has detected 6 Warning Signs with HLF. Click here to check it out.
HLF 15-Year Financial Data
The intrinsic value of HLF
Peter Lynch Chart of HLF
Warning! GuruFocus has detected 6 Warning Signs with HLF. Click here to check it out.
NKE 15-Year Financial Data
The intrinsic value of NKE
Peter Lynch Chart of NKE
Warning! GuruFocus has detected 4 Warning Signs with FBP. Click here to check it out.
FBP 15-Year Financial Data
The intrinsic value of FBP
Peter Lynch Chart of FBP
Warning! GuruFocus has detected 8 Warning Sign with PEP. Click here to check it out.
PEP 15-Year Financial Data
The intrinsic value of PEP
Peter Lynch Chart of PEP
Warning! GuruFocus has detected 9 Warning Signs with GSK. Click here to check it out.
GSK 15-Year Financial Data
The intrinsic value of GSK
Peter Lynch Chart of GSK
Roivant is a private company founded by former hedge fund manager Vivek Ramaswamy. Last year, he led the biggest biotech IPO in U.S. history at the age of 29, raising $360 million launching RoivantAAAs first creation, Axovant ( AXON ). The new company had acquired and started to develop a nearly abandoned AlzheimerAAAs drug from GlaxoSmithKline ( GSK ).
RamaswamyAAAs goal is to gather a pipeline of drugs through partnerships with other medical institutions and develop them faster and cheaper than other companies. RoivantAAAs pipeline contains drugs in various stages of development.
In addition to Axovant, Ramaswamy has been founding many other companies. Most recently, he also paired with JapanAAAs Takeda Pharmaceutical (TYO:4502) in June to launch Myovant, a biopharma focused on therapies for uterine fibroids, endometriosis and prostate cancer. A month later, he partnered with Plexcerta Therapeutics to form Enzyvant Sciences to develop treatments for Farber disease.
Halvorsen, a Norwegian citizen whose massive hedge fund manages $30 billion in capital, began backing Roivant in December though he has not disclosed the amount he has invested. According to SEC filings, the appointment of Andrew Lo on July 8 gave Viking the right to override certain board decisions if it voted unanimously with two other major shareholders. Because of its right to influence decisions about RoivantAAAs direct ownership of shares in its other companies, Viking reported the shares to the SEC.
AAAThe filing of this statement shall not be deemed an admission that the Reporting Persons are, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owners of any securities covered by this statement,AAA the filing said.
The filing referred to two stakes in particular. Roivant owns 75 million common shares of Axovant Sciences, or 75.6% of the company. AxovantAAAs shares have fallen 18% from their IPO price of $15 and trade around $12.38 Thursday.
Second, Roivant owns 16,013,540 shares, or 29.3%, of Arbutus Biopharma Corp. ( ABUS ), which is pursuing a cure for hepatitis B. Roivant acquired most of the shares on March 25, 2015.
Arbutus formed when Tekmira Pharmaceuticals merged with OnCore Biopharma in March and flipped its specialization from Ebola to hepatitis. The company has eight treatments in development as it expects a cure to result from a combination of products. Its share price declined 9% year to date and closed at $4.05 on Thursday.
See Andreas Halvorsen (Trades, Portfolio)AAAs Viking Global Investors portfolio here. Start afree 7-day trial of Premium Membershipto GuruFocus.
About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Second, Roivant owns 16,013,540 shares, or 29.3%, of Arbutus Biopharma Corp. ( ABUS ), which is pursuing a cure for hepatitis B. Roivant acquired most of the shares on March 25, 2015. Roivant Sciences, a company dedicated to promoting forgotten or waylaid drugs, disclosed HalvorsenAAAs financial backing in an announcement that MIT Professor Andrew Lo, Ph.D., would join the board as an independent director. Most recently, he also paired with JapanAAAs Takeda Pharmaceutical (TYO:4502) in June to launch Myovant, a biopharma focused on therapies for uterine fibroids, endometriosis and prostate cancer. | Second, Roivant owns 16,013,540 shares, or 29.3%, of Arbutus Biopharma Corp. ( ABUS ), which is pursuing a cure for hepatitis B. Roivant acquired most of the shares on March 25, 2015. Andreas Halvorsen ( Trades , Portfolio )AAAs Viking Global Investors said Wednesday it had invested in one of biotechAAAs hottest companies and in the process two of the companies it is involved in. GSK 15-Year Financial Data The intrinsic value of GSK Peter Lynch Chart of GSK Roivant is a private company founded by former hedge fund manager Vivek Ramaswamy. | Second, Roivant owns 16,013,540 shares, or 29.3%, of Arbutus Biopharma Corp. ( ABUS ), which is pursuing a cure for hepatitis B. Roivant acquired most of the shares on March 25, 2015. Andreas Halvorsen ( Trades , Portfolio )AAAs Viking Global Investors said Wednesday it had invested in one of biotechAAAs hottest companies and in the process two of the companies it is involved in. GSK 15-Year Financial Data The intrinsic value of GSK Peter Lynch Chart of GSK Roivant is a private company founded by former hedge fund manager Vivek Ramaswamy. | Second, Roivant owns 16,013,540 shares, or 29.3%, of Arbutus Biopharma Corp. ( ABUS ), which is pursuing a cure for hepatitis B. Roivant acquired most of the shares on March 25, 2015. AAAThe appointment follows the closing of RoivantAAAs financing led by Viking Global Investors,AAA the release said. The new company had acquired and started to develop a nearly abandoned AlzheimerAAAs drug from GlaxoSmithKline ( GSK ). |
34751.0 | 2016-04-11 00:00:00 UTC | Will Arbutus Biopharma (ABUS) Continue to Surge Higher? | ABUS | https://www.nasdaq.com/articles/will-arbutus-biopharma-abus-continue-to-surge-higher-2016-04-11 | nan | nan | As of late, it has definitely been a great time to be an investor in Arbutus Biopharma CorporationABUS . The stock has moved higher by 35% in the past month, while it is also above its 20 Day SMA. This combination of strong price performance and favorable technicals suggest that the stock may be on the right path.
We certainly think so, particularly if you consider ABUS's recent earnings estimate revision activity. From this look, the company's future is quite favorable; as ABUS has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn't the top for the in-focus company.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | From this look, the company's future is quite favorable; as ABUS has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn't the top for the in-focus company. As of late, it has definitely been a great time to be an investor in Arbutus Biopharma CorporationABUS . We certainly think so, particularly if you consider ABUS's recent earnings estimate revision activity. | Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. As of late, it has definitely been a great time to be an investor in Arbutus Biopharma CorporationABUS . We certainly think so, particularly if you consider ABUS's recent earnings estimate revision activity. | From this look, the company's future is quite favorable; as ABUS has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn't the top for the in-focus company. Click to get this free report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. As of late, it has definitely been a great time to be an investor in Arbutus Biopharma CorporationABUS . | As of late, it has definitely been a great time to be an investor in Arbutus Biopharma CorporationABUS . We certainly think so, particularly if you consider ABUS's recent earnings estimate revision activity. From this look, the company's future is quite favorable; as ABUS has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn't the top for the in-focus company. |
34752.0 | 2016-04-11 00:00:00 UTC | DaVita to Acquire Mountain View, Expand Footprint in Colorado | ABUS | https://www.nasdaq.com/articles/davita-to-acquire-mountain-view-expand-footprint-in-colorado-2016-04-11 | nan | nan | DaVita HealthCare Partners Inc.DVA intends to acquire Mountain View Medical Group to enhance its kidney care services and extend footprint in Colorado Springs. Financial details of the deal remained undisclosed.
Per the proposal, Mountain View will be joining the acquirer's HealthCare Partners division. The deal is expected to culminate in Jul 2016.
Mountain View is the second-largest physician group in Colorado Springs. The company operates independently and provides services such as family medicine, internal medicine, neurology and pediatrics to name a few. Mountain View caters to more than 80,000 patients through 14 medical office locations.
Joining forces with DaVita HealthCare will help Mountain View to improve the health and lives of its patients as well as their families. In addition, Mountain View aims to become the most preferred healthcare provider for Colorado's Pikes Peak region. Armed with DaVita's capabilities, the company has taken a step forward toward its goal.
Mountain View's superior clinical performance and solid reputation in the Pikes Peak region will enable the acquirer to boost its services and expand its operations in Colorado.
The company regularly undertakes strategic acquisitions to enhance its growth profile. To that end, in Sep 2015, the acquirer announced its intention to acquire Seattle-based The Everett Clinic to boost its healthcare delivery. The transaction was closed in Mar 1, 2016.
Zacks Rank and Stocks to Consider
Currently DaVita HealthCare carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the medical sector include Almost Family Inc. AFAM , Amedisys Inc. AMED and Arbutus Biopharma Corporation ABUS . Each of these stocks holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AMEDISYS INC (AMED): Free Stock Analysis Report
DAVITA HEALTHCR (DVA): Free Stock Analysis Report
ALMOST FAMILY (AFAM): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the medical sector include Almost Family Inc. AFAM , Amedisys Inc. AMED and Arbutus Biopharma Corporation ABUS . Click to get this free report AMEDISYS INC (AMED): Free Stock Analysis Report DAVITA HEALTHCR (DVA): Free Stock Analysis Report ALMOST FAMILY (AFAM): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. DaVita HealthCare Partners Inc.DVA intends to acquire Mountain View Medical Group to enhance its kidney care services and extend footprint in Colorado Springs. | Click to get this free report AMEDISYS INC (AMED): Free Stock Analysis Report DAVITA HEALTHCR (DVA): Free Stock Analysis Report ALMOST FAMILY (AFAM): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the medical sector include Almost Family Inc. AFAM , Amedisys Inc. AMED and Arbutus Biopharma Corporation ABUS . DaVita HealthCare Partners Inc.DVA intends to acquire Mountain View Medical Group to enhance its kidney care services and extend footprint in Colorado Springs. | Click to get this free report AMEDISYS INC (AMED): Free Stock Analysis Report DAVITA HEALTHCR (DVA): Free Stock Analysis Report ALMOST FAMILY (AFAM): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the medical sector include Almost Family Inc. AFAM , Amedisys Inc. AMED and Arbutus Biopharma Corporation ABUS . DaVita HealthCare Partners Inc.DVA intends to acquire Mountain View Medical Group to enhance its kidney care services and extend footprint in Colorado Springs. | Some better-ranked stocks in the medical sector include Almost Family Inc. AFAM , Amedisys Inc. AMED and Arbutus Biopharma Corporation ABUS . Click to get this free report AMEDISYS INC (AMED): Free Stock Analysis Report DAVITA HEALTHCR (DVA): Free Stock Analysis Report ALMOST FAMILY (AFAM): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. DaVita HealthCare Partners Inc.DVA intends to acquire Mountain View Medical Group to enhance its kidney care services and extend footprint in Colorado Springs. |
34753.0 | 2016-04-02 00:00:00 UTC | Ebola Can Teach Investors an Important Lesson About Economic Viability | ABUS | https://www.nasdaq.com/articles/ebola-can-teach-investors-important-lesson-about-economic-viability-2016-04-02 | nan | nan | Image source: Flickr user UNMEER.
It's been a little more than two years since the fear of an Ebola pandemic gripped the world, but according to the World Health Organization the Ebola virus is no longer considered an international public threat. This represents the true testament of cross-border cooperation since the disease primary focused on underdeveloped countries in West Africa such as Guinea, Liberia, and Sierra Leone.
In total, 28,646 cases of Ebola have been reported through March 27, 2016, leading to 11,323 deaths. This 40% mortality rate is one aspect of what made the disease so incredibly scary.
The other component of Ebola that was worrisome was its potentially long incubation period. Although the disease could only be spread when someone with the Ebola virus was actively feverish, the virus itself could incubate within a person and not show signs of activation until two to 21 days after infection. This made quarantining potential Ebola candidates extremely difficult in West Africa.
Ebola's mixed clinical results
Of course, the most glaring deficiency of all could be that no Ebola cure currently exists. At the height of the Ebola scare more than a dozen drug developers took to their labs to develop an Ebola vaccine that would hopefully cure the disease. Some unfortunately fell flat on their face.
Arbutus Biopharma , which was previously known as Tekmira Pharmaceuticals until this past July, was an early strong contender to have an Ebola cure. However, Arbutus in June ended its midstage trial into TKM-Ebola-Guinea after noting that the drug wasn't expect to provide a therapeutic benefit. Shares of Arbutus have lost more than 70% of their value since announcing its disappointing midstage results.
Image source: Flickr user UNMEER.
However, other trials have been quite successful. Most notably I'd point to NewLink Genetics ' and Merck 's rVSV-ZEBOV vaccine, which demonstrated statistically significant efficacy in phase 3 studies last year.
The trial, which was published in The Lancet and sponsored by WHO, involved 7,651 patients that were split into two groups. The first group was inoculated immediately with rVSV-ZEBOV while the second group was inoculated after an initial delay. An interim analysis showed that the first group had zero instances of infection after 10 days, whereas the group with a delayed inoculation had 16 instances of Ebola virus infection over the same time period. In simpler terms, rVSV-ZEBOV demonstrated 100% vaccine effectiveness, and it looked as if NewLink Genetics and Merck had beaten everyone else to the punch.
Yet, here we are more than a half-year since the release of this initial interim data and not a single drugmaker has filed paperwork with any global regulatory agency to bring an Ebola vaccine or drug to market. Wondering why? The simple answer is economic viability.
Here's why there's no approved Ebola vaccine on the market
Drug developers are in business to improve the lives of people domestically and worldwide. The vast majority of drugmakers (at least large drugmakers) do offer charitable and compassionate use of their products, meaning they do indeed donate their medicines to those in need who may not be able to afford them.
Ebola virus from blood sample in Mali. Image source: NIAID via Flickr.
However, drug developers aren't charities in nature. They need capital to survive. They need to be able to research new therapies in the lab, bring them into pre-clinical and clinical testing, pay their employees, market existing products, hire lawyers to protect their intellectual property, and even pay fees to the Food and Drug Administration in order to review their drug applications. This means that like any business, drugmakers have to make tough decisions regarding what therapies are worth pursuing economically and which indications are not. The general consensus based on the lack of new drug filings is that an Ebola vaccine or drug just isn't economically viable.
Recently, GAVI, the Vaccine Alliance, announced in January that it had awarded Merck and NewLink $5 million under an advanced purchase commitment for rVSV-ZEBOV. The terms include that Merck would submit regulatory approval for its vaccine by the end of 2017, and that it would make 300,000 doses available for clinical trials and other possible near-term outbreaks by May of this year. Should Merck and NewLink meet their end of the bargain, GAVI would presumably begin stockpiling the vaccine to help slow or prevent the next Ebola outbreak. It seemingly took an advanced purchase agreement to light a fire under Merck and NewLink to advance their Ebola vaccine.
Image source: Pixabay.
Economic viability is critical
The important lesson here? Drugmakers really do care about consumers' well-being, but they also have to keep the lights on. When evaluating a disease with pandemic potential, really try to dig deep to understand what sort of market potential it could have.
With Ebola, for example, it didn't appear as if global governments would warrant the need for millions of vaccines or drugs annually to thwart the disease (since the response from global health organization was so strong), meaning the valuations being attached to so-called "Ebola stocks" was likely unwarranted from the start. Infectious diseases tend to come and go, and they occasionally mutate, meaning vaccine developers can have very lumpy revenue recognition when focusing on a single disease. In even plainer terms, an Ebola vaccine was never on track to be a profit producer, yet investors bid up some companies by the hundreds of millions, or even billions, of dollars on the prospect that Ebola vaccines would be a profit machine.
Before jumping at the next stock leading the charge in a currently untreated infectious disease that has pandemic potential, really dig into the economics behind the company researching a cure and establish whether or not there's really an investable opportunity to be had. More times than not, I'd surmise there won't be one.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Ebola Can Teach Investors an Important Lesson About Economic Viability originally appeared on Fool.com.
Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, track every pick he makes under the screen nameTrackUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insights makes us better investors. The Motley Fool has adisclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This represents the true testament of cross-border cooperation since the disease primary focused on underdeveloped countries in West Africa such as Guinea, Liberia, and Sierra Leone. Yet, here we are more than a half-year since the release of this initial interim data and not a single drugmaker has filed paperwork with any global regulatory agency to bring an Ebola vaccine or drug to market. Before jumping at the next stock leading the charge in a currently untreated infectious disease that has pandemic potential, really dig into the economics behind the company researching a cure and establish whether or not there's really an investable opportunity to be had. | Image source: Flickr user UNMEER. An interim analysis showed that the first group had zero instances of infection after 10 days, whereas the group with a delayed inoculation had 16 instances of Ebola virus infection over the same time period. Yet, here we are more than a half-year since the release of this initial interim data and not a single drugmaker has filed paperwork with any global regulatory agency to bring an Ebola vaccine or drug to market. | At the height of the Ebola scare more than a dozen drug developers took to their labs to develop an Ebola vaccine that would hopefully cure the disease. With Ebola, for example, it didn't appear as if global governments would warrant the need for millions of vaccines or drugs annually to thwart the disease (since the response from global health organization was so strong), meaning the valuations being attached to so-called "Ebola stocks" was likely unwarranted from the start. In even plainer terms, an Ebola vaccine was never on track to be a profit producer, yet investors bid up some companies by the hundreds of millions, or even billions, of dollars on the prospect that Ebola vaccines would be a profit machine. | This made quarantining potential Ebola candidates extremely difficult in West Africa. At the height of the Ebola scare more than a dozen drug developers took to their labs to develop an Ebola vaccine that would hopefully cure the disease. The article Ebola Can Teach Investors an Important Lesson About Economic Viability originally appeared on Fool.com. |
34754.0 | 2016-03-14 00:00:00 UTC | New Strong Buy Stocks for March 14th | ABUS | https://www.nasdaq.com/articles/new-strong-buy-stocks-for-march-14th-2016-03-14 | nan | nan | Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) list today:
Arbutus Biopharma CorpABUS
Arc Logistics Partners LPARCX
Box IncBOX
Cincinnati Financial CorporationCINF
Destination XL Group IncDXLG
View the entire Zacks Rank #1 List .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BOX INC-A (BOX): Free Stock Analysis Report
CINCINNATI FINL (CINF): Free Stock Analysis Report
ARC LOGISTICS (ARCX): Free Stock Analysis Report
DESTINATION XL (DXLG): Free Stock Analysis Report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) list today: Arbutus Biopharma CorpABUS Arc Logistics Partners LPARCX Box IncBOX Cincinnati Financial CorporationCINF Destination XL Group IncDXLG View the entire Zacks Rank #1 List . Click to get this free report BOX INC-A (BOX): Free Stock Analysis Report CINCINNATI FINL (CINF): Free Stock Analysis Report ARC LOGISTICS (ARCX): Free Stock Analysis Report DESTINATION XL (DXLG): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) list today: Arbutus Biopharma CorpABUS Arc Logistics Partners LPARCX Box IncBOX Cincinnati Financial CorporationCINF Destination XL Group IncDXLG View the entire Zacks Rank #1 List . Click to get this free report BOX INC-A (BOX): Free Stock Analysis Report CINCINNATI FINL (CINF): Free Stock Analysis Report ARC LOGISTICS (ARCX): Free Stock Analysis Report DESTINATION XL (DXLG): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) list today: Arbutus Biopharma CorpABUS Arc Logistics Partners LPARCX Box IncBOX Cincinnati Financial CorporationCINF Destination XL Group IncDXLG View the entire Zacks Rank #1 List . Click to get this free report BOX INC-A (BOX): Free Stock Analysis Report CINCINNATI FINL (CINF): Free Stock Analysis Report ARC LOGISTICS (ARCX): Free Stock Analysis Report DESTINATION XL (DXLG): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) list today: Arbutus Biopharma CorpABUS Arc Logistics Partners LPARCX Box IncBOX Cincinnati Financial CorporationCINF Destination XL Group IncDXLG View the entire Zacks Rank #1 List . Click to get this free report BOX INC-A (BOX): Free Stock Analysis Report CINCINNATI FINL (CINF): Free Stock Analysis Report ARC LOGISTICS (ARCX): Free Stock Analysis Report DESTINATION XL (DXLG): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days. |
34755.0 | 2015-12-28 00:00:00 UTC | The Worst Biotech Stocks in 2015 | ABUS | https://www.nasdaq.com/articles/worst-biotech-stocks-2015-2015-12-28 | nan | nan | Image Source: Wikimedia Commons
Disastrous.
That's the best description for the performance of a handful of biotech stocks in 2015. Four biotech stocks with market caps over $250 million managed to lose more than 65% of their market cap during the year. Here's a rundown of which ones they were -- and how they failed so miserably.
1.OvaScience
During the first few months of the year, OvaScience 's stock held its own. The first round of bad news for the biotech, though, came on March 26, when the company announced results from studies of its Augment fertility treatment for women. Shares plunged around 40% over the following weeks.
Were the results that bad? Not on the surface. OvaScience reported nine clinical pregnancies out of 17 embryo transfers. Detailed parsing of the results, however, highlighted some concerns. There were 28 patients in the study, 26 of whom underwent the Augment treatment. Also, the average age of the women who became pregnant was 33 -- relatively young for in vitro fertilization.
In June, OvaScience announced more Augment treatment results. Despite seemingly good news, the stock tanked yet again. Skeptical investors still weren't convinced that the company's studies were solid.
They say that bad news comes in threes. For OvaScience, that saying rang true this year. The company announced on Sept. 28 that it didn't expect to meet its goal of 1,000 Augment treatment cycles in 2015. Shares were pummeled the next day, opening more than 37% below the previous close. The combination of all this negativity resulted in OvaScience losing three quarters of its market cap during 2015, ranking it among the worst-performing large biotech stocks of the year.
2.MannKind Corp.
Things didn't look much better for MannKind in 2015. Shares of the biotech sank just over 70% due to a series of disappointing sales results for its inhaled insulin treatment, Afrezza.
Sales for Afrezza started out slowly after MannKind and partner Sanofi launched the product in February. Unfortunately, the situation only worsened from that point. Shipments of Afrezza declined each quarter.
By late November, MannKind CEO Hakan Edstrom was gone. That left 90-year-old founder Al Mann at the helm once again. Despite Mann's personal popularity, the change didn't leave investors feeling warm and fuzzy. The stock continued to fall in December, landing MannKind on the list of the year's worst-performing biotechs.
3.Arbutus Biopharma Corporation
For Arbutus Biopharma shareholders, 2015 delivered a dramatic reversal of fortune. The year started off great for Arbutus, known previously as Tekmira Pharmaceuticals. The company's stock shot up over 75% by the end of January following the announcement of a merger with OnCore Biopharma. Then came the downward slide.
Excitement over the OnCore deal fizzled out. A secondary public offering in March generated plenty of cash, but caused share prices to fall because of dilution. In June, Arbutus announced that its mid-stage clinical study of a potential Ebola treatment would likely fail.
Arbutus did have some good news during the year. TKM-HBV, the biotech's experimental hepatitis B drug, advanced to a phase 2 clinical trial. That positive development wasn't enough to turn things around, though. Arbutus shares ultimately fell a hair under 70% for the year -- over 87% off its late January high mark.
4. Orexigen Therapeutics
Obesity drugmaker Orexigen Therapeutics seemed to be on the right track early in 2015. The stock was up almost 40% in early March. The good times didn't roll for long, though.
On May 12, Orexigen announced that the termination of the Light study, a clinical trial comparing cardiovascular outcomes of the company's obesity drug Contrave to placebo. Orexigen also revealed a dispute with partner Takeda Pharmaceuticals over their collaboration agreement for Contrave. Shares of the small biotech nosedived on the news.Orexigen and Takeda announced on August 6 that they had resolved their differences, but Orexigen's stock continued its downward slide.
The challenge for Orexigen was and is that the FDA still requires a cardiovascular study of Contrave. Takeda won't pick up the tab, so Orexigen will have to pay for the study, which is estimated to cost $210 million. The combination of 2015's run of bad news resulted in the biotech losing around 70% of its value during the year.
Rising from the ashes?
Can any of these stocks rebound in 2016? It's possible.
There's lots of potential for OvaScience's Augment in vitro fertilization treatment, although the company's drugs aren't available in the U.S. Likewise, MannKind's Afrezza could have plenty of potential if reimbursement issues can be overcome. Arbutus just might have an eventual winner on its hands with its hep-B drug. Orexigen's Contrave could become the clear obesity drug of choice.
But while each of these biotechs has potential, they also all come with significant risks. What goes down doesn't necessarily bounce back. And for these four stocks, there'd be quite a lot of bouncing needed.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article The Worst Biotech Stocks in 2015 originally appeared on Fool.com.
Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2015 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The combination of all this negativity resulted in OvaScience losing three quarters of its market cap during 2015, ranking it among the worst-performing large biotech stocks of the year. On May 12, Orexigen announced that the termination of the Light study, a clinical trial comparing cardiovascular outcomes of the company's obesity drug Contrave to placebo. Shares of the small biotech nosedived on the news.Orexigen and Takeda announced on August 6 that they had resolved their differences, but Orexigen's stock continued its downward slide. | The first round of bad news for the biotech, though, came on March 26, when the company announced results from studies of its Augment fertility treatment for women. In June, OvaScience announced more Augment treatment results. There's lots of potential for OvaScience's Augment in vitro fertilization treatment, although the company's drugs aren't available in the U.S. | The first round of bad news for the biotech, though, came on March 26, when the company announced results from studies of its Augment fertility treatment for women. The combination of all this negativity resulted in OvaScience losing three quarters of its market cap during 2015, ranking it among the worst-performing large biotech stocks of the year. Shares of the small biotech nosedived on the news.Orexigen and Takeda announced on August 6 that they had resolved their differences, but Orexigen's stock continued its downward slide. | The first round of bad news for the biotech, though, came on March 26, when the company announced results from studies of its Augment fertility treatment for women. Arbutus did have some good news during the year. There's lots of potential for OvaScience's Augment in vitro fertilization treatment, although the company's drugs aren't available in the U.S. |
34756.0 | 2023-12-16 00:00:00 UTC | Southwest Airlines agrees to $140 million penalty over 2022 holiday meltdown | AC | https://www.nasdaq.com/articles/southwest-airlines-agrees-to-%24140-million-penalty-over-2022-holiday-meltdown | nan | nan | By David Shepardson
WASHINGTON, Dec 18 (Reuters) - Southwest Airlines LUV.N agreed to a record-setting $140 million civil penalty over the December 2022 holiday meltdown that led to 16,900 flight cancellations and stranded 2 million passengers, the U.S. government said on Monday.
The U.S. Department of Transportation (USDOT) consent order resolves a lengthy government investigation into the massive travel disruption and provides "a strong deterrent," the agency said.
The settlement includes a $35 million cash fine and a three-year mandate that Southwest provide $90 million in travel vouchers of $75 or more to passengers delayed at least three hours getting to final destinations because of an airline-caused issue or cancellation.
"If airlines fail their passengers, we will use the full extent of our authority to hold them accountable," said Transportation Secretary Pete Buttigieg.
The 2022 massive winter storm and subsequent chaos prompted travel horror stories: people missing funerals or long-awaited holiday gatherings, passengers with canceled flights forced to make cross-country drives of 17 or more hours across and some cancer patients could not get treatment. One senior executive told angry lawmakers bluntly: "We messed up."
Southwest, which paid over $600 million to passengers impacted by the storm that cost it more than $1 billion, has over the last year made significant technology and consumer service upgrades and other investments including more de-icing equipment across its network, new staffing and softwareand using artificial intelligence to predict network health.
The airline has seen significant operational improvements this year.
"We are absolutely prepared for winter," Southwest CEO Bob Jordan said in a Reuters interview on Monday pointing to its strong performance this year.
He said the airline was pleased to resolve the investigation even though it did not admit wrongdoing. "It was a historic storm that led to a historic week of operational disruption," Jordan said. A disruption of that magnitude "is not going to happen again."
The largest penalty previously was $4.5 million imposed on Air Canada AC.TO after USDOT initially sought $25.5 million. Southwest's penalty -- which includes the $35 million fine payable over three years -- is more than all penalties assessed by USDOT combined since 1996. USDOT said in January it planned to start seeking higher fines.
USDOT found Southwest violated consumer protection laws by failing to provide adequate customer service assistance "via its call center to hundreds of thousands of customers" as well as failing to provide prompt flight status notifications to more than 1 million passengers and prompt refunds to thousands.
Jordan, who said over 99% of refunds were processed within seven days,said the $30 million in vouchers annually is "roughly equivalent to our operational performance.... It's the right number."
He said Southwest would make it "really easy" to request the compensation. Asked if Southwest would end the program after three years, Jordan said consumer programs "rarely change or go away."
USDOT also said it closed its "unrealistic scheduling investigation" without making any finding. The agency credited Southwest with $33 million toward the penalty for voluntarily awarding frequent flyer points to hundreds of thousands impacted passengers "to incentivize other airlines to take similar measures" during operational woes.
In May, President Joe Biden said USDOT would propose new rules requiring airlines compensate passengers with cash for significant flight delays or cancellations when carriers are responsible.
USDOT last year asked carriers if they would pay at least $100 for delays of at least three hours caused by airlines and none agreed.
Most carriers - including Southwest - voluntarily committed in August 2022 to provide hotels, meals and ground transportation for airline-caused delays or cancellations but resisted providing cash compensation.
(Reporting by David Shepardson; Editing by Christian Schmollinger)
((David.Shepardson@thomsonreuters.com; 2028988324;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The 2022 massive winter storm and subsequent chaos prompted travel horror stories: people missing funerals or long-awaited holiday gatherings, passengers with canceled flights forced to make cross-country drives of 17 or more hours across and some cancer patients could not get treatment. The agency credited Southwest with $33 million toward the penalty for voluntarily awarding frequent flyer points to hundreds of thousands impacted passengers "to incentivize other airlines to take similar measures" during operational woes. "If airlines fail their passengers, we will use the full extent of our authority to hold them accountable," said Transportation Secretary Pete Buttigieg. | "If airlines fail their passengers, we will use the full extent of our authority to hold them accountable," said Transportation Secretary Pete Buttigieg. The 2022 massive winter storm and subsequent chaos prompted travel horror stories: people missing funerals or long-awaited holiday gatherings, passengers with canceled flights forced to make cross-country drives of 17 or more hours across and some cancer patients could not get treatment. Southwest, which paid over $600 million to passengers impacted by the storm that cost it more than $1 billion, has over the last year made significant technology and consumer service upgrades and other investments including more de-icing equipment across its network, new staffing and softwareand using artificial intelligence to predict network health. | "If airlines fail their passengers, we will use the full extent of our authority to hold them accountable," said Transportation Secretary Pete Buttigieg. The 2022 massive winter storm and subsequent chaos prompted travel horror stories: people missing funerals or long-awaited holiday gatherings, passengers with canceled flights forced to make cross-country drives of 17 or more hours across and some cancer patients could not get treatment. Southwest, which paid over $600 million to passengers impacted by the storm that cost it more than $1 billion, has over the last year made significant technology and consumer service upgrades and other investments including more de-icing equipment across its network, new staffing and softwareand using artificial intelligence to predict network health. | "If airlines fail their passengers, we will use the full extent of our authority to hold them accountable," said Transportation Secretary Pete Buttigieg. The 2022 massive winter storm and subsequent chaos prompted travel horror stories: people missing funerals or long-awaited holiday gatherings, passengers with canceled flights forced to make cross-country drives of 17 or more hours across and some cancer patients could not get treatment. Southwest, which paid over $600 million to passengers impacted by the storm that cost it more than $1 billion, has over the last year made significant technology and consumer service upgrades and other investments including more de-icing equipment across its network, new staffing and softwareand using artificial intelligence to predict network health. |
34757.0 | 2023-11-15 00:00:00 UTC | Airfare to leisure destinations to cost less this winter, WestJet CEO says | AC | https://www.nasdaq.com/articles/airfare-to-leisure-destinations-to-cost-less-this-winter-westjet-ceo-says | nan | nan | By Allison Lampert
MONTREAL, Nov 15 (Reuters) - Airfare to popular international leisure destinations should cost less this winter and next summer than a year ago as carriers add capacity, the CEO of Canada's WestJet Airlines told Reuters on Wednesday.
For North American carriers, prices for international travel soared over the past year as pent-up demand for leisure flights after pandemic-related lockdowns outstripped supply. But Onex Corp-backed ONEX.TO WestJet, Canada's second-largest airline, and other carriers are adding more capacity on routes to Europe and the Asia Pacific region.
"Last year, our observation was that there was probably more demand than the industry could serve. That's why we also saw pricing going up quite substantially," WestJet CEO Alexis von Hoensbroech said in an interview on the sidelines of an Air Transport Association of Canada (ATAC) conference in Montreal.
"This winter is going to be different. I think this winter we'll have a better supply-to-demand balance, which will give more affordability to Canadians," von Hoensbroech added.
WestJet expects to fly almost half of the seats to sun destinations after acquiring leisure carrier Sunwing this year.
WestJet, which competes with larger rival Air Canada AC.TO, sees strong demand for winter travel, although there has been "some trading down happening from higher-end vacations to more-affordable vacations," von Hoensbroech said.
"We see strong bookings, slightly softer than what we saw last winter," von Hoensbroech added.
Similarly, von Hoensbroech predicted more "balanced pricing" on travel to Europe next summer as more capacity comes online following an exceptional season in 2023.
"I would expect next summer there would be a different demand-to-supply equation on transatlantic," von Hoensbroech said.
WestJet has 48 firm orders for Boeing Co's BA.N larger MAX 10 aircraft. Von Hoensbroech said the airline hopes to take its first delivery in September 2024 following expected certification by the U.S. Federal Aviation Administration next summer, "if the time plan doesn't slip."
Boeing has said it expects FAA certification for the MAX 10 in 2024 but has not specified a month.
(Reporting By Allison Lampert in Montreal; Additional reporting by Valerie Insinna in Washington; Editing by Will Dunham)
((Allison.Lampert@thomsonreuters.com; 514-796-4212))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | That's why we also saw pricing going up quite substantially," WestJet CEO Alexis von Hoensbroech said in an interview on the sidelines of an Air Transport Association of Canada (ATAC) conference in Montreal. By Allison Lampert MONTREAL, Nov 15 (Reuters) - Airfare to popular international leisure destinations should cost less this winter and next summer than a year ago as carriers add capacity, the CEO of Canada's WestJet Airlines told Reuters on Wednesday. But Onex Corp-backed ONEX.TO WestJet, Canada's second-largest airline, and other carriers are adding more capacity on routes to Europe and the Asia Pacific region. | By Allison Lampert MONTREAL, Nov 15 (Reuters) - Airfare to popular international leisure destinations should cost less this winter and next summer than a year ago as carriers add capacity, the CEO of Canada's WestJet Airlines told Reuters on Wednesday. WestJet, which competes with larger rival Air Canada AC.TO, sees strong demand for winter travel, although there has been "some trading down happening from higher-end vacations to more-affordable vacations," von Hoensbroech said. Similarly, von Hoensbroech predicted more "balanced pricing" on travel to Europe next summer as more capacity comes online following an exceptional season in 2023. | By Allison Lampert MONTREAL, Nov 15 (Reuters) - Airfare to popular international leisure destinations should cost less this winter and next summer than a year ago as carriers add capacity, the CEO of Canada's WestJet Airlines told Reuters on Wednesday. That's why we also saw pricing going up quite substantially," WestJet CEO Alexis von Hoensbroech said in an interview on the sidelines of an Air Transport Association of Canada (ATAC) conference in Montreal. WestJet, which competes with larger rival Air Canada AC.TO, sees strong demand for winter travel, although there has been "some trading down happening from higher-end vacations to more-affordable vacations," von Hoensbroech said. | By Allison Lampert MONTREAL, Nov 15 (Reuters) - Airfare to popular international leisure destinations should cost less this winter and next summer than a year ago as carriers add capacity, the CEO of Canada's WestJet Airlines told Reuters on Wednesday. But Onex Corp-backed ONEX.TO WestJet, Canada's second-largest airline, and other carriers are adding more capacity on routes to Europe and the Asia Pacific region. That's why we also saw pricing going up quite substantially," WestJet CEO Alexis von Hoensbroech said in an interview on the sidelines of an Air Transport Association of Canada (ATAC) conference in Montreal. |
34758.0 | 2023-11-13 00:00:00 UTC | FOCUS-North American airlines bet on Asia to drive profit | AC | https://www.nasdaq.com/articles/focus-north-american-airlines-bet-on-asia-to-drive-profit | nan | nan | By Allison Lampert and Rajesh Kumar Singh
MONTREAL/CHICAGO, Nov 13 (Reuters) - The return of North American flights to Asia-Pacific is accelerating heading in to 2024, as carriers bet on the region as the next source of high-margin revenue at a time of soaring costs.
A rebound in Asia is especially important for airlines where long-haul travel makes up a bigger mix of revenue. Carriers tapped pent-up demand last summer with sky-high fares on flights to Europe, but a return of those prices may not be in the cards next year as capacity grows, some analysts said.
Business travel, a cash cow for airlines, is also rebounding in Asia. Travel spending in Asia Pacific is set to grow 41% this year to $567 billion, and rise to $800 billion by 2027, according to data from the Global Business Travel Association.
Air Canada's AC.TO estimated traffic to Asia would be "closer to 80-something percent" of 2019 levels next year, the carrier's vice president of network planning told Reuters. The planned capacity, which has not been previously reported, is a strong rebound from 2022, when the carrier's Asia-Pacific traffic was 33% of 2019 levels.
While United Airlines UAL.O, American Airlines AAL.O and Delta Air Lines DAL.N are offering fewer seats to Asia Pacific in the current quarter compared with 2019, the numbers are up 75% on an annual basis, according to aviation analytics company Cirium.
In the first three months of 2024, the numbers will be up about 79% year-on-year. In contrast, seats on the flights of the three U.S. carriers to Europe will grow an annual 6%.
Travel to Asia is also a source of high-margin revenue at a time when soaring labor and fuel costs are pressuring profit and domestic fares are declining.
"The market here in the United States is more mature," United's chief commercial officer, Andrew Nocella, said at a conference earlier this month. "The growth rates of 7% or 8% or 9% for the industry are just not going to be possible, but growing overseas, we think there's just a lot more opportunity."
SUPPLY-DEMAND MISMATCH
Asia-Pacific has lagged behind the U.S. and Europe in global travel demand recovery after the pandemic. While passenger traffic in the region has surged since the reopening of borders, international airline capacity remains below 2019 levels.
The supply-demand mismatch is driving up profit margins for carriers. Asia-Pacific was the second-best market for passenger earnings after transatlantic for both United and Delta in the third quarter.
Delta is shifting capacity to international leisure destinations as domestic flights grow more modestly. The Atlanta-based carrier will increase capacity to Asia-Pacific by as much as 50% in the December quarter and expects the new flying to be "profit-accretive."
Rival United also plans to ramp up capacity in Asia Pacific at the cost of domestic growth, as it bets on flights like U.S. to Manila, Philippines, and San Francisco to New Zealand to deliver the "strongest short-term results."
Overall, Chicago-based United has almost doubled the number of seats on flights to Asia in the current quarter from a year ago, according to Cirium.
Across the border, Air Canada said the increase in Asia Pacific capacity would more than double its overall system growth.
Demand for increasing flights to Asia out of Air Canada's Vancouver hub is expected to come partly from growing Asian immigration to Canada, along with U.S. passengers, Mark Galardo, vice president for network planning, said in an interview.
Canada's largest carrier has a strategy of flying Americans from U.S. cities that connect through its Canadian hubs toward overseas destinations.
About 80% of that traffic now goes to Europe, compared with 20% to Asia, but it would shift as Asian travel grows, Galardo said.
"Our forecast is that ... it would shift within a range of 5 to 10 percentage points," said Galardo, adding it was too early to give a specific number for next year.
However, closed Russian airspace as well as depressed Chinese travel to North America remain hurdles.
The need to avoid Russian airspace due to the war with Ukraine has made it tougher for North American carriers to fly to destinations like Hong Kong from East Coast hubs Newark, New Jersey; and Atlanta and Toronto.
Similarly, Chinese tourists are still not back in full force. In 2019, 2.8 million tourists from China came to the U.S., but research group Tourism Economics expects a mere 991,000 to arrive this year.
Uneven recovery in Chinese travel demand is an unknown for the carriers, but tight supply should help profit, Raymond James analyst Savanthi Syth said.
"I feel like Asia-Pacific is six-to-12 months behind what you've seen on the transatlantic – China being the wild card in all this," she said.
(Reporting by Allison Lampert in Montreal and Rajesh Kumar Singh in Chicago Editing by Ben Klayman and Matthew Lewis)
((Allison.Lampert@thomsonreuters.com; 514-796-4212; Reuters Messaging: allison.lampert.reuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Allison Lampert and Rajesh Kumar Singh MONTREAL/CHICAGO, Nov 13 (Reuters) - The return of North American flights to Asia-Pacific is accelerating heading in to 2024, as carriers bet on the region as the next source of high-margin revenue at a time of soaring costs. Rival United also plans to ramp up capacity in Asia Pacific at the cost of domestic growth, as it bets on flights like U.S. to Manila, Philippines, and San Francisco to New Zealand to deliver the "strongest short-term results." The need to avoid Russian airspace due to the war with Ukraine has made it tougher for North American carriers to fly to destinations like Hong Kong from East Coast hubs Newark, New Jersey; and Atlanta and Toronto. | By Allison Lampert and Rajesh Kumar Singh MONTREAL/CHICAGO, Nov 13 (Reuters) - The return of North American flights to Asia-Pacific is accelerating heading in to 2024, as carriers bet on the region as the next source of high-margin revenue at a time of soaring costs. Air Canada's AC.TO estimated traffic to Asia would be "closer to 80-something percent" of 2019 levels next year, the carrier's vice president of network planning told Reuters. Carriers tapped pent-up demand last summer with sky-high fares on flights to Europe, but a return of those prices may not be in the cards next year as capacity grows, some analysts said. | Travel spending in Asia Pacific is set to grow 41% this year to $567 billion, and rise to $800 billion by 2027, according to data from the Global Business Travel Association. While United Airlines UAL.O, American Airlines AAL.O and Delta Air Lines DAL.N are offering fewer seats to Asia Pacific in the current quarter compared with 2019, the numbers are up 75% on an annual basis, according to aviation analytics company Cirium. By Allison Lampert and Rajesh Kumar Singh MONTREAL/CHICAGO, Nov 13 (Reuters) - The return of North American flights to Asia-Pacific is accelerating heading in to 2024, as carriers bet on the region as the next source of high-margin revenue at a time of soaring costs. | Carriers tapped pent-up demand last summer with sky-high fares on flights to Europe, but a return of those prices may not be in the cards next year as capacity grows, some analysts said. Across the border, Air Canada said the increase in Asia Pacific capacity would more than double its overall system growth. By Allison Lampert and Rajesh Kumar Singh MONTREAL/CHICAGO, Nov 13 (Reuters) - The return of North American flights to Asia-Pacific is accelerating heading in to 2024, as carriers bet on the region as the next source of high-margin revenue at a time of soaring costs. |
34759.0 | 2023-10-30 00:00:00 UTC | CANADA STOCKS-TSX set to snap eight-day losing streak, Industrials rise | AC | https://www.nasdaq.com/articles/canada-stocks-tsx-set-to-snap-eight-day-losing-streak-industrials-rise | nan | nan | By Khushi Singh
Oct 30 (Reuters) - Canada's main stock index seemed on track to snap an eight-day losing streak as TSX moved higher on Monday after Air Canada's annual profit forecast lifted the industrial sector while investor sentiment was optimistic ahead of a week full of scheduled economic data.
At 10:32 a.m. ET (14:32 GMT), the Toronto Stock Exchange's S&P/TSX composite index .GSPTSE was up 53.76 points, or 0.29%, at 18,791.15.
Air CanadaAC.TO said it expects 2023 core profit towards the higher range of its previous forecast after strong demand for international travel helped the carrier beat third-quarter profit estimates.
Although the airline company reversed early gains to fall 2.2%, the broader industrial .GSPTTIN sector added 1.0%, its biggest jump in over six weeks.
Markets will closely monitor Canada's GDP for August and manufacturing data for October slated for later in the week.
"There is a lot of fear that Canada is already getting close to entering a recession, so the GDP number is going to be important," said Greg Taylor, chief investment officer at Purpose Investments.
Investors will also be keeping tabs on the U.S. Federal Reserve's crucial monetary policy meeting on Wednesday, where the central bank is widely expected to keep interest rates unchanged, boosting shares of rate-sensitive sectors.
The information technology .SPTTTK index was up 0.7%, while financials .SPTTFS added 0.9%.
Consumer staples .GSPTTCS sector made the most gains, up 1.7%, while the materials sector .GSPTTMT was the only outlier, down 2.4% as a sell-off in First Quantum FM.TO shares weighed on the sub-index. GOL/MET/L
Panama will be holding a referendum to decide whether to scrap a contract with First Quantum's local unit after days of protests by thousands of people who have opposed the open-pit copper mine project. The miner dropped 18.1% to the bottom of the index.
Canadian SolarCSIQ.O shares were up 0.5% after the Ontario-based company said it would invest $800 million to build a solar photovoltaic (PV) cell production facility in Jeffersonville, Indiana.
(Reporting by Khushi Singh in Bengaluru; Editing by Tasim Zahid)
((Khushi.Singh@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Khushi Singh Oct 30 (Reuters) - Canada's main stock index seemed on track to snap an eight-day losing streak as TSX moved higher on Monday after Air Canada's annual profit forecast lifted the industrial sector while investor sentiment was optimistic ahead of a week full of scheduled economic data. GOL/MET/L Panama will be holding a referendum to decide whether to scrap a contract with First Quantum's local unit after days of protests by thousands of people who have opposed the open-pit copper mine project. Canadian SolarCSIQ.O shares were up 0.5% after the Ontario-based company said it would invest $800 million to build a solar photovoltaic (PV) cell production facility in Jeffersonville, Indiana. | By Khushi Singh Oct 30 (Reuters) - Canada's main stock index seemed on track to snap an eight-day losing streak as TSX moved higher on Monday after Air Canada's annual profit forecast lifted the industrial sector while investor sentiment was optimistic ahead of a week full of scheduled economic data. Markets will closely monitor Canada's GDP for August and manufacturing data for October slated for later in the week. Air CanadaAC.TO said it expects 2023 core profit towards the higher range of its previous forecast after strong demand for international travel helped the carrier beat third-quarter profit estimates. | By Khushi Singh Oct 30 (Reuters) - Canada's main stock index seemed on track to snap an eight-day losing streak as TSX moved higher on Monday after Air Canada's annual profit forecast lifted the industrial sector while investor sentiment was optimistic ahead of a week full of scheduled economic data. Air CanadaAC.TO said it expects 2023 core profit towards the higher range of its previous forecast after strong demand for international travel helped the carrier beat third-quarter profit estimates. Markets will closely monitor Canada's GDP for August and manufacturing data for October slated for later in the week. | By Khushi Singh Oct 30 (Reuters) - Canada's main stock index seemed on track to snap an eight-day losing streak as TSX moved higher on Monday after Air Canada's annual profit forecast lifted the industrial sector while investor sentiment was optimistic ahead of a week full of scheduled economic data. Markets will closely monitor Canada's GDP for August and manufacturing data for October slated for later in the week. Air CanadaAC.TO said it expects 2023 core profit towards the higher range of its previous forecast after strong demand for international travel helped the carrier beat third-quarter profit estimates. |
34760.0 | 2023-10-30 00:00:00 UTC | CANADA STOCKS-Toronto stocks open higher after eight sessions of declines | AC | https://www.nasdaq.com/articles/canada-stocks-toronto-stocks-open-higher-after-eight-sessions-of-declines | nan | nan | Oct 30 (Reuters) - Canada's main stock index opened higher on Monday, after an eight-day losing streak, as Air Canada's earnings boosted the industrial index, while investor sentiment was optimistic ahead of a slew of economic data through the week.
At 9:40 a.m. ET (13:40 GMT), the Toronto Stock Exchange's S&P/TSX composite index .GSPTSE was up 191.9 points, or 1.02%, at 18,929.29.
(Reporting by Khushi Singh in Bengaluru; Editing by Tasim Zahid)
((Khushi.Singh@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Oct 30 (Reuters) - Canada's main stock index opened higher on Monday, after an eight-day losing streak, as Air Canada's earnings boosted the industrial index, while investor sentiment was optimistic ahead of a slew of economic data through the week. ET (13:40 GMT), the Toronto Stock Exchange's S&P/TSX composite index .GSPTSE was up 191.9 points, or 1.02%, at 18,929.29. (Reporting by Khushi Singh in Bengaluru; Editing by Tasim Zahid) ((Khushi.Singh@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Oct 30 (Reuters) - Canada's main stock index opened higher on Monday, after an eight-day losing streak, as Air Canada's earnings boosted the industrial index, while investor sentiment was optimistic ahead of a slew of economic data through the week. ET (13:40 GMT), the Toronto Stock Exchange's S&P/TSX composite index .GSPTSE was up 191.9 points, or 1.02%, at 18,929.29. (Reporting by Khushi Singh in Bengaluru; Editing by Tasim Zahid) ((Khushi.Singh@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Oct 30 (Reuters) - Canada's main stock index opened higher on Monday, after an eight-day losing streak, as Air Canada's earnings boosted the industrial index, while investor sentiment was optimistic ahead of a slew of economic data through the week. ET (13:40 GMT), the Toronto Stock Exchange's S&P/TSX composite index .GSPTSE was up 191.9 points, or 1.02%, at 18,929.29. (Reporting by Khushi Singh in Bengaluru; Editing by Tasim Zahid) ((Khushi.Singh@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Oct 30 (Reuters) - Canada's main stock index opened higher on Monday, after an eight-day losing streak, as Air Canada's earnings boosted the industrial index, while investor sentiment was optimistic ahead of a slew of economic data through the week. ET (13:40 GMT), the Toronto Stock Exchange's S&P/TSX composite index .GSPTSE was up 191.9 points, or 1.02%, at 18,929.29. (Reporting by Khushi Singh in Bengaluru; Editing by Tasim Zahid) ((Khushi.Singh@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
34761.0 | 2023-10-30 00:00:00 UTC | CANADA STOCKS-TSX futures rise amid busy week of economic data, Fed meet | AC | https://www.nasdaq.com/articles/canada-stocks-tsx-futures-rise-amid-busy-week-of-economic-data-fed-meet | nan | nan | Oct 30 (Reuters) - Futures for Canada's main stock index rose on Monday, tracking gains in global stocks as investor sentiment was optimistic ahead of a slew of domestic economic data and the Federal Reserve's rate decision later this week despite the conflict in the Middle East.
December futures on the S&P/TSX index SXFc1 were up 0.8% at 6:49 a.m. ET (1049 GMT).
Israeli troops stepped up ground operations in Gaza early on Monday, with Palestinians in the enclave reporting fierce air and artillery strikes as the conflict entered its fourth week.
Materials stocks are likely to get a boost as most non-ferrous metal prices rose with stimulus measures from top consumer China boosting sentiment, with low inventories and solid demand further supporting copper prices. MET/L
Energy shares, however, may witness a decline after oil prices slipped more than 1% as concerns eased about the Israel-Hamas war affecting supply from the region. O/R
Markets will closely monitor Canada's GDP for August and manufacturing data for October through the week while also keeping tabs on the U.S. central bank's crucial rate-setting meeting on Wednesday, where rates are expected to stay unchanged.
Futures tracking Wall Street's main indexes also surged on Monday as the market got ready for a busy week of earning reports and the Fed's interest rate decision. .N
The Toronto Stock Exchange's S&P/TSX composite index .GSPTSE ended lower last week, with shares falling for eight consecutive sessions. .TO
In company news, Air CanadaAC.TO reported a quarterly profit compared with a year-ago loss as the carrier benefited from strong demand for international travel.
Canadian pipeline operator TC EnergyTRP.TO is exploring a multibillion-dollar asset sale plan to lower its debt and fund new investments, Bloomberg News reported on Friday, citing people familiar with the matter.
COMMODITIES AT 6:49 a.m. ET
Gold futures GCc2: $2,005.6; +0.4% GOL/
US crude CLc1: $84.46; -1.3% O/R
Brent crude LCOc1: $89.53; -1.1% O/R
($1= C$1.3847)
(Reporting by Shubham Batra in Bengaluru; Editing by Tasim Zahid)
((Siddarth.s@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | O/R Markets will closely monitor Canada's GDP for August and manufacturing data for October through the week while also keeping tabs on the U.S. central bank's crucial rate-setting meeting on Wednesday, where rates are expected to stay unchanged. Oct 30 (Reuters) - Futures for Canada's main stock index rose on Monday, tracking gains in global stocks as investor sentiment was optimistic ahead of a slew of domestic economic data and the Federal Reserve's rate decision later this week despite the conflict in the Middle East. Futures tracking Wall Street's main indexes also surged on Monday as the market got ready for a busy week of earning reports and the Fed's interest rate decision. | Oct 30 (Reuters) - Futures for Canada's main stock index rose on Monday, tracking gains in global stocks as investor sentiment was optimistic ahead of a slew of domestic economic data and the Federal Reserve's rate decision later this week despite the conflict in the Middle East. Futures tracking Wall Street's main indexes also surged on Monday as the market got ready for a busy week of earning reports and the Fed's interest rate decision. .TO In company news, Air CanadaAC.TO reported a quarterly profit compared with a year-ago loss as the carrier benefited from strong demand for international travel. | Oct 30 (Reuters) - Futures for Canada's main stock index rose on Monday, tracking gains in global stocks as investor sentiment was optimistic ahead of a slew of domestic economic data and the Federal Reserve's rate decision later this week despite the conflict in the Middle East. Futures tracking Wall Street's main indexes also surged on Monday as the market got ready for a busy week of earning reports and the Fed's interest rate decision. O/R Markets will closely monitor Canada's GDP for August and manufacturing data for October through the week while also keeping tabs on the U.S. central bank's crucial rate-setting meeting on Wednesday, where rates are expected to stay unchanged. | Futures tracking Wall Street's main indexes also surged on Monday as the market got ready for a busy week of earning reports and the Fed's interest rate decision. Oct 30 (Reuters) - Futures for Canada's main stock index rose on Monday, tracking gains in global stocks as investor sentiment was optimistic ahead of a slew of domestic economic data and the Federal Reserve's rate decision later this week despite the conflict in the Middle East. O/R Markets will closely monitor Canada's GDP for August and manufacturing data for October through the week while also keeping tabs on the U.S. central bank's crucial rate-setting meeting on Wednesday, where rates are expected to stay unchanged. |
34762.0 | 2023-10-30 00:00:00 UTC | Air Canada reports profit versus year-ago loss on strong international travel demand | AC | https://www.nasdaq.com/articles/air-canada-reports-profit-versus-year-ago-loss-on-strong-international-travel-demand | nan | nan | Adds revenue in paragraph 6, background throughout
Oct 30 (Reuters) - Air Canada AC.TO reported a quarterly profit compared with a year-ago loss on Monday, as the carrier benefited from strong demand for international travel.
North American airlines operating international flights are benefiting from sustained demand for long-haul journeys as more people plan holidays abroad, despite contending with higher costs.
Such airlines face pressure from higher labor costs, with pilots at U.S. legacy carriers nabbing steep pay increases in new contracts or tentative agreements.
Last month, Air Canada pilots staged a protest demanding better pay and benefits as talks over a new contract covering 4,500 pilots at the company continue.
Canada's largest airline posted net profit of C$1.25 billion, or C$3.08 per share, for the quarter ended Sept. 30, compared with the net loss of C$508 million, or C$1.42 per share, a year earlier.
The Canadian carrier's quarterly operating revenue rose 19.2% to C$6.34 billion.
(Reporting by Shivansh Tiwary in Bengaluru; Editing by Shilpi Majumdar)
((Shivansh.Tiwary@thomsonreuters.com; +91 9708363192;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds revenue in paragraph 6, background throughout Oct 30 (Reuters) - Air Canada AC.TO reported a quarterly profit compared with a year-ago loss on Monday, as the carrier benefited from strong demand for international travel. Such airlines face pressure from higher labor costs, with pilots at U.S. legacy carriers nabbing steep pay increases in new contracts or tentative agreements. Last month, Air Canada pilots staged a protest demanding better pay and benefits as talks over a new contract covering 4,500 pilots at the company continue. | Adds revenue in paragraph 6, background throughout Oct 30 (Reuters) - Air Canada AC.TO reported a quarterly profit compared with a year-ago loss on Monday, as the carrier benefited from strong demand for international travel. Last month, Air Canada pilots staged a protest demanding better pay and benefits as talks over a new contract covering 4,500 pilots at the company continue. Such airlines face pressure from higher labor costs, with pilots at U.S. legacy carriers nabbing steep pay increases in new contracts or tentative agreements. | Adds revenue in paragraph 6, background throughout Oct 30 (Reuters) - Air Canada AC.TO reported a quarterly profit compared with a year-ago loss on Monday, as the carrier benefited from strong demand for international travel. Last month, Air Canada pilots staged a protest demanding better pay and benefits as talks over a new contract covering 4,500 pilots at the company continue. Such airlines face pressure from higher labor costs, with pilots at U.S. legacy carriers nabbing steep pay increases in new contracts or tentative agreements. | Adds revenue in paragraph 6, background throughout Oct 30 (Reuters) - Air Canada AC.TO reported a quarterly profit compared with a year-ago loss on Monday, as the carrier benefited from strong demand for international travel. Such airlines face pressure from higher labor costs, with pilots at U.S. legacy carriers nabbing steep pay increases in new contracts or tentative agreements. Last month, Air Canada pilots staged a protest demanding better pay and benefits as talks over a new contract covering 4,500 pilots at the company continue. |
34763.0 | 2023-10-25 00:00:00 UTC | Air Canada right to apologize over questioning of UK lawmaker named 'Mohammad' | AC | https://www.nasdaq.com/articles/air-canada-right-to-apologize-over-questioning-of-uk-lawmaker-named-mohammad | nan | nan | MONTREAL, Oct 25 (Reuters) - Air Canada AC.TO did the right thing in apologizing to a British lawmaker named Mohammad Yasin who was recently singled out for additional questioning while flying to and from Canada, the country's transport minister said on Wednesday.
Canadian Transport Minister Pablo Rodriguez said "we called Air Canada" after hearing about the incident where British Labour Member of Parliament Mohammad Yasin was peppered with questions while traveling with a British parliamentary committee to Canada last week.
"Air Canada apologized and apologizing was the right thing to do," Rodriguez told reporters in Ottawa. Air Canada was not immediately available for comment.
Labour MP Clive Betts told the U.K. House of Commons on Monday that Yasin was asked whether he was carrying a knife or other weapon and where he was born.
"He was told it was because his name was Mohammad," Betts said. "The questioning was undertaken by officials from Air Canada and we believe the Canadian government."
The challenges of a "racist and islamophobic" nature were raised both at airports in London, England, and in Montreal, Betts said. Yasin was again challenged in Toronto.
He was eventually able to board.
Yasin told the BBC on Tuesday that "it was stressful and humiliating to be singled out in such an aggressive way by immigration control, especially when travelling in a group as a representative of the British Parliament on long arranged committee business."
Canada Border Services Agency (CBSA) was not immediately reachable for comment.
(Reporting By Allison Lampert in Montreal Editing by Marguerita Choy)
((Allison.Lampert@thomsonreuters.com; 514-796-4212; Reuters Messaging: allison.lampert.reuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The challenges of a "racist and islamophobic" nature were raised both at airports in London, England, and in Montreal, Betts said. MONTREAL, Oct 25 (Reuters) - Air Canada AC.TO did the right thing in apologizing to a British lawmaker named Mohammad Yasin who was recently singled out for additional questioning while flying to and from Canada, the country's transport minister said on Wednesday. Canada Border Services Agency (CBSA) was not immediately reachable for comment. | MONTREAL, Oct 25 (Reuters) - Air Canada AC.TO did the right thing in apologizing to a British lawmaker named Mohammad Yasin who was recently singled out for additional questioning while flying to and from Canada, the country's transport minister said on Wednesday. The challenges of a "racist and islamophobic" nature were raised both at airports in London, England, and in Montreal, Betts said. Canada Border Services Agency (CBSA) was not immediately reachable for comment. | MONTREAL, Oct 25 (Reuters) - Air Canada AC.TO did the right thing in apologizing to a British lawmaker named Mohammad Yasin who was recently singled out for additional questioning while flying to and from Canada, the country's transport minister said on Wednesday. The challenges of a "racist and islamophobic" nature were raised both at airports in London, England, and in Montreal, Betts said. Canada Border Services Agency (CBSA) was not immediately reachable for comment. | MONTREAL, Oct 25 (Reuters) - Air Canada AC.TO did the right thing in apologizing to a British lawmaker named Mohammad Yasin who was recently singled out for additional questioning while flying to and from Canada, the country's transport minister said on Wednesday. The challenges of a "racist and islamophobic" nature were raised both at airports in London, England, and in Montreal, Betts said. Canada Border Services Agency (CBSA) was not immediately reachable for comment. |
34764.0 | 2023-10-12 00:00:00 UTC | CANADA STOCKS-TSX snaps five-day winning streak on higher U.S. inflation data | AC | https://www.nasdaq.com/articles/canada-stocks-tsx-snaps-five-day-winning-streak-on-higher-u.s.-inflation-data | nan | nan | By Khushi Singh
Oct 12 (Reuters) - Canada's main stock index slipped on Thursday, snapping a five-day winning streak as Treasury yields spiked after September U.S. inflation rose more than expected, while energy stocks gained on higher oil prices.
At 10:15 a.m. ET (1415 GMT), the Toronto Stock Exchange's S&P/TSX composite index .GSPTSE was down 86.09 points, or 0.44%, at 19,577.75.
The highly anticipated U.S. consumer prices data showed an increase in Sept. pushed by higher rent and gasoline prices.
However, core inflation slowed last month, supporting financial market expectations that the Federal Reserve would not raise interest rates at its November policy meeting.
"You could still expect a bit of a volatile path for equities ahead because the path down from inflation is quite a bumpy one," said Susannah Streeter, head of money and markets, Hargreaves Lansdown.
Yields on the U.S. US10YT=RR and Canadian CA10YT=RR benchmark bonds rose after the CPI data came out, while the U.S. dollar =USD gained.
Rate-sensitive real estate stocks .GSPTTRE led sectoral declines, down 1.1%.
The energy sector .SPTTEN was an outlier and climbed 0.5%, touching an over one-week high as oil prices rose on expectations that U.S. interest rates had peaked and the OPEC reiterated its demand forecast. O/R
The Organization of the Petroleum Exporting Countries stuck to its forecast for relatively strong growth in global oil demand in 2024, citing signs of a resilient world economy and expectations of more robust demand from China.
In corporate news, Air CanadaAC.TO was sued by Miami-based transport and security services provider Brink's for alleged "negligence and carelessness" over a gold and cash heist at a Toronto cargo facility in April. The stock was down 1.2%.
(Reporting by Khushi Singh in Bengaluru; Editing by Tasim Zahid)
((Khushi.Singh@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In corporate news, Air CanadaAC.TO was sued by Miami-based transport and security services provider Brink's for alleged "negligence and carelessness" over a gold and cash heist at a Toronto cargo facility in April. However, core inflation slowed last month, supporting financial market expectations that the Federal Reserve would not raise interest rates at its November policy meeting. The energy sector .SPTTEN was an outlier and climbed 0.5%, touching an over one-week high as oil prices rose on expectations that U.S. interest rates had peaked and the OPEC reiterated its demand forecast. | In corporate news, Air CanadaAC.TO was sued by Miami-based transport and security services provider Brink's for alleged "negligence and carelessness" over a gold and cash heist at a Toronto cargo facility in April. By Khushi Singh Oct 12 (Reuters) - Canada's main stock index slipped on Thursday, snapping a five-day winning streak as Treasury yields spiked after September U.S. inflation rose more than expected, while energy stocks gained on higher oil prices. However, core inflation slowed last month, supporting financial market expectations that the Federal Reserve would not raise interest rates at its November policy meeting. | In corporate news, Air CanadaAC.TO was sued by Miami-based transport and security services provider Brink's for alleged "negligence and carelessness" over a gold and cash heist at a Toronto cargo facility in April. By Khushi Singh Oct 12 (Reuters) - Canada's main stock index slipped on Thursday, snapping a five-day winning streak as Treasury yields spiked after September U.S. inflation rose more than expected, while energy stocks gained on higher oil prices. The energy sector .SPTTEN was an outlier and climbed 0.5%, touching an over one-week high as oil prices rose on expectations that U.S. interest rates had peaked and the OPEC reiterated its demand forecast. | In corporate news, Air CanadaAC.TO was sued by Miami-based transport and security services provider Brink's for alleged "negligence and carelessness" over a gold and cash heist at a Toronto cargo facility in April. By Khushi Singh Oct 12 (Reuters) - Canada's main stock index slipped on Thursday, snapping a five-day winning streak as Treasury yields spiked after September U.S. inflation rose more than expected, while energy stocks gained on higher oil prices. The energy sector .SPTTEN was an outlier and climbed 0.5%, touching an over one-week high as oil prices rose on expectations that U.S. interest rates had peaked and the OPEC reiterated its demand forecast. |
34765.0 | 2023-10-12 00:00:00 UTC | CANADA STOCKS-Commodities push TSX futures higher, US CPI data in focus | AC | https://www.nasdaq.com/articles/canada-stocks-commodities-push-tsx-futures-higher-us-cpi-data-in-focus | nan | nan | Oct 12 (Reuters) - Futures for Canada's main stock index rose on Thursday, as commodity prices edged higher on hopes of fresh China stimulus, while yields retreated ahead of key inflation data from the United States.
December futures on the S&P/TSX index SXFc1 were up 0.5% at 7:01 a.m. ET (11:01 GMT).
The materials sector is expected to get a boost as prices of both copper and gold moved upwards on a softer dollar and a | Oct 12 (Reuters) - Futures for Canada's main stock index rose on Thursday, as commodity prices edged higher on hopes of fresh China stimulus, while yields retreated ahead of key inflation data from the United States. December futures on the S&P/TSX index SXFc1 were up 0.5% at 7:01 a.m. The materials sector is expected to get a boost as prices of both copper and gold moved upwards on a softer dollar and a | Oct 12 (Reuters) - Futures for Canada's main stock index rose on Thursday, as commodity prices edged higher on hopes of fresh China stimulus, while yields retreated ahead of key inflation data from the United States. December futures on the S&P/TSX index SXFc1 were up 0.5% at 7:01 a.m. ET (11:01 GMT). | Oct 12 (Reuters) - Futures for Canada's main stock index rose on Thursday, as commodity prices edged higher on hopes of fresh China stimulus, while yields retreated ahead of key inflation data from the United States. ET (11:01 GMT). The materials sector is expected to get a boost as prices of both copper and gold moved upwards on a softer dollar and a | Oct 12 (Reuters) - Futures for Canada's main stock index rose on Thursday, as commodity prices edged higher on hopes of fresh China stimulus, while yields retreated ahead of key inflation data from the United States. December futures on the S&P/TSX index SXFc1 were up 0.5% at 7:01 a.m. ET (11:01 GMT). |
34766.0 | 2023-10-11 00:00:00 UTC | Air Canada sued by Miami-based Brink's in relation to $17 mln gold and cash heist | AC | https://www.nasdaq.com/articles/air-canada-sued-by-miami-based-brinks-in-relation-to-%2417-mln-gold-and-cash-heist | nan | nan | Oct 11 (Reuters) - Air Canada AC.TO has been sued by Miami-based transport and security services provider Brink's, which alleged the airline of "negligence and carelessness" related to a gold and cash heist at a Toronto cargo facility in April, a court filing showed.
Brink's claimed that the airline allowed an unidentified individual inside its cargo facility at the Toronto Pearson airport and released about 400 kilograms of gold and $1.95 million in cash upon being presented with a fraudulent waybill.
According to the lawsuit, Brink's was hired by Swiss bank Raiffeisen Schweiz and precious metals refining company Valcambi to move the cash and gold from Zurich to Toronto.
A police investigation is ongoing but there have been no arrests or convictions and the shipments have not been recovered, the lawsuit said.
Brink's alleged that Canada's largest airline failed to enlist reasonable and appropriate security measures and protocols to prevent the heist, according to a statement of claim filed in Canada's federal court on Oct. 6.
Air Canada did not immediately respond to Reuters' request for a comment.
Brink's claimed that Air Canada is liable for the full amount of the value of shipments, which would be worth about $17 million.
(Reporting by Shivansh Tiwary in Bengaluru; Editing by Shilpi Majumdar)
((Shivansh.Tiwary@thomsonreuters.com; +91 9708363192;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Oct 11 (Reuters) - Air Canada AC.TO has been sued by Miami-based transport and security services provider Brink's, which alleged the airline of "negligence and carelessness" related to a gold and cash heist at a Toronto cargo facility in April, a court filing showed. Brink's claimed that the airline allowed an unidentified individual inside its cargo facility at the Toronto Pearson airport and released about 400 kilograms of gold and $1.95 million in cash upon being presented with a fraudulent waybill. According to the lawsuit, Brink's was hired by Swiss bank Raiffeisen Schweiz and precious metals refining company Valcambi to move the cash and gold from Zurich to Toronto. | Oct 11 (Reuters) - Air Canada AC.TO has been sued by Miami-based transport and security services provider Brink's, which alleged the airline of "negligence and carelessness" related to a gold and cash heist at a Toronto cargo facility in April, a court filing showed. Brink's alleged that Canada's largest airline failed to enlist reasonable and appropriate security measures and protocols to prevent the heist, according to a statement of claim filed in Canada's federal court on Oct. 6. Brink's claimed that the airline allowed an unidentified individual inside its cargo facility at the Toronto Pearson airport and released about 400 kilograms of gold and $1.95 million in cash upon being presented with a fraudulent waybill. | Oct 11 (Reuters) - Air Canada AC.TO has been sued by Miami-based transport and security services provider Brink's, which alleged the airline of "negligence and carelessness" related to a gold and cash heist at a Toronto cargo facility in April, a court filing showed. Brink's claimed that the airline allowed an unidentified individual inside its cargo facility at the Toronto Pearson airport and released about 400 kilograms of gold and $1.95 million in cash upon being presented with a fraudulent waybill. Brink's alleged that Canada's largest airline failed to enlist reasonable and appropriate security measures and protocols to prevent the heist, according to a statement of claim filed in Canada's federal court on Oct. 6. | Oct 11 (Reuters) - Air Canada AC.TO has been sued by Miami-based transport and security services provider Brink's, which alleged the airline of "negligence and carelessness" related to a gold and cash heist at a Toronto cargo facility in April, a court filing showed. According to the lawsuit, Brink's was hired by Swiss bank Raiffeisen Schweiz and precious metals refining company Valcambi to move the cash and gold from Zurich to Toronto. Brink's claimed that the airline allowed an unidentified individual inside its cargo facility at the Toronto Pearson airport and released about 400 kilograms of gold and $1.95 million in cash upon being presented with a fraudulent waybill. |
34767.0 | 2023-10-10 00:00:00 UTC | Boeing 737 MAX monthly deliveries fall to lowest since 2021 | AC | https://www.nasdaq.com/articles/boeing-737-max-monthly-deliveries-fall-to-lowest-since-2021 | nan | nan | By David Shepardson
WASHINGTON, Oct 10 (Reuters) - Boeing BA.N deliveries of its best-selling 737 MAX fell in September to the lowest level since August 2021, the plane maker said on Tuesday, as it continues struggling with work needed to correct a manufacturing defect.
Boeing is inspecting and fixing thousands of holes that were drilled wrong on the 737 MAX aft pressure bulkhead. While new orders improved sharply, the largest U.S. planemaker said deliveries in September fell to 15 737 MAX planes, 10 787s and two 777s, for a total of 27 deliveries.
The monthly number of MAX 8 and MAX 9 deliveries was the fourth-lowest since deliveries resumed in December 2020 after a worldwide grounding following two MAX crashes in 2018 and 2019 that killed 346 people.
The planemaker booked significant new orders in September for 224 planes and reported 10 cancellations. The new orders include 50 787s for United Airlines UAL.Oand 18 787s for Air CanadaAC.TO.
Boeing shares rose 2.6% on Tuesday in mid-day trading.
Investors closely watch delivery numbers, as airplane makers receive the majority of payment for an aircraft when the customer receives it.
Overall, Boeing has handed over 371 planes to customers during the first nine months of 2023, including 286 737s and 50 787salong with 35 other planes. By comparison, European rival Airbus AIR.PA has delivered 488 aircraft over the first nine months, including 55 in September.
Carriers have been placing orders with urgency as Boeing and Airbus backlogs have grown and as jet deliveries have been pushed out toward the end of the decade.
Boeing's gross orders since the start of January rose to 848 in September, or 724 net orders after factoring in cancellations and conversions. Airbus has booked 1,280 gross orders or 1,241 after cancellations.
Boeing's commercial backlog increased from 4,971 to 5,172. Boeing said September was the first month since December 2019 that its official backlog surpassed 5,000.
Separately, Boeing is still awaiting certification of the smaller 737 MAX 7 from the Federal Aviation Administration that has been reviewing the plane for more than a year. The planemaker said in July the first delivery of the 737 MAX 7 had been delayed to 2024.
Boeing sets record 737 production goal for July 2025 -sources
Boeing boosts monthly 737 production as results beat estimates
Boeing pauses deliveries of some 737 MAXs amid new supplier problem
Boeing says about 90% of China 737 MAX jets have resumed commercial operations
Airbus nears decision on new planemaking leadership - sources
ANALYSIS-Behind aviation recovery, suppliers struggle to keep up
(Reporting by David Shepardson and Tim Hepher Editing by Nick Zieminski and David Gregorio)
((David.Shepardson@thomsonreuters.com; 2028988324;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By David Shepardson WASHINGTON, Oct 10 (Reuters) - Boeing BA.N deliveries of its best-selling 737 MAX fell in September to the lowest level since August 2021, the plane maker said on Tuesday, as it continues struggling with work needed to correct a manufacturing defect. Carriers have been placing orders with urgency as Boeing and Airbus backlogs have grown and as jet deliveries have been pushed out toward the end of the decade. The new orders include 50 787s for United Airlines UAL.Oand 18 787s for Air CanadaAC.TO. | By David Shepardson WASHINGTON, Oct 10 (Reuters) - Boeing BA.N deliveries of its best-selling 737 MAX fell in September to the lowest level since August 2021, the plane maker said on Tuesday, as it continues struggling with work needed to correct a manufacturing defect. The new orders include 50 787s for United Airlines UAL.Oand 18 787s for Air CanadaAC.TO. Carriers have been placing orders with urgency as Boeing and Airbus backlogs have grown and as jet deliveries have been pushed out toward the end of the decade. | By David Shepardson WASHINGTON, Oct 10 (Reuters) - Boeing BA.N deliveries of its best-selling 737 MAX fell in September to the lowest level since August 2021, the plane maker said on Tuesday, as it continues struggling with work needed to correct a manufacturing defect. The new orders include 50 787s for United Airlines UAL.Oand 18 787s for Air CanadaAC.TO. Carriers have been placing orders with urgency as Boeing and Airbus backlogs have grown and as jet deliveries have been pushed out toward the end of the decade. | By David Shepardson WASHINGTON, Oct 10 (Reuters) - Boeing BA.N deliveries of its best-selling 737 MAX fell in September to the lowest level since August 2021, the plane maker said on Tuesday, as it continues struggling with work needed to correct a manufacturing defect. The new orders include 50 787s for United Airlines UAL.Oand 18 787s for Air CanadaAC.TO. Carriers have been placing orders with urgency as Boeing and Airbus backlogs have grown and as jet deliveries have been pushed out toward the end of the decade. |
34768.0 | 2023-10-06 00:00:00 UTC | CANADA STOCKS-TSX set for third weekly loss as robust jobs data fuel rate hike fears | AC | https://www.nasdaq.com/articles/canada-stocks-tsx-set-for-third-weekly-loss-as-robust-jobs-data-fuel-rate-hike-fears | nan | nan | By Khushi Singh
Oct 6 (Reuters) - Canada's main stock index tumbled on Friday, marking its third consecutive weekly decline, as domestic and U.S. data showed more-than-expected job additions in September, spurring speculation of another interest rate hike this year.
At 10:29 a.m. ET (14:29 GMT), the Toronto Stock Exchange's S&P/TSX composite index .GSPTSE was down 147.94 points, or 0.77%, at 18,989.87.
U.S. job growth surged in September, suggesting that the labor market in the world's largest economy remains strong enough for the Federal Reserve to raise interest rates this year, though wage growth moderated.
Canada added 63,800 jobs in September, three times the expected number, even as wages continued to soar, increasing the chances for another rate hike by the Bank of Canada.
Money markets increased bets on a domestic rate hike later this month after the employment figures were published. They now see about a 40% chance for a hike in October compared to a 28% chance before the data came out.
"Markets have taken the jobs data as an indication that the economy is strong, which is certainly good for corporate earnings," said Colin Cieszynski, chief market strategist at SIA Wealth Management.
"However, it has also sparked a sell-off, which is more related to monetary policy than to corporate earnings."
Markets saw an uptick in long-term government bond yields, and the dollar strengthened over fears of interest rates staying elevated for longer.
Rate-sensitive real estate .GSPTTRE stocks fell 1.8%, while the materials sector .GSPTTMT, which includes precious and base metals miners and fertilizer companies, gained 0.2% despite a fall in the prices of most metals. GOL/MET/L
The energy sector .SPTTENclocked its worst weekly performance in seven months, down 0.3%. O/R
The healthcare sector .GSPTTHC slipped 2.2%, weighed down by a 3.1% fall in Tilray Brands TLRY.TO shares as TD Cowen slashed its price target for the cannabis-lifestyle company.
Canada's largest airline, Air Canada AC.TO fell 0.7% after CIBC cut its price target on the stock over fuel hike concerns.
(Reporting by Khushi Singh in Bengaluru; Editing by Tasim Zahid)
((Khushi.Singh@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Canada's largest airline, Air Canada AC.TO fell 0.7% after CIBC cut its price target on the stock over fuel hike concerns. By Khushi Singh Oct 6 (Reuters) - Canada's main stock index tumbled on Friday, marking its third consecutive weekly decline, as domestic and U.S. data showed more-than-expected job additions in September, spurring speculation of another interest rate hike this year. Markets saw an uptick in long-term government bond yields, and the dollar strengthened over fears of interest rates staying elevated for longer. | Canada's largest airline, Air Canada AC.TO fell 0.7% after CIBC cut its price target on the stock over fuel hike concerns. By Khushi Singh Oct 6 (Reuters) - Canada's main stock index tumbled on Friday, marking its third consecutive weekly decline, as domestic and U.S. data showed more-than-expected job additions in September, spurring speculation of another interest rate hike this year. U.S. job growth surged in September, suggesting that the labor market in the world's largest economy remains strong enough for the Federal Reserve to raise interest rates this year, though wage growth moderated. | Canada's largest airline, Air Canada AC.TO fell 0.7% after CIBC cut its price target on the stock over fuel hike concerns. By Khushi Singh Oct 6 (Reuters) - Canada's main stock index tumbled on Friday, marking its third consecutive weekly decline, as domestic and U.S. data showed more-than-expected job additions in September, spurring speculation of another interest rate hike this year. U.S. job growth surged in September, suggesting that the labor market in the world's largest economy remains strong enough for the Federal Reserve to raise interest rates this year, though wage growth moderated. | Canada's largest airline, Air Canada AC.TO fell 0.7% after CIBC cut its price target on the stock over fuel hike concerns. U.S. job growth surged in September, suggesting that the labor market in the world's largest economy remains strong enough for the Federal Reserve to raise interest rates this year, though wage growth moderated. Canada added 63,800 jobs in September, three times the expected number, even as wages continued to soar, increasing the chances for another rate hike by the Bank of Canada. |
34769.0 | 2023-10-06 00:00:00 UTC | CANADA STOCKS-TSX futures rise ahead of US jobs data | AC | https://www.nasdaq.com/articles/canada-stocks-tsx-futures-rise-ahead-of-us-jobs-data | nan | nan | Oct 6 (Reuters) - Futures for Canada's main stock index rose on Friday with investors focusing on the U.S. non-farm payrolls report for insights into the global interest rate path, while rising oil prices boosted sentiment.
December futures on the S&P/TSX index SXFc1 were up 0.2% at 7:10 a.m. ET (1110 GMT).
The benchmark index is, however, set to post weekly declines after a turbulent week of rising bond yields and a stronger dollar.
Long-term government bond yields skyrocketed to a 16-year high earlier in the week on fears of higher interest rates, hurting the equities.
The Toronto Stock Exchange's S&P/TSX composite index .GSPTSE ended Thursday up 103 points, or 0.5%, at 19,137.81, led by gains in interest-rate sensitive sectors after bond yields eased. .TO
Following mixed signals from the job reports earlier this week, the focus has shifted to the more comprehensive U.S. non-farm payrolls data for September, due at 08:30 am ET, whichshould provide a clearer picture on whether the Fed would keep rates higher for longer.
Futures tracking Wall Street's main indexes were subdued on Friday as investors awaited the jobs report to look for signs of a slowing labor market. .N
On the Canadian front, domestic employment change and unemployment rate data, scheduled for 08:30 am ET, will likely set Bank of Canada hike expectations.
Currently, money markets attach a 27% chance of a 25-basis-point hike in the benchmark rate in October by the BoC, according to LSEG data.
Among sectors, energy shares are expected to get some relief with oil prices stable on Friday but are set to post their worst weekly losses in over 7 months.
In corporate news, CIBC downgraded its price target for Air CanadaAC.TO to C$30 from C$33 over fuel hike concerns.
COMMODITIES AT 7:10 a.m. ET
Gold futures GCc2: $1,827.8; +0.3% GOL/
US crude CLc1: $82.48; +0.2% O/R
Brent crude LCOc1: $84.24; +0.2% O/R
($1= C$1.371)
(Reporting by Khushi Singh in Bengaluru; Editing by Tasim Zahid)
((Khushi.Singh@thomsonreuters.com ;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Futures tracking Wall Street's main indexes were subdued on Friday as investors awaited the jobs report to look for signs of a slowing labor market. Currently, money markets attach a 27% chance of a 25-basis-point hike in the benchmark rate in October by the BoC, according to LSEG data. In corporate news, CIBC downgraded its price target for Air CanadaAC.TO to C$30 from C$33 over fuel hike concerns. | Futures tracking Wall Street's main indexes were subdued on Friday as investors awaited the jobs report to look for signs of a slowing labor market. Currently, money markets attach a 27% chance of a 25-basis-point hike in the benchmark rate in October by the BoC, according to LSEG data. In corporate news, CIBC downgraded its price target for Air CanadaAC.TO to C$30 from C$33 over fuel hike concerns. | Futures tracking Wall Street's main indexes were subdued on Friday as investors awaited the jobs report to look for signs of a slowing labor market. Currently, money markets attach a 27% chance of a 25-basis-point hike in the benchmark rate in October by the BoC, according to LSEG data. In corporate news, CIBC downgraded its price target for Air CanadaAC.TO to C$30 from C$33 over fuel hike concerns. | Futures tracking Wall Street's main indexes were subdued on Friday as investors awaited the jobs report to look for signs of a slowing labor market. Currently, money markets attach a 27% chance of a 25-basis-point hike in the benchmark rate in October by the BoC, according to LSEG data. In corporate news, CIBC downgraded its price target for Air CanadaAC.TO to C$30 from C$33 over fuel hike concerns. |
34770.0 | 2023-09-27 00:00:00 UTC | Air Canada to operate as usual during informational picket by pilots union | AC | https://www.nasdaq.com/articles/air-canada-to-operate-as-usual-during-informational-picket-by-pilots-union | nan | nan | Sept 27 (Reuters) - Air Canada AC.TO said on Wednesday it will operate the airline as usual when its pilots conduct an informational picket at the company's main hub, the Pearson International Airport, on Friday.
Canadian pilots are pressing for higher salaries and better scheduling after U.S. counterparts at companies including Delta Air Lines DAL.N and American Airlines AAL.O made big gains in deals struck over the last few months.
"As we watch Air Canada cut routes due to an industry-wide shortage of pilots, we encourage them to close the growing wage gap between Canada and the United States," said Charlene Hudy, chair of the Air Canada Master Executive Council, in a statement on Tuesday.
The move also comes amid wider strike action in North America that has seen workers across industries demand better pay and benefits in a tight labor market and as inflation stays high.
Air Canada's estimated 4,500 pilots have received a 2% wage increase per year since 2014. The country's inflation rate was running at 4.3% in March, a 19-month low.
The pilots, represented by the Air Line Pilots Association (ALPA) union, began bargaining for new labor terms this summer, before the end of their decade-long contract.
The company said on Wednesday its contract with ALPA's provisions remains in effect ahead of the picket.
The union had a May deadline for using a type of escape clause that would allow for negotiations this year. The agreement now runs until Sept. 29, although its provisions will apply beyond that date.
(Reporting by Ananta Agarwal in Bengaluru; Editing by Devika Syamnath)
((Ananta.agarwal@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Sept 27 (Reuters) - Air Canada AC.TO said on Wednesday it will operate the airline as usual when its pilots conduct an informational picket at the company's main hub, the Pearson International Airport, on Friday. The move also comes amid wider strike action in North America that has seen workers across industries demand better pay and benefits in a tight labor market and as inflation stays high. The pilots, represented by the Air Line Pilots Association (ALPA) union, began bargaining for new labor terms this summer, before the end of their decade-long contract. | The pilots, represented by the Air Line Pilots Association (ALPA) union, began bargaining for new labor terms this summer, before the end of their decade-long contract. The company said on Wednesday its contract with ALPA's provisions remains in effect ahead of the picket. Sept 27 (Reuters) - Air Canada AC.TO said on Wednesday it will operate the airline as usual when its pilots conduct an informational picket at the company's main hub, the Pearson International Airport, on Friday. | Sept 27 (Reuters) - Air Canada AC.TO said on Wednesday it will operate the airline as usual when its pilots conduct an informational picket at the company's main hub, the Pearson International Airport, on Friday. The pilots, represented by the Air Line Pilots Association (ALPA) union, began bargaining for new labor terms this summer, before the end of their decade-long contract. The move also comes amid wider strike action in North America that has seen workers across industries demand better pay and benefits in a tight labor market and as inflation stays high. | The company said on Wednesday its contract with ALPA's provisions remains in effect ahead of the picket. Sept 27 (Reuters) - Air Canada AC.TO said on Wednesday it will operate the airline as usual when its pilots conduct an informational picket at the company's main hub, the Pearson International Airport, on Friday. The move also comes amid wider strike action in North America that has seen workers across industries demand better pay and benefits in a tight labor market and as inflation stays high. |
34771.0 | 2023-09-26 00:00:00 UTC | CANADA STOCKS-TSX eyes lower open as commodity prices fall, rate woes remain | AC | https://www.nasdaq.com/articles/canada-stocks-tsx-eyes-lower-open-as-commodity-prices-fall-rate-woes-remain | nan | nan | Sept 26 (Reuters) - Futures linked to Canada's main stock index declined on Tuesday as commodity prices slipped over demand concerns from top consumer China and fears that interest rates will not fall any time soon.
September futures on the S&P/TSX index SXFc1 were down 0.4% at 7:35 a.m. ET (1135 GMT).
Shares of energy and material stocks are expected to take a hit after most metals and oil prices fell tracking a rising dollar and higher-for-longer interest rate expectations. GOL/MET/LO/R
Copper prices were also hurt by growing concerns over China's property sector along with a week-long holiday in China starting on Sept. 29.
Minneapolis Fed President Neel Kashkari said on Monday that given the surprising resilience of the U.S. economy, the Fed probably needs to raise borrowing rates further and keep them high for some time to bring inflation to 2%.
The Toronto Stock Exchange's S&P/TSX composite index .GSPTSE ended Monday up 20.64 points, or 0.1%, higher at 19,800.61, its first gain after five straight days of declines as energy shares rallied. .TO
U.S. stock index futures declined on Tuesday, with the likelihood of a partial shutdown of the U.S. government by Sunday added to investor anxiety of rigid rates. .N
In corporate news, Air Canada AC.TO on Monday signed an agreement with U.S. planemaker Boeing BA.N to buy 18 widebody 787 Dreamliner jets.
COMMODITIES AT 7:35 a.m. ET
Gold futures GCc2: $1,913; -+-0.3% GOL/
US crude CLc1: $89.06; -+-0.7% O/R
Brent crude LCOc1: $92.63; -+-0.7% O/R
FOR CANADIAN MARKETS NEWS, CLICK ON CODES:
TSX market report .TO
Canadian dollar and bonds report CAD/CA/
Reuters global stocks poll for Canada EQUITYPOLL1, EPOLL/CA
Canadian markets directory CANADA
($1= C$1.3492)
(Reporting by Khushi Singh in Bengaluru; Editing by Tasim Zahid)
((Khushi.Singh@thomsonreuters.com ;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shares of energy and material stocks are expected to take a hit after most metals and oil prices fell tracking a rising dollar and higher-for-longer interest rate expectations. .N In corporate news, Air Canada AC.TO on Monday signed an agreement with U.S. planemaker Boeing BA.N to buy 18 widebody 787 Dreamliner jets. Sept 26 (Reuters) - Futures linked to Canada's main stock index declined on Tuesday as commodity prices slipped over demand concerns from top consumer China and fears that interest rates will not fall any time soon. | Shares of energy and material stocks are expected to take a hit after most metals and oil prices fell tracking a rising dollar and higher-for-longer interest rate expectations. .N In corporate news, Air Canada AC.TO on Monday signed an agreement with U.S. planemaker Boeing BA.N to buy 18 widebody 787 Dreamliner jets. Sept 26 (Reuters) - Futures linked to Canada's main stock index declined on Tuesday as commodity prices slipped over demand concerns from top consumer China and fears that interest rates will not fall any time soon. | Shares of energy and material stocks are expected to take a hit after most metals and oil prices fell tracking a rising dollar and higher-for-longer interest rate expectations. .N In corporate news, Air Canada AC.TO on Monday signed an agreement with U.S. planemaker Boeing BA.N to buy 18 widebody 787 Dreamliner jets. Sept 26 (Reuters) - Futures linked to Canada's main stock index declined on Tuesday as commodity prices slipped over demand concerns from top consumer China and fears that interest rates will not fall any time soon. | Shares of energy and material stocks are expected to take a hit after most metals and oil prices fell tracking a rising dollar and higher-for-longer interest rate expectations. .N In corporate news, Air Canada AC.TO on Monday signed an agreement with U.S. planemaker Boeing BA.N to buy 18 widebody 787 Dreamliner jets. Sept 26 (Reuters) - Futures linked to Canada's main stock index declined on Tuesday as commodity prices slipped over demand concerns from top consumer China and fears that interest rates will not fall any time soon. |
34772.0 | 2023-09-25 00:00:00 UTC | Air Canada to buy 18 Boeing 787 jets | AC | https://www.nasdaq.com/articles/air-canada-to-buy-18-boeing-787-jets | nan | nan | Sept 25 (Reuters) - Air Canada AC.TO said on Monday it had signed an agreement with Boeing BA.N to buy 18 widebody 787 Dreamliner jets, as the carrier looks to capitalize on strong travel demand and deploy fuel-efficient airplanes.
The contract for Boeing's 787-10 jets includes an option to purchase 12 more aircraft.
"The 787 is highly fuel efficient and will generate operational savings as well as support our sustainability goals of reducing emissions," Air Canada CEO Michael Rousseau said.
Bloomberg in May first reported that the carrier was nearing a 787 Dreamliner deal with Boeing.
(Reporting by Abhinav Parmar in Bengaluru; Editing by Shinjini Ganguli)
((Abhinav.Parmar@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Sept 25 (Reuters) - Air Canada AC.TO said on Monday it had signed an agreement with Boeing BA.N to buy 18 widebody 787 Dreamliner jets, as the carrier looks to capitalize on strong travel demand and deploy fuel-efficient airplanes. The contract for Boeing's 787-10 jets includes an option to purchase 12 more aircraft. "The 787 is highly fuel efficient and will generate operational savings as well as support our sustainability goals of reducing emissions," Air Canada CEO Michael Rousseau said. | Sept 25 (Reuters) - Air Canada AC.TO said on Monday it had signed an agreement with Boeing BA.N to buy 18 widebody 787 Dreamliner jets, as the carrier looks to capitalize on strong travel demand and deploy fuel-efficient airplanes. The contract for Boeing's 787-10 jets includes an option to purchase 12 more aircraft. "The 787 is highly fuel efficient and will generate operational savings as well as support our sustainability goals of reducing emissions," Air Canada CEO Michael Rousseau said. | Sept 25 (Reuters) - Air Canada AC.TO said on Monday it had signed an agreement with Boeing BA.N to buy 18 widebody 787 Dreamliner jets, as the carrier looks to capitalize on strong travel demand and deploy fuel-efficient airplanes. The contract for Boeing's 787-10 jets includes an option to purchase 12 more aircraft. "The 787 is highly fuel efficient and will generate operational savings as well as support our sustainability goals of reducing emissions," Air Canada CEO Michael Rousseau said. | Sept 25 (Reuters) - Air Canada AC.TO said on Monday it had signed an agreement with Boeing BA.N to buy 18 widebody 787 Dreamliner jets, as the carrier looks to capitalize on strong travel demand and deploy fuel-efficient airplanes. The contract for Boeing's 787-10 jets includes an option to purchase 12 more aircraft. "The 787 is highly fuel efficient and will generate operational savings as well as support our sustainability goals of reducing emissions," Air Canada CEO Michael Rousseau said. |
34773.0 | 2023-09-20 00:00:00 UTC | Air Canada says unauthorised group briefly had access to internal system | AC | https://www.nasdaq.com/articles/air-canada-says-unauthorised-group-briefly-had-access-to-internal-system | nan | nan | Adds details on unauthorised access in paragraphs 2-3
Sept 20 (Reuters) - Air Canada AC.TO said on Wednesday an unauthorised group briefly had limited access to an internal Air Canada system that had personal information of some employees and certain records.
"We can confirm that our flight operations systems and customer facing systems were not affected. No customer information was accessed," according to the airline.
Air Canada said its systems were fully operational and the company has since implemented enhancements to its security measures. | Adds details on unauthorised access in paragraphs 2-3 Sept 20 (Reuters) - Air Canada AC.TO said on Wednesday an unauthorised group briefly had limited access to an internal Air Canada system that had personal information of some employees and certain records. No customer information was accessed," according to the airline. "We can confirm that our flight operations systems and customer facing systems were not affected. | Adds details on unauthorised access in paragraphs 2-3 Sept 20 (Reuters) - Air Canada AC.TO said on Wednesday an unauthorised group briefly had limited access to an internal Air Canada system that had personal information of some employees and certain records. "We can confirm that our flight operations systems and customer facing systems were not affected. No customer information was accessed," according to the airline. | Adds details on unauthorised access in paragraphs 2-3 Sept 20 (Reuters) - Air Canada AC.TO said on Wednesday an unauthorised group briefly had limited access to an internal Air Canada system that had personal information of some employees and certain records. "We can confirm that our flight operations systems and customer facing systems were not affected. No customer information was accessed," according to the airline. | Adds details on unauthorised access in paragraphs 2-3 Sept 20 (Reuters) - Air Canada AC.TO said on Wednesday an unauthorised group briefly had limited access to an internal Air Canada system that had personal information of some employees and certain records. "We can confirm that our flight operations systems and customer facing systems were not affected. No customer information was accessed," according to the airline. |
34774.0 | 2023-09-18 00:00:00 UTC | FOCUS-China's BYD rides on partnerships to expand EV sales in Southeast Asia | AC | https://www.nasdaq.com/articles/focus-chinas-byd-rides-on-partnerships-to-expand-ev-sales-in-southeast-asia | nan | nan | By Devjyot Ghoshal and Stefanno Sulaiman
BANGKOK/JAKARTA, Sept 19 (Reuters) - China's electric vehicle giant BYD 002594.SZ has been on a tear in Southeast Asia, shooting past rivals including Tesla TSLA.O to take more than a quarter of the share of EVs sold in the region.
Along with attractive prices, BYD's early success is based on a pattern of distribution partnerships with large, local conglomerates that have allowed the carmaker to expand reach, test consumer preferences and navigate complex government regulations in the region, officials from three partners and analysts said.
This partnership model, similar to that pursued by Japanese automakers in some Southeast Asian countries decades ago, is helping BYD to build market share rapidly and contrasts with Tesla's go-it-alone distribution - though it comes at a cost.
"At present, BYD's primary focus is on brand proliferation rather than optimising profit margins," said Soumen Mandal, a senior analyst at Counterpoint Research.
"By providing local dealers with more lucrative profit margins, BYD can cultivate trust and loyalty, paving the way for broader expansion."
BYD did not respond to questions from Reuters.
The Chinese automaker sold more than 26% of all cars in Southeast Asia's small but fast-growing EV market in the second quarter of 2023 and its Atto 3 model, priced starting at $30,000 in Thailand, was the regional bestseller, according to Counterpoint. Tesla prices the most basic Model 3 from about $57,500 in Thailand.
'NOT AN EASY MARKET'
BYD's regional distributors include divisions of Sime Darby SIME.KL in Malaysia and Singapore, Indonesia's Bakrie & Brothers BNBR.JK, Ayala Corp AC.PS in the Philippines and Thailand's Rever Automotive.
BYD's partnerships are helping it in a region where Chinese car brands do not have an established track record, said Chee-Kiang Lim, managing director for China at auto sales consultancy Urban Science.
"If buyers are unsure or have any concerns, partnering with established players like Sime Darby, Bakrie & Brothers, or Ayala Corp will give them the peace of mind, especially for aftersales support," he said.
The Shenzhen-based automaker is investing nearly $500 million in Thailand to build a new factory that will produce 150,000 EVs per year from 2024 for exports to Southeast Asia and European markets.
For Ayala Corp's AC Motors, which plans to open a dozen BYD dealerships in the next 12 months in the Philippines, the focus for initial spending is on brand building and getting more consumers considering EVs, said the head of its automotive business, Antonio Zara.
"It's about busting the myths on range," he said. "It's about busting the myth on price and communicating the total cost of ownership."
In Thailand, an advertising spree is visible from small screens inside elevated trains in the capital Bangkok to massive billboards in provincial towns.
BYD's Thai partner Rever did not respond to questions on its distribution and marketing strategy.
In Indonesia, BYD has able to lean on Bakrie & Brothers' unit VKTR to secure a government contract for 52 EV buses for Jakarta, said its chief strategy officer Alex Kim.
"Indonesia is not an easy market to do business on your own," said Kim, adding that, beyond government sales, VKTR was in talks with large domestic businesses to sell BYD EV buses.
TAKING ON TESLA
Thai EV buyers contributed 24% of BYD's overseas sales in the second quarter, making it the Chinese automaker's largest foreign market, according to Counterpoint, whereas fewer than 1% of Tesla's sales are in Southeast Asia.
Tesla's website currently lists only two stores in the region, both in the wealthy city-state of Singapore, though it is hiring for Thailand and Malaysia.
BYD's Southeast Asia playbook and its embrace of dealerships contrasts with Tesla, whose direct-to-consumer approach is hard to replicate, since no other new EV brand has its buzz or the outsized media presence of its CEO Elon Musk.
BYD and its partner Sime Darby Motors are experimenting with a new approach to draw young, tech-savvy consumers towards the Chinese brand in Singapore.
The partnership has launched five "BYD by 1826" showrooms that double as white-tablecloth restaurants where dishes are named after BYD EV models.
"With BYD by 1826, we are able to reach out to more customers who want to know more about BYD or (are) new to the BYD brand," said Jeffrey Gan, managing director of retail and distribution for Sime Darby Motors in Southeast Asia, Hong Kong and Macau.
($1 = 35.6400 baht)
FACTBOX-Chinese EV major BYD's partnerships in Southeast Asia
(Reporting by Devjyot Ghoshal and Stefanno Sulaiman; Editing by Jamie Freed)
((Devjyot.Ghoshal@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Along with attractive prices, BYD's early success is based on a pattern of distribution partnerships with large, local conglomerates that have allowed the carmaker to expand reach, test consumer preferences and navigate complex government regulations in the region, officials from three partners and analysts said. For Ayala Corp's AC Motors, which plans to open a dozen BYD dealerships in the next 12 months in the Philippines, the focus for initial spending is on brand building and getting more consumers considering EVs, said the head of its automotive business, Antonio Zara. The Chinese automaker sold more than 26% of all cars in Southeast Asia's small but fast-growing EV market in the second quarter of 2023 and its Atto 3 model, priced starting at $30,000 in Thailand, was the regional bestseller, according to Counterpoint. | BYD's regional distributors include divisions of Sime Darby SIME.KL in Malaysia and Singapore, Indonesia's Bakrie & Brothers BNBR.JK, Ayala Corp AC.PS in the Philippines and Thailand's Rever Automotive. "With BYD by 1826, we are able to reach out to more customers who want to know more about BYD or (are) new to the BYD brand," said Jeffrey Gan, managing director of retail and distribution for Sime Darby Motors in Southeast Asia, Hong Kong and Macau. ($1 = 35.6400 baht) FACTBOX-Chinese EV major BYD's partnerships in Southeast Asia (Reporting by Devjyot Ghoshal and Stefanno Sulaiman; Editing by Jamie Freed) ((Devjyot.Ghoshal@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Thai EV buyers contributed 24% of BYD's overseas sales in the second quarter, making it the Chinese automaker's largest foreign market, according to Counterpoint, whereas fewer than 1% of Tesla's sales are in Southeast Asia. "With BYD by 1826, we are able to reach out to more customers who want to know more about BYD or (are) new to the BYD brand," said Jeffrey Gan, managing director of retail and distribution for Sime Darby Motors in Southeast Asia, Hong Kong and Macau. Along with attractive prices, BYD's early success is based on a pattern of distribution partnerships with large, local conglomerates that have allowed the carmaker to expand reach, test consumer preferences and navigate complex government regulations in the region, officials from three partners and analysts said. | The Chinese automaker sold more than 26% of all cars in Southeast Asia's small but fast-growing EV market in the second quarter of 2023 and its Atto 3 model, priced starting at $30,000 in Thailand, was the regional bestseller, according to Counterpoint. BYD's regional distributors include divisions of Sime Darby SIME.KL in Malaysia and Singapore, Indonesia's Bakrie & Brothers BNBR.JK, Ayala Corp AC.PS in the Philippines and Thailand's Rever Automotive. Thai EV buyers contributed 24% of BYD's overseas sales in the second quarter, making it the Chinese automaker's largest foreign market, according to Counterpoint, whereas fewer than 1% of Tesla's sales are in Southeast Asia. |
34775.0 | 2023-09-08 00:00:00 UTC | World food price index back at two-year low despite rice surge -FAO | AC | https://www.nasdaq.com/articles/world-food-price-index-back-at-two-year-low-despite-rice-surge-fao | nan | nan | Adds details, background in paragraph 3 and from paragraph 5
PARIS, Sept 8 (Reuters) - The United Nations food agency's world price index fell in August to a new two-year low, reversing a rebound seen the previous month, as a decline in most food commodities offset increases for rice and sugar.
The Food and Agriculture Organization's (FAO) price index, which tracks the most globally traded food commodities, averaged 121.4 points in August against a revised 124.0 for the previous month, the agency said on Friday.
The July reading was initially given as 123.9 in a rebound from a two-year low in June.
The August figure was the lowest since March 2021 and also 24% below an all-time high reached in March 2022 in the wake of Russia's invasion of Ukraine.
The drop in the overall index reflected declines for dairy products, vegetable oils, meat and cereals, despite a jump in FAO's rice benchmark to a 15-year high following Indian export restrictions, the agency said.
FAO's cereal index edged down 0.7% from July as wheat prices fell in the face of northern hemisphere harvests while maize (corn) fell for a seventh straight month to a near three-year low, pressured by a record Brazilian crop and the approaching U.S. harvest, it said.
In contrast, the agency's rice index surged by almost 10% month-on-month as India's decision in July to ban Indica white rice exports disrupted trade at a time of tight availabilities ahead of new-crop harvests, FAO said.
FAO's sugar index rose 1.3% month-on-month in August, putting it 34% above the year-earlier level, supported by concerns about impact of the El Nino weather pattern on global production.
Vegetable oil prices were down 3.1% in August, while dairy prices slipped 4%, an eighth straight monthly drop that reflected ample supply in Oceania and slower Chinese imports.
In a separate report on cereal supply and demand, the FAO forecast world cereal production this year at 2.815 billion tonnes, down slightly from a previous estimate of 2.819 billion.
The latest forecast was nonetheless up 0.9% on 2022 and matched record output from 2021, the FAO said.
The downward revision mainly reflected a cut to projected wheat output as dry weather affected Canada and the European Union and heavy rain affected Chinese crops, FAO said.
(Reporting by Gus Trompiz; Editing by Hugh Lawson and Andrew Cawthorne)
((gus.trompiz@thomsonreuters.com; +33 1 49 49 52 18; Reuters Messaging: gus.trompiz.thomsonreuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds details, background in paragraph 3 and from paragraph 5 PARIS, Sept 8 (Reuters) - The United Nations food agency's world price index fell in August to a new two-year low, reversing a rebound seen the previous month, as a decline in most food commodities offset increases for rice and sugar. FAO's sugar index rose 1.3% month-on-month in August, putting it 34% above the year-earlier level, supported by concerns about impact of the El Nino weather pattern on global production. The Food and Agriculture Organization's (FAO) price index, which tracks the most globally traded food commodities, averaged 121.4 points in August against a revised 124.0 for the previous month, the agency said on Friday. | Adds details, background in paragraph 3 and from paragraph 5 PARIS, Sept 8 (Reuters) - The United Nations food agency's world price index fell in August to a new two-year low, reversing a rebound seen the previous month, as a decline in most food commodities offset increases for rice and sugar. The Food and Agriculture Organization's (FAO) price index, which tracks the most globally traded food commodities, averaged 121.4 points in August against a revised 124.0 for the previous month, the agency said on Friday. The August figure was the lowest since March 2021 and also 24% below an all-time high reached in March 2022 in the wake of Russia's invasion of Ukraine. | Adds details, background in paragraph 3 and from paragraph 5 PARIS, Sept 8 (Reuters) - The United Nations food agency's world price index fell in August to a new two-year low, reversing a rebound seen the previous month, as a decline in most food commodities offset increases for rice and sugar. The Food and Agriculture Organization's (FAO) price index, which tracks the most globally traded food commodities, averaged 121.4 points in August against a revised 124.0 for the previous month, the agency said on Friday. FAO's cereal index edged down 0.7% from July as wheat prices fell in the face of northern hemisphere harvests while maize (corn) fell for a seventh straight month to a near three-year low, pressured by a record Brazilian crop and the approaching U.S. harvest, it said. | Adds details, background in paragraph 3 and from paragraph 5 PARIS, Sept 8 (Reuters) - The United Nations food agency's world price index fell in August to a new two-year low, reversing a rebound seen the previous month, as a decline in most food commodities offset increases for rice and sugar. The August figure was the lowest since March 2021 and also 24% below an all-time high reached in March 2022 in the wake of Russia's invasion of Ukraine. The Food and Agriculture Organization's (FAO) price index, which tracks the most globally traded food commodities, averaged 121.4 points in August against a revised 124.0 for the previous month, the agency said on Friday. |
34776.0 | 2023-09-05 00:00:00 UTC | Canadian pilots eye higher-paid U.S. cockpits as staffing shortages bite | AC | https://www.nasdaq.com/articles/canadian-pilots-eye-higher-paid-u.s.-cockpits-as-staffing-shortages-bite | nan | nan | By Allison Lampert
MONTREAL, Sept 5 (Reuters) - The number of Canadian pilots seeking to fly in the United States tripled in 2022, according to previously unreported U.S. government data, raising fears of deepening shortages in Canada as pilots seek higher wages.
Some 147 Canadian pilots applied for licenses to fly commercial jets in the United States in 2022, up from 39 in 2021, according to Federal Aviation Administration (FAA) data. The number of overall foreign applications roughly doubled to 1,442.
High travel demand in the United States, where pilots are securing historic wage increases, isattracting foreign aviators, despite delays and high costs of immigrating, according to lawyers, unions and pilots.
While small, the increase in U.S. applications is worrisome for regional Canadian carriers, which like their U.S. counterparts, are wrestling with staffing shortages as they lose pilots to larger airlines, industry experts say.
It could also put pressure on Air Canada AC.TO during negotiations with its pilots, whose contract expires on September 29.
Air Canada said this week it would halt six non-stop flights from Calgary at the end of October because of "resource pressures" due to an industry wide shortage of regional pilots.
"It's definitely a concern," said John Gradek, a faculty lecturer in aviation management at McGill University in Montreal.
At Sunwing Airlines, at least 10% of the roughly 490 pilots are applying to work in the U.S., said Mark Taylor, president of the Unifor union local, which represents aviators at the company.
Taylor said he has raised the issue with Sunwing, which didn't return requests for comment. Sunwing has been acquired by WestJet Airlines, which likewise did not respond to requests for comment.
Two Sunwing pilots, who spoke on condition of anonymity because they have not advised their employer of their plans, said they have obtained licenses to fly in the U.S. and are awaiting immigration paperwork to move, due to the higher pay and the high cost of living in Canada's large cities.
Attorney Jean-Francois Harvey said about 29% of the 560 foreign pilots he's helped over the last 12 months are Canadian and fly for Air Canada, WestJet and Sunwing.
Air Canada said it could not comment on "individual pilot career choices," but said it does not "have difficulty attracting pilots" to its main carrier.
According to Air Canada pilots represented by the Air Line Pilots Association (ALPA), the hourly pay gap between the Canadian carrier and United Airlines UAL.O is expected to grow from 3% in 2013 to 92% in 2024 for one category of experienced pilot. Air Canada pilots earned more before 2013.
Gradek warned that the "cascading effect" of larger airlines recruiting pilots away from smaller carriers would lead to reduced frequencies and service cuts on regional routes.
John McKenna, chief executive of the Air Transport Association of Canada (ATAC), which represents smaller Canadian carriers, said his members are already cutting frequencies due to staffing shortages.
"Everyone is suffering right now," he said.
(Reporting By Allison Lampert in Montreal; Editing by Andy Sullivan)
((Allison.Lampert@thomsonreuters.com; 514-796-4212; Reuters Messaging: allison.lampert.reuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | John McKenna, chief executive of the Air Transport Association of Canada (ATAC), which represents smaller Canadian carriers, said his members are already cutting frequencies due to staffing shortages. By Allison Lampert MONTREAL, Sept 5 (Reuters) - The number of Canadian pilots seeking to fly in the United States tripled in 2022, according to previously unreported U.S. government data, raising fears of deepening shortages in Canada as pilots seek higher wages. Some 147 Canadian pilots applied for licenses to fly commercial jets in the United States in 2022, up from 39 in 2021, according to Federal Aviation Administration (FAA) data. | By Allison Lampert MONTREAL, Sept 5 (Reuters) - The number of Canadian pilots seeking to fly in the United States tripled in 2022, according to previously unreported U.S. government data, raising fears of deepening shortages in Canada as pilots seek higher wages. High travel demand in the United States, where pilots are securing historic wage increases, isattracting foreign aviators, despite delays and high costs of immigrating, according to lawyers, unions and pilots. According to Air Canada pilots represented by the Air Line Pilots Association (ALPA), the hourly pay gap between the Canadian carrier and United Airlines UAL.O is expected to grow from 3% in 2013 to 92% in 2024 for one category of experienced pilot. | By Allison Lampert MONTREAL, Sept 5 (Reuters) - The number of Canadian pilots seeking to fly in the United States tripled in 2022, according to previously unreported U.S. government data, raising fears of deepening shortages in Canada as pilots seek higher wages. Air Canada said it could not comment on "individual pilot career choices," but said it does not "have difficulty attracting pilots" to its main carrier. According to Air Canada pilots represented by the Air Line Pilots Association (ALPA), the hourly pay gap between the Canadian carrier and United Airlines UAL.O is expected to grow from 3% in 2013 to 92% in 2024 for one category of experienced pilot. | Some 147 Canadian pilots applied for licenses to fly commercial jets in the United States in 2022, up from 39 in 2021, according to Federal Aviation Administration (FAA) data. By Allison Lampert MONTREAL, Sept 5 (Reuters) - The number of Canadian pilots seeking to fly in the United States tripled in 2022, according to previously unreported U.S. government data, raising fears of deepening shortages in Canada as pilots seek higher wages. High travel demand in the United States, where pilots are securing historic wage increases, isattracting foreign aviators, despite delays and high costs of immigrating, according to lawyers, unions and pilots. |
34777.0 | 2023-08-17 00:00:00 UTC | Air Canada caps Yellowknife flight prices as crews battle wildfires | AC | https://www.nasdaq.com/articles/air-canada-caps-yellowknife-flight-prices-as-crews-battle-wildfires | nan | nan | (Adds context paragraphs 12-13, additional flight from AC, comment from Canadian Northern paragraph 9)
By Allison Lampert and Ismail Shakil
Aug 17 (Reuters) - Air Canada said it is capping fares and adding flights on Thursday from Yellowknife, a northern Canadian city facing an evacuation order due to wildfires, as social media users complain of soaring prices by multiple carriers.
Canadian fire crews battled on Thursday to prevent wildfires from reaching Yellowknife, where all 20,000 residents are leaving by car and plane.
"We have put in place a cap on our fares for non-stop flights out of Yellowknife," said Air Canada, the country's largest carrier, in a statement. They also denied price gouging and said they were working with authorities on how long they could continue flying in the area.
The carrier said it added two extra flights on Thursday and an additional flight on Friday.
WestJet Airlines, the country's second largest carrier, said it has taken steps to avoid fare escalation and has added a flight.
By Thursday afternoon, Air Canada's website showed there were no flights available connecting Yellowknife to Calgary, which has committed to accommodate up to 5,000 evacuees, until Monday. One way flights on the site for Friday were listed for as low as C$303 ($223.72).
Air Canada said it has cancelled flights out of Yellowknife on Saturday to comply with the evacuation order given by the Northwest Territories government.
WestJet said it has cancelled six flights on Friday and Saturday.
Inuit-owned airline Canadian North said in a statement it had cancelled its Yellowknife commercial flights starting on Friday but those aircraft would be deployed to assist government-led evacuation efforts.
Earlier in the day, an image showing a C$4,665 flight ticket from Yellowknife to Calgary caused outrage on social media, with some users accusing Air Canada of taking advantage of increased demand from forced evacuees.
"This is how Air Canada plans on helping?" a Northwest Territories resident wrote on Facebook, tagging the airline.
In fact, the referenced fare which appeared on travel booking sites was not for a direct Air Canada flight, but rather involved trips with three stops operated by different carriers.
It was not clear who set the prices that high. Canada's Transport Minister Pablo Rodriguez is speaking with Air Canada on Thursday to receive an update on the situation on the ground, a spokesperson said. ($1 = 1.3544 Canadian dollars) (Reporting By Allison Lampert in Montreal and Ismail Shakhil in Ottawa; Editing by Josie Kao) ((Allison.Lampert@thomsonreuters.com; 514-796-4212; Reuters Messaging: allison.lampert.reuters.com@reuters.net)) Keywords: CANADA WILDFIRES/FLIGHTS (UPDATE 2, PIX)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (Adds context paragraphs 12-13, additional flight from AC, comment from Canadian Northern paragraph 9) By Allison Lampert and Ismail Shakil Aug 17 (Reuters) - Air Canada said it is capping fares and adding flights on Thursday from Yellowknife, a northern Canadian city facing an evacuation order due to wildfires, as social media users complain of soaring prices by multiple carriers. Inuit-owned airline Canadian North said in a statement it had cancelled its Yellowknife commercial flights starting on Friday but those aircraft would be deployed to assist government-led evacuation efforts. Earlier in the day, an image showing a C$4,665 flight ticket from Yellowknife to Calgary caused outrage on social media, with some users accusing Air Canada of taking advantage of increased demand from forced evacuees. | (Adds context paragraphs 12-13, additional flight from AC, comment from Canadian Northern paragraph 9) By Allison Lampert and Ismail Shakil Aug 17 (Reuters) - Air Canada said it is capping fares and adding flights on Thursday from Yellowknife, a northern Canadian city facing an evacuation order due to wildfires, as social media users complain of soaring prices by multiple carriers. "We have put in place a cap on our fares for non-stop flights out of Yellowknife," said Air Canada, the country's largest carrier, in a statement. Earlier in the day, an image showing a C$4,665 flight ticket from Yellowknife to Calgary caused outrage on social media, with some users accusing Air Canada of taking advantage of increased demand from forced evacuees. | (Adds context paragraphs 12-13, additional flight from AC, comment from Canadian Northern paragraph 9) By Allison Lampert and Ismail Shakil Aug 17 (Reuters) - Air Canada said it is capping fares and adding flights on Thursday from Yellowknife, a northern Canadian city facing an evacuation order due to wildfires, as social media users complain of soaring prices by multiple carriers. "We have put in place a cap on our fares for non-stop flights out of Yellowknife," said Air Canada, the country's largest carrier, in a statement. Air Canada said it has cancelled flights out of Yellowknife on Saturday to comply with the evacuation order given by the Northwest Territories government. | (Adds context paragraphs 12-13, additional flight from AC, comment from Canadian Northern paragraph 9) By Allison Lampert and Ismail Shakil Aug 17 (Reuters) - Air Canada said it is capping fares and adding flights on Thursday from Yellowknife, a northern Canadian city facing an evacuation order due to wildfires, as social media users complain of soaring prices by multiple carriers. Air Canada said it has cancelled flights out of Yellowknife on Saturday to comply with the evacuation order given by the Northwest Territories government. Canadian fire crews battled on Thursday to prevent wildfires from reaching Yellowknife, where all 20,000 residents are leaving by car and plane. |
34778.0 | 2023-08-11 00:00:00 UTC | CANADA STOCKS-TSX gains on energy, material stock boost | AC | https://www.nasdaq.com/articles/canada-stocks-tsx-gains-on-energy-material-stock-boost-0 | nan | nan | *
US PPI rises 0.2% in June
*
Energy lifts TSX
*
TSX up 0.32%
(Adds commentary in paragraph 5 and 6)
By Siddarth S and Nivedita Balu
Aug 11 (Reuters) - Toronto stocks ended higher on Friday, lifted by energy and material stocks, recovering from choppy trading after stronger-than-expected U.S. producer price data prompted investor worries over sticky inflation in the world's largest economy.
The Toronto Stock Exchange's S&P/TSX composite index was up 64.76 points, or 0.32%, at 20,407.64. The index was set to snap two consecutive weekly declines.
Data showed U.S. PPI increased 0.2% in June. On an annual basis, PPI increased 0.8% through June, while economists polled by Reuters had forecast a 0.7% rise.
U.S. consumer prices increased moderately in July at 3.2%, up from 3.0% in June, data showed on Wednesday, but core inflation continued to remain sticky, which worried investors on the Fed's rate hike plans for the rest of 2023.
"Today's numbers partly counter the recent trend we have seen with core inflation easing," said Angelo Kourkafas, investment strategist at Edward Jones Investments. "They didn't necessarily provide the confidence that investors were hoping for."
The S&P 500 and the Nasdaq Composite fell to post their second straight weekly losses, as hotter-than-expected U.S. producer prices data pushed Treasury yields higher and sank rate-sensitive megacap growth stocks.[.N]
In Canada, the energy sector rose 0.9% as oil prices firmed, while materials gained 1%, tracking higher gold prices. [O/R][GOL/]
Rate-sensitive technology stocks lost 0.3% after the data.
Utilities shed over 0.6% as shares of Northland Power fell over 6%, after the power producer reported a drop in quarterly net income. The stock was the worst performer on the benchmark index.
Air Canada rose over 3%, after the Canada's largest airline reported a better than expected quarterly profit on Friday compared with a year-ago loss.
Satellite operator Telesat closed up 17.5% after it gave space tech firm MDA a C$2.1 billion contract to build 198 satellites for its low-earth orbit program. Shares of MDA gained 10.42%. (Reporting by Siddarth S in Bengaluru and Nivedita Balu in Toronto; Editing by Shweta Agarwal, Krishna Chandra Eluri and Deepa Babington) ((Siddarth.s@thomsonreuters.com;)) Keywords: CANADA STOCKS/ (UPDATE 1)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The S&P 500 and the Nasdaq Composite fell to post their second straight weekly losses, as hotter-than-expected U.S. producer prices data pushed Treasury yields higher and sank rate-sensitive megacap growth stocks. [.N] In Canada, the energy sector rose 0.9% as oil prices firmed, while materials gained 1%, tracking higher gold prices. Satellite operator Telesat closed up 17.5% after it gave space tech firm MDA a C$2.1 billion contract to build 198 satellites for its low-earth orbit program. | [.N] In Canada, the energy sector rose 0.9% as oil prices firmed, while materials gained 1%, tracking higher gold prices. The S&P 500 and the Nasdaq Composite fell to post their second straight weekly losses, as hotter-than-expected U.S. producer prices data pushed Treasury yields higher and sank rate-sensitive megacap growth stocks. Satellite operator Telesat closed up 17.5% after it gave space tech firm MDA a C$2.1 billion contract to build 198 satellites for its low-earth orbit program. | The S&P 500 and the Nasdaq Composite fell to post their second straight weekly losses, as hotter-than-expected U.S. producer prices data pushed Treasury yields higher and sank rate-sensitive megacap growth stocks. [.N] In Canada, the energy sector rose 0.9% as oil prices firmed, while materials gained 1%, tracking higher gold prices. Satellite operator Telesat closed up 17.5% after it gave space tech firm MDA a C$2.1 billion contract to build 198 satellites for its low-earth orbit program. | The S&P 500 and the Nasdaq Composite fell to post their second straight weekly losses, as hotter-than-expected U.S. producer prices data pushed Treasury yields higher and sank rate-sensitive megacap growth stocks. [.N] In Canada, the energy sector rose 0.9% as oil prices firmed, while materials gained 1%, tracking higher gold prices. Satellite operator Telesat closed up 17.5% after it gave space tech firm MDA a C$2.1 billion contract to build 198 satellites for its low-earth orbit program. |
34779.0 | 2023-08-11 00:00:00 UTC | CANADA STOCKS-TSX gains on energy, material stock boost | AC | https://www.nasdaq.com/articles/canada-stocks-tsx-gains-on-energy-material-stock-boost | nan | nan | By Siddarth S and Nivedita Balu
Aug 11 (Reuters) - Toronto stocks ended higher on Friday, lifted by energy and material stocks, recovering from choppy trading after stronger-than-expected U.S. producer price data worried investors about sticky inflation in the world's largest economy.
The Toronto Stock Exchange's S&P/TSX composite index .GSPTSE was up 64.76 points, or 0.32%, at 20,407.64. The index was set to snap two consecutive weekly declines.
Data showed U.S. PPI increased 0.2% in June. On an annual basis, PPI increased 0.8% through June, while economists polled by Reuters had forecast a 0.7% rise.
"It would confirm that inflation is back to reasonable levels," said Philip Petursson, chief investment strategist at IG Wealth Management.
"The real question is will the U.S. Federal Reserve be satisfied. From here, will it be a much slower grind or are they going to say we got to get there faster and raise rates further and that's what the market is trying to assess today."
U.S. consumer prices increased moderately in July at 3.2%, up from 3.0% in June, data showed on Wednesday, but core inflation continued to remain sticky, which worried investors on the Fed's rate hike plans for the rest of 2023.
The energy sector .SPTTEN rose 0.9% as oil prices firmed, while materials .GSPTTMT gained 1%, tracking higher gold prices. O/RGOL/
Rate-sensitive technology stocks .SPTTTKlost 0.3% after the data.
Utilities .GSPTTUT shed over 0.6% as shares of Northland Power NPI.TO fell over 6%, after the power producer reported a drop in quarterly net income. The stock was the worst performer on the benchmark index.
Air Canada AC.TOrose over 3%, after the Canada's largest airline reported a better than expected quarterly profit on Friday compared with a year-ago loss.
(Reporting by Siddarth S in Bengaluru and Nivedita Balu in Toronto; Editing by Shweta Agarwal, Krishna Chandra Eluri and Deepa Babington)
((Siddarth.s@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | "It would confirm that inflation is back to reasonable levels," said Philip Petursson, chief investment strategist at IG Wealth Management. The energy sector .SPTTEN rose 0.9% as oil prices firmed, while materials .GSPTTMT gained 1%, tracking higher gold prices. Air Canada AC.TOrose over 3%, after the Canada's largest airline reported a better than expected quarterly profit on Friday compared with a year-ago loss. | "It would confirm that inflation is back to reasonable levels," said Philip Petursson, chief investment strategist at IG Wealth Management. The energy sector .SPTTEN rose 0.9% as oil prices firmed, while materials .GSPTTMT gained 1%, tracking higher gold prices. Air Canada AC.TOrose over 3%, after the Canada's largest airline reported a better than expected quarterly profit on Friday compared with a year-ago loss. | "It would confirm that inflation is back to reasonable levels," said Philip Petursson, chief investment strategist at IG Wealth Management. The energy sector .SPTTEN rose 0.9% as oil prices firmed, while materials .GSPTTMT gained 1%, tracking higher gold prices. Air Canada AC.TOrose over 3%, after the Canada's largest airline reported a better than expected quarterly profit on Friday compared with a year-ago loss. | "It would confirm that inflation is back to reasonable levels," said Philip Petursson, chief investment strategist at IG Wealth Management. The energy sector .SPTTEN rose 0.9% as oil prices firmed, while materials .GSPTTMT gained 1%, tracking higher gold prices. Air Canada AC.TOrose over 3%, after the Canada's largest airline reported a better than expected quarterly profit on Friday compared with a year-ago loss. |
34780.0 | 2023-08-11 00:00:00 UTC | CANADA STOCKS-Energy stocks lift TSX as US PPI data sparks concerns of sticky inflation | AC | https://www.nasdaq.com/articles/canada-stocks-energy-stocks-lift-tsx-as-us-ppi-data-sparks-concerns-of-sticky-inflation | nan | nan | By Siddarth S
Aug 11 (Reuters) - Toronto stocks inched higher in choppy trading on Friday and were set for weekly gains, after stronger-than-expected U.S. producer price data caused investors to fret over sticky inflation in the world's largest economy.
At 10:05 a.m. ET (1405 GMT), the Toronto Stock Exchange's S&P/TSX composite index .GSPTSE was up 29.21 points, or 0.14%, at 20,372.09. The index was set to snap two consecutive weekly declines.
Data showed U.S. PPI increased 0.2% in June. On an annual basis, PPI increased 0.8% through June, while economists polled by Reuters had forecast a 0.7% rise.
"It would confirm that inflation is back to reasonable levels," said Philip Petursson, chief investment strategist at IG Wealth Management.
"The real question is will the U.S. Federal Reserve be satisfied. From here, will it be a much slower grind or are they going to say we got to get there faster and raise rates further and that's what the market is trying to assess today."
U.S. consumer prices increased moderately in July at 3.2%, up from 3.0% in June, data showed on Wednesday, but core inflation continued to remain sticky, which worried investors on Fed's rate hike plans for the rest of 2023.
Energy sector .SPTTEN rose 0.8% as oil prices firmed, while materials gained 0.3% tracking higher gold prices. O/RGOL/
Rate-sensitive technology stocks .SPTTTK dropped 1.1% after the data.
Utilities .GSPTTUT shed over 0.6% as shares of Northland Power NPI.TO fell over 6%, after the power producer reported a drop in quarterly net income. The stock was the worst performer on the benchmark index.
Meanwhile, Air Canada AC.TO edged 0.1% higher, after the Canada's largest airline reported a better than expected quarterly profit on Friday compared with a year-ago loss.
(Reporting by Siddarth S in Bengaluru; Editing by Shweta Agarwal and Krishna Chandra Eluri)
((Siddarth.s@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | "It would confirm that inflation is back to reasonable levels," said Philip Petursson, chief investment strategist at IG Wealth Management. Energy sector .SPTTEN rose 0.8% as oil prices firmed, while materials gained 0.3% tracking higher gold prices. Meanwhile, Air Canada AC.TO edged 0.1% higher, after the Canada's largest airline reported a better than expected quarterly profit on Friday compared with a year-ago loss. | "It would confirm that inflation is back to reasonable levels," said Philip Petursson, chief investment strategist at IG Wealth Management. Energy sector .SPTTEN rose 0.8% as oil prices firmed, while materials gained 0.3% tracking higher gold prices. Meanwhile, Air Canada AC.TO edged 0.1% higher, after the Canada's largest airline reported a better than expected quarterly profit on Friday compared with a year-ago loss. | Meanwhile, Air Canada AC.TO edged 0.1% higher, after the Canada's largest airline reported a better than expected quarterly profit on Friday compared with a year-ago loss. "It would confirm that inflation is back to reasonable levels," said Philip Petursson, chief investment strategist at IG Wealth Management. Energy sector .SPTTEN rose 0.8% as oil prices firmed, while materials gained 0.3% tracking higher gold prices. | "It would confirm that inflation is back to reasonable levels," said Philip Petursson, chief investment strategist at IG Wealth Management. Energy sector .SPTTEN rose 0.8% as oil prices firmed, while materials gained 0.3% tracking higher gold prices. Meanwhile, Air Canada AC.TO edged 0.1% higher, after the Canada's largest airline reported a better than expected quarterly profit on Friday compared with a year-ago loss. |
34781.0 | 2023-08-11 00:00:00 UTC | CANADA STOCKS-TSX futures flat on caution ahead of US producer prices data | AC | https://www.nasdaq.com/articles/canada-stocks-tsx-futures-flat-on-caution-ahead-of-us-producer-prices-data | nan | nan | Aug 11 (Reuters) - Futures for Canada's main stock were subdued on Friday ahead of U.S. economic data later in the day, after recent numbers showed consumer prices in the United States increased moderately in July.
September futures on the S&P/TSX index SXFc1 were flat at 7:04 a.m. ET (1104 GMT). The underlying index closed 0.33% higher on Thursday.
Market participants will keep a tab on the U.S. producer prices data, due at 8:30 a.m. ET, that will provide further evidence on the U.S. Federal Reserve's interest rate trajectory.
Data on Thursday showed U.S. consumer prices increased moderately in July at 3.2%, up from 3.0% in June, but core inflation continued to remain sticky, which worried investors on Fed's rate hike plans for the rest of 2023.
Wall Street futures were also subdued as investors were cautious ahead of PPI data. .N
Among commodities, oil held near recent highs amid optimistic demand forecasts from the OPEC producer group and the International Energy Agency. O/R
Gold prices were flat, but on track for their worst week in seven weeks, hurt by an overall stronger dollar and elevated bond yields, while base metals dropped. GOL/MET/L
Among company earnings, Canada's largest airline Air Canada AC.TOreported a quarterly profit compared with a year-ago loss.
Satellite operator Telesat TSAT.TO said space technology company MDA MDA.TO would build 198 advanced satellites for the company's Lightspeed low earth orbit (LEO) program for C$2.1 billion ($1.56 billion).
COMMODITIES AT 7:04 a.m. ET
Gold futures GCc2: $1,920.9; 0.0% GOL/
US crude CLc1: $83.06; +0.3% O/R
Brent crude LCOc1: $86.68; +0.3% O/R
($1= C$1.3446)
(Reporting by Siddarth S in Bengaluru; Editing by Shounak Dasgupta)
((Siddarth.s@thomsonreuters.com))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | O/R Gold prices were flat, but on track for their worst week in seven weeks, hurt by an overall stronger dollar and elevated bond yields, while base metals dropped. GOL/MET/L Among company earnings, Canada's largest airline Air Canada AC.TOreported a quarterly profit compared with a year-ago loss. Satellite operator Telesat TSAT.TO said space technology company MDA MDA.TO would build 198 advanced satellites for the company's Lightspeed low earth orbit (LEO) program for C$2.1 billion ($1.56 billion). | O/R Gold prices were flat, but on track for their worst week in seven weeks, hurt by an overall stronger dollar and elevated bond yields, while base metals dropped. GOL/MET/L Among company earnings, Canada's largest airline Air Canada AC.TOreported a quarterly profit compared with a year-ago loss. Satellite operator Telesat TSAT.TO said space technology company MDA MDA.TO would build 198 advanced satellites for the company's Lightspeed low earth orbit (LEO) program for C$2.1 billion ($1.56 billion). | O/R Gold prices were flat, but on track for their worst week in seven weeks, hurt by an overall stronger dollar and elevated bond yields, while base metals dropped. GOL/MET/L Among company earnings, Canada's largest airline Air Canada AC.TOreported a quarterly profit compared with a year-ago loss. Satellite operator Telesat TSAT.TO said space technology company MDA MDA.TO would build 198 advanced satellites for the company's Lightspeed low earth orbit (LEO) program for C$2.1 billion ($1.56 billion). | O/R Gold prices were flat, but on track for their worst week in seven weeks, hurt by an overall stronger dollar and elevated bond yields, while base metals dropped. GOL/MET/L Among company earnings, Canada's largest airline Air Canada AC.TOreported a quarterly profit compared with a year-ago loss. Satellite operator Telesat TSAT.TO said space technology company MDA MDA.TO would build 198 advanced satellites for the company's Lightspeed low earth orbit (LEO) program for C$2.1 billion ($1.56 billion). |
34782.0 | 2023-08-11 00:00:00 UTC | Air Canada posts quarterly profit versus year-ago loss | AC | https://www.nasdaq.com/articles/air-canada-posts-quarterly-profit-versus-year-ago-loss | nan | nan | Adds revenue, background
Aug 11 (Reuters) - Air Canada AC.TO reported a quarterly profit on Friday compared with a year-ago loss as Canada's largest airline cashed in on strong international travel demand.
A rush by North American travelers to make up for lost time during the pandemic has bolstered earnings for legacy carriers, with international destinations enjoying especially high demand.
Canada, which lifted all COVID-related restrictions last year, has seen a strong rebound in international leisure and corporate travel.
The carrier posted a net profit of C$838 million ($622.77 million), or C$2.34 per share, for the quarter ended June 30, compared with a net loss of C$386 million, or C$1.60 per share, a year earlier.
Profits have also benefited from a roughly 30% drop in jet fuel prices.
The Canadian company's quarterly operating revenue rose 36% to C$5.43 billion.
($1 = 1.3456 Canadian dollars)
(Reporting by Shivansh Tiwary in Bengaluru; Editing by Devika Syamnath)
((Shivansh.Tiwary@thomsonreuters.com; +91 9708363192;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds revenue, background Aug 11 (Reuters) - Air Canada AC.TO reported a quarterly profit on Friday compared with a year-ago loss as Canada's largest airline cashed in on strong international travel demand. A rush by North American travelers to make up for lost time during the pandemic has bolstered earnings for legacy carriers, with international destinations enjoying especially high demand. Canada, which lifted all COVID-related restrictions last year, has seen a strong rebound in international leisure and corporate travel. | Adds revenue, background Aug 11 (Reuters) - Air Canada AC.TO reported a quarterly profit on Friday compared with a year-ago loss as Canada's largest airline cashed in on strong international travel demand. A rush by North American travelers to make up for lost time during the pandemic has bolstered earnings for legacy carriers, with international destinations enjoying especially high demand. The carrier posted a net profit of C$838 million ($622.77 million), or C$2.34 per share, for the quarter ended June 30, compared with a net loss of C$386 million, or C$1.60 per share, a year earlier. | Adds revenue, background Aug 11 (Reuters) - Air Canada AC.TO reported a quarterly profit on Friday compared with a year-ago loss as Canada's largest airline cashed in on strong international travel demand. A rush by North American travelers to make up for lost time during the pandemic has bolstered earnings for legacy carriers, with international destinations enjoying especially high demand. The carrier posted a net profit of C$838 million ($622.77 million), or C$2.34 per share, for the quarter ended June 30, compared with a net loss of C$386 million, or C$1.60 per share, a year earlier. | Adds revenue, background Aug 11 (Reuters) - Air Canada AC.TO reported a quarterly profit on Friday compared with a year-ago loss as Canada's largest airline cashed in on strong international travel demand. A rush by North American travelers to make up for lost time during the pandemic has bolstered earnings for legacy carriers, with international destinations enjoying especially high demand. Canada, which lifted all COVID-related restrictions last year, has seen a strong rebound in international leisure and corporate travel. |
34783.0 | 2023-07-21 00:00:00 UTC | Mexican bottler Arca corks 11% profit growth, sees raw material costs easing | AC | https://www.nasdaq.com/articles/mexican-bottler-arca-corks-11-profit-growth-sees-raw-material-costs-easing | nan | nan | Updates with details fromearnings callin paragraphs 2 and 9, analyst comment in paragraph 5, context in paragraphs 1 and 3
MEXICO CITY, July 21 (Reuters) - Mexican bottler Arca Continental AC.MXon Friday posted a second quarter net profit that was up 11% as the company shifted more volumes across Latin America and benefited from a strategy of price hikes it has used to offset raw material costs.
Costs of raw materials, particularly for aluminum and PET plastic, should ease in the second half of this year, executives said in anearnings call adding Arca's pricing in the United States "is obviously going to be more moderate."
Arca, which sells water and soft drinks, makes the bulk of its sales in Mexico and the United States, though it also operates across Peru, Ecuador, and Argentina.
The group posted a profit of 4.69 billion pesos ($274 million) over April through June, from revenues 5% higher at 56.05 billion pesos.
"A key management agenda is balancing cost relief versus potential price elasticity among U.S. and Mexico consumers," analysts at Citi said, pointing also to Mexico's surging peso which boosted Arca's capacity to spend on dollar-denominated raw materials, whose prices rose some 2% over the quarter.
The Mexican peso appreciated nearly 15% against the U.S. dollar over the last year. Arca said sales would have risen 13.6% on a currency-neutral basis.
The bottler has increased prices across its regions and in Mexico, its largest market, average prices per unit case rose nearly 10%. In the United States, where net prices rose 14.3%, volumes dropped 2.3% causing sales to dip 1.4%.
Arca's core earnings rose 8.4% to 11.31 billion pesos over the quarter, Arca said, and capital expenditures totaled around 34% of the $800 million Arca had said it planned to spend for the year.
Arca, which had forecast full-year sales growth in the single digits in February, said its outlook was now more upbeat than earlier in the year.
($1 = 17.1156 pesos at end-June)
(Reporting by Noe Torres, Kylie Madry and Aida Pelaez Fernandez; Writing by Sarah Morland; Editing by Miral Fahmy and Chris Reese)
((sarah.morland@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Arca, which sells water and soft drinks, makes the bulk of its sales in Mexico and the United States, though it also operates across Peru, Ecuador, and Argentina. Updates with details fromearnings callin paragraphs 2 and 9, analyst comment in paragraph 5, context in paragraphs 1 and 3 MEXICO CITY, July 21 (Reuters) - Mexican bottler Arca Continental AC.MXon Friday posted a second quarter net profit that was up 11% as the company shifted more volumes across Latin America and benefited from a strategy of price hikes it has used to offset raw material costs. "A key management agenda is balancing cost relief versus potential price elasticity among U.S. and Mexico consumers," analysts at Citi said, pointing also to Mexico's surging peso which boosted Arca's capacity to spend on dollar-denominated raw materials, whose prices rose some 2% over the quarter. | Updates with details fromearnings callin paragraphs 2 and 9, analyst comment in paragraph 5, context in paragraphs 1 and 3 MEXICO CITY, July 21 (Reuters) - Mexican bottler Arca Continental AC.MXon Friday posted a second quarter net profit that was up 11% as the company shifted more volumes across Latin America and benefited from a strategy of price hikes it has used to offset raw material costs. "A key management agenda is balancing cost relief versus potential price elasticity among U.S. and Mexico consumers," analysts at Citi said, pointing also to Mexico's surging peso which boosted Arca's capacity to spend on dollar-denominated raw materials, whose prices rose some 2% over the quarter. Arca, which sells water and soft drinks, makes the bulk of its sales in Mexico and the United States, though it also operates across Peru, Ecuador, and Argentina. | Updates with details fromearnings callin paragraphs 2 and 9, analyst comment in paragraph 5, context in paragraphs 1 and 3 MEXICO CITY, July 21 (Reuters) - Mexican bottler Arca Continental AC.MXon Friday posted a second quarter net profit that was up 11% as the company shifted more volumes across Latin America and benefited from a strategy of price hikes it has used to offset raw material costs. "A key management agenda is balancing cost relief versus potential price elasticity among U.S. and Mexico consumers," analysts at Citi said, pointing also to Mexico's surging peso which boosted Arca's capacity to spend on dollar-denominated raw materials, whose prices rose some 2% over the quarter. Arca, which sells water and soft drinks, makes the bulk of its sales in Mexico and the United States, though it also operates across Peru, Ecuador, and Argentina. | "A key management agenda is balancing cost relief versus potential price elasticity among U.S. and Mexico consumers," analysts at Citi said, pointing also to Mexico's surging peso which boosted Arca's capacity to spend on dollar-denominated raw materials, whose prices rose some 2% over the quarter. Updates with details fromearnings callin paragraphs 2 and 9, analyst comment in paragraph 5, context in paragraphs 1 and 3 MEXICO CITY, July 21 (Reuters) - Mexican bottler Arca Continental AC.MXon Friday posted a second quarter net profit that was up 11% as the company shifted more volumes across Latin America and benefited from a strategy of price hikes it has used to offset raw material costs. Arca, which sells water and soft drinks, makes the bulk of its sales in Mexico and the United States, though it also operates across Peru, Ecuador, and Argentina. |
34784.0 | 2023-06-23 00:00:00 UTC | Off-duty Air Canada pilot helped land plane after first officer fell ill | AC | https://www.nasdaq.com/articles/off-duty-air-canada-pilot-helped-land-plane-after-first-officer-fell-ill | nan | nan | Adds Air Canada comments in paragraphs 3-4
OTTAWA, June 23 (Reuters) - One of the pilots flying an Air Canada jet airliner became sick during a domestic flight but the plane landed safely after an off-duty pilot stepped in to help, the carrier said on Friday.
Air Canada said the first officer had begin feeling ill towards the end of a 2,115 km (1,300 mile) flight from Toronto to St. John's in the Atlantic province of Newfoundland on June 7.
"Another off-duty Air Canada pilot traveling on the aircraft substituted for the first officer so that there were two pilots on the flight deck as usual," it said in an emailed statement. The plane landed safely.
The airline did not respond to a question about the state of health of the sick pilot.
According to Air Canada's website, the carrier generally operates the flight with an Airbus A-220 twin-engine airliner, which can carry around 140 passengers.
(Reporting by David Ljunggren; editing by Grant McCool; Editing by Richard Chang)
((david.ljunggren@tr.com; +1 647 480 7891;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | According to Air Canada's website, the carrier generally operates the flight with an Airbus A-220 twin-engine airliner, which can carry around 140 passengers. Adds Air Canada comments in paragraphs 3-4 OTTAWA, June 23 (Reuters) - One of the pilots flying an Air Canada jet airliner became sick during a domestic flight but the plane landed safely after an off-duty pilot stepped in to help, the carrier said on Friday. Air Canada said the first officer had begin feeling ill towards the end of a 2,115 km (1,300 mile) flight from Toronto to St. John's in the Atlantic province of Newfoundland on June 7. | According to Air Canada's website, the carrier generally operates the flight with an Airbus A-220 twin-engine airliner, which can carry around 140 passengers. Adds Air Canada comments in paragraphs 3-4 OTTAWA, June 23 (Reuters) - One of the pilots flying an Air Canada jet airliner became sick during a domestic flight but the plane landed safely after an off-duty pilot stepped in to help, the carrier said on Friday. "Another off-duty Air Canada pilot traveling on the aircraft substituted for the first officer so that there were two pilots on the flight deck as usual," it said in an emailed statement. | According to Air Canada's website, the carrier generally operates the flight with an Airbus A-220 twin-engine airliner, which can carry around 140 passengers. Adds Air Canada comments in paragraphs 3-4 OTTAWA, June 23 (Reuters) - One of the pilots flying an Air Canada jet airliner became sick during a domestic flight but the plane landed safely after an off-duty pilot stepped in to help, the carrier said on Friday. "Another off-duty Air Canada pilot traveling on the aircraft substituted for the first officer so that there were two pilots on the flight deck as usual," it said in an emailed statement. | According to Air Canada's website, the carrier generally operates the flight with an Airbus A-220 twin-engine airliner, which can carry around 140 passengers. Adds Air Canada comments in paragraphs 3-4 OTTAWA, June 23 (Reuters) - One of the pilots flying an Air Canada jet airliner became sick during a domestic flight but the plane landed safely after an off-duty pilot stepped in to help, the carrier said on Friday. Air Canada said the first officer had begin feeling ill towards the end of a 2,115 km (1,300 mile) flight from Toronto to St. John's in the Atlantic province of Newfoundland on June 7. |
34785.0 | 2023-06-13 00:00:00 UTC | Pre-Market Earnings Report for June 14, 2023 : ATEX, ACB | AC | https://www.nasdaq.com/articles/pre-market-earnings-report-for-june-14-2023-%3A-atex-acb | nan | nan | The following companies are expected to report earnings prior to market open on 06/14/2023. Visit our Earnings Calendar for a full list of expected earnings releases.
Anterix Inc. (ATEX)is reporting for the quarter ending March 31, 2023. The infrastructure company's consensus earnings per share forecast from the 3 analysts that follow the stock is $-0.71. This value represents a 18.33% decrease compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ATEX is -13.78 vs. an industry ratio of -16.10, implying that they will have a higher earnings growth than their competitors in the same industry.
Aurora Cannabis Inc. (ACB)is reporting for the quarter ending March 31, 2023. The medical products company's consensus earnings per share forecast from the 2 analysts that follow the stock is $-0.04. This value represents a 96.15% increase compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ACB is -1.65 vs. an industry ratio of 9.90.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Zacks Investment Research reports that the 2023 Price to Earnings ratio for ATEX is -13.78 vs. an industry ratio of -16.10, implying that they will have a higher earnings growth than their competitors in the same industry. Aurora Cannabis Inc. (ACB)is reporting for the quarter ending March 31, 2023. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ACB is -1.65 vs. an industry ratio of 9.90. | Zacks Investment Research reports that the 2023 Price to Earnings ratio for ATEX is -13.78 vs. an industry ratio of -16.10, implying that they will have a higher earnings growth than their competitors in the same industry. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ACB is -1.65 vs. an industry ratio of 9.90. Aurora Cannabis Inc. (ACB)is reporting for the quarter ending March 31, 2023. | Zacks Investment Research reports that the 2023 Price to Earnings ratio for ATEX is -13.78 vs. an industry ratio of -16.10, implying that they will have a higher earnings growth than their competitors in the same industry. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ACB is -1.65 vs. an industry ratio of 9.90. Aurora Cannabis Inc. (ACB)is reporting for the quarter ending March 31, 2023. | Zacks Investment Research reports that the 2023 Price to Earnings ratio for ATEX is -13.78 vs. an industry ratio of -16.10, implying that they will have a higher earnings growth than their competitors in the same industry. Aurora Cannabis Inc. (ACB)is reporting for the quarter ending March 31, 2023. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ACB is -1.65 vs. an industry ratio of 9.90. |
34786.0 | 2023-06-13 00:00:00 UTC | FACTBOX-Pilots seek new contracts with airlines amid booming travel demand | AC | https://www.nasdaq.com/articles/factbox-pilots-seek-new-contracts-with-airlines-amid-booming-travel-demand | nan | nan | Updates with United Airlines labor agreement
July 17 (Reuters) - North American pilots are pushing for better pay and working conditions during their talks over new job contracts with company managements. Members at some unions have voted to authorize a strike if a new contract is not reached.
The aggressive stance comes at a time of pilot shortages and a rise in public support for unions. The following is the status of contract negotiations at various companies:
AMERICAN AIRLINES GROUP INC AAL.O:
Pilots at American Airlines have reached an agreement in principle on a new contract, their union said on May 19.
The Allied Pilots Association (APA), which represents over 13,000 pilots at the Texas-based carrier, said it will move forward with completing contractual language of the contract before presenting it to its board for an approval.
SOUTHWEST AIRLINES CO LUV.N:
The Southwest Airlines Pilots Association (SWAPA) in May said its members at the company approved a strike mandate. It added that 98% of its members participated in the vote and 99% voted in favor of authorizing a strike.
DELTA AIR LINES DAL.N:
In March, the Air Line Pilots Association (ALPA) said that pilots at Delta had ratified a new contract that includes over $7 billion in cumulative increases in wages and benefits over four years.
The new contract, which covers 15,000 Delta pilots, provides a 34% cumulative pay increase, a lump-sum one-time payment, reduced health insurance premiums and improvements in holiday pay, vacation, company contributions to 401(k) and work rules.
AIR CANADA AC.TO:
Air Canada's pilots on May 29 ended a decade-long contract framework, opening the door to "full bargaining this summer," their union leadership said in a note to members seen by Reuters.
Previously, Air Canada pilots said they are pressing for "historic" gains to narrow the earnings gap with higher-paid aviators at U.S. carriers.
WESTJET AIRLINES:
WestJet Airlines pilots will get a 24% hourly raise over four years, plus other pay and benefits as part of a tentative agreement reached in May, according to a copy seen by Reuters on May 26.
The tentative agreement was reached by Onex Corp's ONEX.TO WestJet and the Air Line Pilots Association (ALPA) less than 24 hours before the start of an expected strike at Canada's second-largest carrier.
UNITED AIRLINES HOLDINGS INC UAL.O:
The Chicago-based carrier reached a new four-year labor agreement with its pilots on July 15, in which they will get a cumulative 34.5%-40.2% pay hike over four years, the Air Line Pilots Association that represents about 14,000 pilots at United, said.
SPIRIT AIRLINES INC SAVE.N:
In January, ALPA said pilots at Spirit Airlines voted to ratify a new contract.
The union that represents the ultra-low-cost carrier said 69% of the airline's pilots voted in favor of the new collective bargaining agreement, which offers an economic gain of $463 million, or 27%, over the next two years.
JETBLUE AIRWAYS CORP JBLU.O:
In January, ALPA said pilots at JetBlue Airways Corp have overwhelmingly approved a two-year contract extension.
ALPA, which represents more than 4,600 pilots at JetBlue, said 75% of the pilots voted in favor of ratifying the agreement, which provides for a compensation increase of 21.5% over 18 months as well as other monetary improvements.
FEDEX CORP FDX.N:
Governing body of ALPA unit representing FedEx pilots on June 12 said it has approved a tentative contract agreement that includes a 30% pay increase and a 30% increase to the pilots' legacy pension.
The FedEx Master Executive Council said the vote will open on July 5 and close on July 24.
(Reporting by Priyamvada C, Amna Karimi and Shivansh Tiwary in Bengaluru; Editing by Dhanya Ann Thoppil, Sriraj Kalluvila and Arun Koyyur)
((Amna.Karimi@thomsonreuters.com; +91 8083261226;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Updates with United Airlines labor agreement July 17 (Reuters) - North American pilots are pushing for better pay and working conditions during their talks over new job contracts with company managements. Air Canada's pilots on May 29 ended a decade-long contract framework, opening the door to "full bargaining this summer," their union leadership said in a note to members seen by Reuters. The tentative agreement was reached by Onex Corp's ONEX.TO WestJet and the Air Line Pilots Association (ALPA) less than 24 hours before the start of an expected strike at Canada's second-largest carrier. | Updates with United Airlines labor agreement July 17 (Reuters) - North American pilots are pushing for better pay and working conditions during their talks over new job contracts with company managements. In March, the Air Line Pilots Association (ALPA) said that pilots at Delta had ratified a new contract that includes over $7 billion in cumulative increases in wages and benefits over four years. The tentative agreement was reached by Onex Corp's ONEX.TO WestJet and the Air Line Pilots Association (ALPA) less than 24 hours before the start of an expected strike at Canada's second-largest carrier. | In March, the Air Line Pilots Association (ALPA) said that pilots at Delta had ratified a new contract that includes over $7 billion in cumulative increases in wages and benefits over four years. The Chicago-based carrier reached a new four-year labor agreement with its pilots on July 15, in which they will get a cumulative 34.5%-40.2% pay hike over four years, the Air Line Pilots Association that represents about 14,000 pilots at United, said. Governing body of ALPA unit representing FedEx pilots on June 12 said it has approved a tentative contract agreement that includes a 30% pay increase and a 30% increase to the pilots' legacy pension. | Members at some unions have voted to authorize a strike if a new contract is not reached. The Chicago-based carrier reached a new four-year labor agreement with its pilots on July 15, in which they will get a cumulative 34.5%-40.2% pay hike over four years, the Air Line Pilots Association that represents about 14,000 pilots at United, said. Updates with United Airlines labor agreement July 17 (Reuters) - North American pilots are pushing for better pay and working conditions during their talks over new job contracts with company managements. |
34787.0 | 2023-06-01 00:00:00 UTC | Air Canada says technical issue forcing flight delays | AC | https://www.nasdaq.com/articles/air-canada-says-technical-issue-forcing-flight-delays | nan | nan | By Allison Lampert
MONTREAL, June 1 (Reuters) - Air Canada AC.TOsaid on Thursday a technical issue has affected flights for the second time in two weeks, leading to delays.
Canada's largest carrier said a technical issue with its communicator system used to communicate with aircraft and monitor performance was "resulting in flight delays across our system, but we continue to operate flights at a reduced rate."
Technical problems have resulted in delays globally for airlines. Southwest Airlines Co LUV.N blamed a one-hour stoppage of its flights in April on a vendor-supplied computer network firewall.
Last week, Air Canada said a temporary ground stop on May 25 was undertaken due to an issue with the communicator system.
Air Canada did not describe the specific issue.
"We’re now working our way back to normal operations," Spirit said in an emailed statement.
(Reporting by Allison Lampert in Montreal. Additional reporting by David Shepardson in Washington; Writing by Ismail Shakil; Editing by David Gregorio)
((ismail.shakil@tr.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Allison Lampert MONTREAL, June 1 (Reuters) - Air Canada AC.TOsaid on Thursday a technical issue has affected flights for the second time in two weeks, leading to delays. Canada's largest carrier said a technical issue with its communicator system used to communicate with aircraft and monitor performance was "resulting in flight delays across our system, but we continue to operate flights at a reduced rate." "We’re now working our way back to normal operations," Spirit said in an emailed statement. | By Allison Lampert MONTREAL, June 1 (Reuters) - Air Canada AC.TOsaid on Thursday a technical issue has affected flights for the second time in two weeks, leading to delays. Canada's largest carrier said a technical issue with its communicator system used to communicate with aircraft and monitor performance was "resulting in flight delays across our system, but we continue to operate flights at a reduced rate." "We’re now working our way back to normal operations," Spirit said in an emailed statement. | By Allison Lampert MONTREAL, June 1 (Reuters) - Air Canada AC.TOsaid on Thursday a technical issue has affected flights for the second time in two weeks, leading to delays. Canada's largest carrier said a technical issue with its communicator system used to communicate with aircraft and monitor performance was "resulting in flight delays across our system, but we continue to operate flights at a reduced rate." "We’re now working our way back to normal operations," Spirit said in an emailed statement. | By Allison Lampert MONTREAL, June 1 (Reuters) - Air Canada AC.TOsaid on Thursday a technical issue has affected flights for the second time in two weeks, leading to delays. Canada's largest carrier said a technical issue with its communicator system used to communicate with aircraft and monitor performance was "resulting in flight delays across our system, but we continue to operate flights at a reduced rate." "We’re now working our way back to normal operations," Spirit said in an emailed statement. |
34788.0 | 2023-05-29 00:00:00 UTC | Air Canada pilots end 10-year contract framework, eye bargaining | AC | https://www.nasdaq.com/articles/air-canada-pilots-end-10-year-contract-framework-eye-bargaining-0 | nan | nan | By Allison Lampert
MONTREAL, May 29 (Reuters) - Air Canada's AC.TO pilots have ended a decade-long contract framework, opening the door to "full bargaining this summer," their union leadership said on Monday in a note to members seen by Reuters.
Air Canada pilots have previously said they are pressing for "historic" gains to narrow the earnings gap with higher-paid aviators at U.S. carriers.
The estimated 4,500 pilots at Canada's largest carrier have received a 2% wage increase per year since reaching a deal in 2014.
The union had a Monday deadline for using a type of escape clause that would allow for negotiations this year. The agreement now runs until Sept. 29, 2023, although its provisions will apply beyond that date.
"We were willing to meet with the company if they wanted to provide us with a substantial proposal that would further our membership’s goals," said the letter, adding Air Canada did not seek to open discussions.
The Air Canada pilots group, which joined the Air Line Pilots Association (ALPA) this month, said in a separate document it expects a notice to bargain to be provided in early June.
"Our pilots may elect to use the option that was available to them to initiate bargaining for a new collective agreement," Montreal-based Air Canada said in an emailed statement.
"The current agreement, which has been in place for nine years, is testimony of the productive relationship we have with our pilots."
U.S. pilots made gains in a recent tentative agreement with American Airlines AAL.Oand a separate deal with Delta Air Lines DAL.Nwhich delivers a 34% pay increase over four years.
(Reporting By Allison Lampert in Montreal; Editing by Chris Reese)
((Allison.Lampert@thomsonreuters.com; 514-796-4212; Reuters Messaging: allison.lampert.reuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Allison Lampert MONTREAL, May 29 (Reuters) - Air Canada's AC.TO pilots have ended a decade-long contract framework, opening the door to "full bargaining this summer," their union leadership said on Monday in a note to members seen by Reuters. The estimated 4,500 pilots at Canada's largest carrier have received a 2% wage increase per year since reaching a deal in 2014. "The current agreement, which has been in place for nine years, is testimony of the productive relationship we have with our pilots." | By Allison Lampert MONTREAL, May 29 (Reuters) - Air Canada's AC.TO pilots have ended a decade-long contract framework, opening the door to "full bargaining this summer," their union leadership said on Monday in a note to members seen by Reuters. The estimated 4,500 pilots at Canada's largest carrier have received a 2% wage increase per year since reaching a deal in 2014. "The current agreement, which has been in place for nine years, is testimony of the productive relationship we have with our pilots." | By Allison Lampert MONTREAL, May 29 (Reuters) - Air Canada's AC.TO pilots have ended a decade-long contract framework, opening the door to "full bargaining this summer," their union leadership said on Monday in a note to members seen by Reuters. The estimated 4,500 pilots at Canada's largest carrier have received a 2% wage increase per year since reaching a deal in 2014. "The current agreement, which has been in place for nine years, is testimony of the productive relationship we have with our pilots." | By Allison Lampert MONTREAL, May 29 (Reuters) - Air Canada's AC.TO pilots have ended a decade-long contract framework, opening the door to "full bargaining this summer," their union leadership said on Monday in a note to members seen by Reuters. The estimated 4,500 pilots at Canada's largest carrier have received a 2% wage increase per year since reaching a deal in 2014. "The current agreement, which has been in place for nine years, is testimony of the productive relationship we have with our pilots." |
34789.0 | 2023-05-29 00:00:00 UTC | Air Canada pilots end 10-year contract framework, eye bargaining | AC | https://www.nasdaq.com/articles/air-canada-pilots-end-10-year-contract-framework-eye-bargaining | nan | nan | MONTREAL, May 29 (Reuters) - Air Canada's AC.TO pilots have agreed to end a decade-long contract framework, opening the door to "full bargaining this summer," the union representing the carrier's aviators said on Monday in a note to members seen by Reuters.
Air Canada's pilots have previously said they are pressing for "historic" gains by narrowing the pay gap with aviators at major U.S. carriers.
Air Canada was not immediately available for comment.
(Reporting By Allison Lampert in Montreal; Editing by Chris Reese)
((Allison.Lampert@thomsonreuters.com; 514-796-4212; Reuters Messaging: allison.lampert.reuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MONTREAL, May 29 (Reuters) - Air Canada's AC.TO pilots have agreed to end a decade-long contract framework, opening the door to "full bargaining this summer," the union representing the carrier's aviators said on Monday in a note to members seen by Reuters. Air Canada's pilots have previously said they are pressing for "historic" gains by narrowing the pay gap with aviators at major U.S. carriers. (Reporting By Allison Lampert in Montreal; Editing by Chris Reese) ((Allison.Lampert@thomsonreuters.com; 514-796-4212; Reuters Messaging: allison.lampert.reuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MONTREAL, May 29 (Reuters) - Air Canada's AC.TO pilots have agreed to end a decade-long contract framework, opening the door to "full bargaining this summer," the union representing the carrier's aviators said on Monday in a note to members seen by Reuters. Air Canada's pilots have previously said they are pressing for "historic" gains by narrowing the pay gap with aviators at major U.S. carriers. Air Canada was not immediately available for comment. | MONTREAL, May 29 (Reuters) - Air Canada's AC.TO pilots have agreed to end a decade-long contract framework, opening the door to "full bargaining this summer," the union representing the carrier's aviators said on Monday in a note to members seen by Reuters. Air Canada's pilots have previously said they are pressing for "historic" gains by narrowing the pay gap with aviators at major U.S. carriers. (Reporting By Allison Lampert in Montreal; Editing by Chris Reese) ((Allison.Lampert@thomsonreuters.com; 514-796-4212; Reuters Messaging: allison.lampert.reuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MONTREAL, May 29 (Reuters) - Air Canada's AC.TO pilots have agreed to end a decade-long contract framework, opening the door to "full bargaining this summer," the union representing the carrier's aviators said on Monday in a note to members seen by Reuters. Air Canada's pilots have previously said they are pressing for "historic" gains by narrowing the pay gap with aviators at major U.S. carriers. Air Canada was not immediately available for comment. |
34790.0 | 2023-05-29 00:00:00 UTC | Philippines' Ayala to complete $1 bln asset sale this year | AC | https://www.nasdaq.com/articles/philippines-ayala-to-complete-%241-bln-asset-sale-this-year | nan | nan | MANILA, May 29 (Reuters) - Philippine conglomerate Ayala Corp AC.PS is looking to sell about $400 million worth of assets this year, the final step in a multi-year plan to raise $1 billion to fund investments in high-growth businesses, its chief executive said on Monday.
The Philippines' oldest industrial conglomerate unveiled a plan in 2021 to generate $1 billion by selling assets, including some non-core businesses, and could meet its goal this year, Chief Executive Cezar Consing told reporters.
"It is basically recycling capital where there are more immediate opportunities," he added.
Ayala has sold $600 million worth of shares in several companies, through efforts such as cutting its stake in utility Manila Water Co MWC.PS, and divesting from a tollroad concession and a coal-fired power plant by the end of last year.
Ayala could put up for sale its minority share in a railway system in Manila, the capital, Consing said, adding it sees robust interest from both domestic and overseas buyers.
Sale proceeds will fund projects on health and logistics, areas the company sees as offering new sources of revenue beyond its core portfolio of property, banking, telecoms and energy.
Since 2015, its healthcare unit has built a portfolio of generic retail pharmacies, multi-specialty clinics, full-service hospitals, and telemedicine.
(Reporting by Neil Jerome Morales; Editing by Clarence Fernandez)
((neiljerome.morales@thomsonreuters.com; +632 8841 8914;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MANILA, May 29 (Reuters) - Philippine conglomerate Ayala Corp AC.PS is looking to sell about $400 million worth of assets this year, the final step in a multi-year plan to raise $1 billion to fund investments in high-growth businesses, its chief executive said on Monday. Since 2015, its healthcare unit has built a portfolio of generic retail pharmacies, multi-specialty clinics, full-service hospitals, and telemedicine. The Philippines' oldest industrial conglomerate unveiled a plan in 2021 to generate $1 billion by selling assets, including some non-core businesses, and could meet its goal this year, Chief Executive Cezar Consing told reporters. | MANILA, May 29 (Reuters) - Philippine conglomerate Ayala Corp AC.PS is looking to sell about $400 million worth of assets this year, the final step in a multi-year plan to raise $1 billion to fund investments in high-growth businesses, its chief executive said on Monday. Since 2015, its healthcare unit has built a portfolio of generic retail pharmacies, multi-specialty clinics, full-service hospitals, and telemedicine. The Philippines' oldest industrial conglomerate unveiled a plan in 2021 to generate $1 billion by selling assets, including some non-core businesses, and could meet its goal this year, Chief Executive Cezar Consing told reporters. | MANILA, May 29 (Reuters) - Philippine conglomerate Ayala Corp AC.PS is looking to sell about $400 million worth of assets this year, the final step in a multi-year plan to raise $1 billion to fund investments in high-growth businesses, its chief executive said on Monday. Since 2015, its healthcare unit has built a portfolio of generic retail pharmacies, multi-specialty clinics, full-service hospitals, and telemedicine. The Philippines' oldest industrial conglomerate unveiled a plan in 2021 to generate $1 billion by selling assets, including some non-core businesses, and could meet its goal this year, Chief Executive Cezar Consing told reporters. | MANILA, May 29 (Reuters) - Philippine conglomerate Ayala Corp AC.PS is looking to sell about $400 million worth of assets this year, the final step in a multi-year plan to raise $1 billion to fund investments in high-growth businesses, its chief executive said on Monday. Since 2015, its healthcare unit has built a portfolio of generic retail pharmacies, multi-specialty clinics, full-service hospitals, and telemedicine. "It is basically recycling capital where there are more immediate opportunities," he added. |
34791.0 | 2023-05-25 00:00:00 UTC | Air Canada ground stop lifted after technical issue | AC | https://www.nasdaq.com/articles/air-canada-ground-stop-lifted-after-technical-issue | nan | nan | Adds line from FAA advisory in paragraph 4, context and line on British Airways' technical problem
MONTREAL, May 25 (Reuters) - Air Canada said on Thursday that a precautionary ground stop on its flights has been lifted after the country's largest carrier faced a technical issue.
Air Canada said in a statement it experienced a temporary issue with its communicator system, which is used to communicate with aircraft and monitor operational performance.
The problem led to some delays, although the "system is now returning to normal," the carrier said in a statement.
According to an advisory published on Thursday by the Federal Aviation Administration (FAA), the ground stop lasted for roughly an hour.
Airlines globally have been wrestling with technical problems that have lead to delays, with Southwest Airlines Co LUV.N blaming a one-hour stoppage of its flights in April on a vendor-supplied computer network firewall.
On Thursday, British Airways also said it had to cancel a due to a technical problem.
(Reporting By Allison Lampert in Montreal and David Shepardson in Washington; Editing by Sharon Singleton)
((Allison.Lampert@thomsonreuters.com; 514-796-4212; Reuters Messaging: allison.lampert.reuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds line from FAA advisory in paragraph 4, context and line on British Airways' technical problem MONTREAL, May 25 (Reuters) - Air Canada said on Thursday that a precautionary ground stop on its flights has been lifted after the country's largest carrier faced a technical issue. According to an advisory published on Thursday by the Federal Aviation Administration (FAA), the ground stop lasted for roughly an hour. (Reporting By Allison Lampert in Montreal and David Shepardson in Washington; Editing by Sharon Singleton) ((Allison.Lampert@thomsonreuters.com; 514-796-4212; Reuters Messaging: allison.lampert.reuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds line from FAA advisory in paragraph 4, context and line on British Airways' technical problem MONTREAL, May 25 (Reuters) - Air Canada said on Thursday that a precautionary ground stop on its flights has been lifted after the country's largest carrier faced a technical issue. According to an advisory published on Thursday by the Federal Aviation Administration (FAA), the ground stop lasted for roughly an hour. On Thursday, British Airways also said it had to cancel a due to a technical problem. | Adds line from FAA advisory in paragraph 4, context and line on British Airways' technical problem MONTREAL, May 25 (Reuters) - Air Canada said on Thursday that a precautionary ground stop on its flights has been lifted after the country's largest carrier faced a technical issue. According to an advisory published on Thursday by the Federal Aviation Administration (FAA), the ground stop lasted for roughly an hour. Airlines globally have been wrestling with technical problems that have lead to delays, with Southwest Airlines Co LUV.N blaming a one-hour stoppage of its flights in April on a vendor-supplied computer network firewall. | Adds line from FAA advisory in paragraph 4, context and line on British Airways' technical problem MONTREAL, May 25 (Reuters) - Air Canada said on Thursday that a precautionary ground stop on its flights has been lifted after the country's largest carrier faced a technical issue. According to an advisory published on Thursday by the Federal Aviation Administration (FAA), the ground stop lasted for roughly an hour. Air Canada said in a statement it experienced a temporary issue with its communicator system, which is used to communicate with aircraft and monitor operational performance. |
34792.0 | 2023-05-25 00:00:00 UTC | Air Canada technical problem leads to temporary ground stop | AC | https://www.nasdaq.com/articles/air-canada-technical-problem-leads-to-temporary-ground-stop | nan | nan | MONTREAL, May 25 (Reuters) - Air Canada on Thursday experienced a temporary technical issue with a system used to communicate with aircraft, resulting in a precautionary ground stop that has now been lifted, the carrier said in a statement.
Canada's largest carrier said there have been some limited delays as a result, but the system "is now returning to normal."
The Federal Aviation Administration (FAA), which published an advisory on the outage, was not immediately available for comment.
(Reporting By Allison Lampert in Montreal and David Shepardson in Washington)
((Allison.Lampert@thomsonreuters.com; 514-796-4212; Reuters Messaging: allison.lampert.reuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MONTREAL, May 25 (Reuters) - Air Canada on Thursday experienced a temporary technical issue with a system used to communicate with aircraft, resulting in a precautionary ground stop that has now been lifted, the carrier said in a statement. Canada's largest carrier said there have been some limited delays as a result, but the system "is now returning to normal." The Federal Aviation Administration (FAA), which published an advisory on the outage, was not immediately available for comment. | MONTREAL, May 25 (Reuters) - Air Canada on Thursday experienced a temporary technical issue with a system used to communicate with aircraft, resulting in a precautionary ground stop that has now been lifted, the carrier said in a statement. Canada's largest carrier said there have been some limited delays as a result, but the system "is now returning to normal." (Reporting By Allison Lampert in Montreal and David Shepardson in Washington) ((Allison.Lampert@thomsonreuters.com; 514-796-4212; Reuters Messaging: allison.lampert.reuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MONTREAL, May 25 (Reuters) - Air Canada on Thursday experienced a temporary technical issue with a system used to communicate with aircraft, resulting in a precautionary ground stop that has now been lifted, the carrier said in a statement. The Federal Aviation Administration (FAA), which published an advisory on the outage, was not immediately available for comment. (Reporting By Allison Lampert in Montreal and David Shepardson in Washington) ((Allison.Lampert@thomsonreuters.com; 514-796-4212; Reuters Messaging: allison.lampert.reuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | MONTREAL, May 25 (Reuters) - Air Canada on Thursday experienced a temporary technical issue with a system used to communicate with aircraft, resulting in a precautionary ground stop that has now been lifted, the carrier said in a statement. Canada's largest carrier said there have been some limited delays as a result, but the system "is now returning to normal." The Federal Aviation Administration (FAA), which published an advisory on the outage, was not immediately available for comment. |
34793.0 | 2023-05-22 00:00:00 UTC | U.S. fines LATAM Airlines $1 mln over delayed ticket refunds | AC | https://www.nasdaq.com/articles/u.s.-fines-latam-airlines-%241-mln-over-delayed-ticket-refunds | nan | nan | By David Shepardson
WASHINGTON, May 22 (Reuters) - The U.S. Transportation Department (USDOT) said on Monday it had fined LATAM Airlines Group SA LTM.SN $1 million after the airline and several affiliates routinely failed to provide timely refunds to passengers for U.S. flights.
The department said since March 1, 2020, it received over 750 complaints alleging LATAM, the biggest carrier in Latin America, failed to provide timely refunds after cancelling flights to or from the United States. USDOT said it took LATAM more than 100 days to process thousands of refund requests to payment.
LATAM, which did not immediately comment Monday, agreed to the $1 million fine and told USDOT "it always acted in good faith, and that it believes a large penalty is inappropriate given the dire circumstances facing LATAM during the pandemic."
Because of COVID-19, LATAM had to cancel more than 1,100 flights daily and saw refund requests quadrupled, the airline told USDOT noting it filed for Chapter 11 bankruptcy and radically downsized the company, resulting in layoffs of thousands of employees.
LATAM had issued more than $62 million in refunds since the beginning of the pandemic for canceled flights, the company told USDOT.
In January, USDOT said it planned to seek higher penalties for airlines violating consumer protection rules, saying they were necessary to deter future violations. USDOT vowed to "deter future misconduct by seeking higher penalties that would not be viewed as simply a cost of doing business."
USDOT fines for airline consumer violations have often been a fraction of potential penalties. Last year, Air Canada AC.TO agreed to a $4.5 million settlement to resolve a USDOT investigation into claims thousands of air passenger refunds had been delayed. USDOT initially sought a $25.5 million penalty.
Air Canada got $2.5 million credited for passenger refunds and paid $2 million in fines.
In November, USDOT imposed penalties on another six airlines totaling just $7.25 million after they agreed to issue $622 million in passenger refunds.
(Reporting by David Shepardson; Editing by Chris Reese and Stephen Coates)
((David.Shepardson@thomsonreuters.com; 2028988324;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | LATAM, which did not immediately comment Monday, agreed to the $1 million fine and told USDOT "it always acted in good faith, and that it believes a large penalty is inappropriate given the dire circumstances facing LATAM during the pandemic." USDOT fines for airline consumer violations have often been a fraction of potential penalties. Last year, Air Canada AC.TO agreed to a $4.5 million settlement to resolve a USDOT investigation into claims thousands of air passenger refunds had been delayed. | LATAM, which did not immediately comment Monday, agreed to the $1 million fine and told USDOT "it always acted in good faith, and that it believes a large penalty is inappropriate given the dire circumstances facing LATAM during the pandemic." USDOT fines for airline consumer violations have often been a fraction of potential penalties. Last year, Air Canada AC.TO agreed to a $4.5 million settlement to resolve a USDOT investigation into claims thousands of air passenger refunds had been delayed. | LATAM, which did not immediately comment Monday, agreed to the $1 million fine and told USDOT "it always acted in good faith, and that it believes a large penalty is inappropriate given the dire circumstances facing LATAM during the pandemic." USDOT fines for airline consumer violations have often been a fraction of potential penalties. Last year, Air Canada AC.TO agreed to a $4.5 million settlement to resolve a USDOT investigation into claims thousands of air passenger refunds had been delayed. | LATAM, which did not immediately comment Monday, agreed to the $1 million fine and told USDOT "it always acted in good faith, and that it believes a large penalty is inappropriate given the dire circumstances facing LATAM during the pandemic." USDOT fines for airline consumer violations have often been a fraction of potential penalties. Last year, Air Canada AC.TO agreed to a $4.5 million settlement to resolve a USDOT investigation into claims thousands of air passenger refunds had been delayed. |
34794.0 | 2023-05-18 00:00:00 UTC | WestJet pay debate sets scene for Air Canada's pilots | AC | https://www.nasdaq.com/articles/westjet-pay-debate-sets-scene-for-air-canadas-pilots | nan | nan | By Allison Lampert
MONTREAL, May 18 (Reuters) - A faceoff this week between WestJet Airlines and its pilots over pay could set the stage for aviators' demands in future bargaining with Air Canada AC.TO.
Pilots at Onex Corp-owned ONEX.TO WestJet gave that they could go on strike as early as Friday, raising fears of travel disruptions during Canada's Victoria Day holiday weekend.
On Thursday, WestJet said it had already cancelled its flights in anticipation of the strike. The airline said it remained at the bargaining table with the pilots but was ready to "weather labour action for as long as it takes to arrive at a reasonable outcome."
It would be the first major pilots' strike in Canada since 1998, according to a spokesperson for Canada's Labor Minister Seamus O'Regan, who is at the talks.
For both sides, pay remains a hurdle. While WestJet is pricing salaries to the Canadian market, their aviators represented by the Air Line Pilots Association (ALPA) want to capitalize on U.S. gains, following a recent deal with Delta Air LinesDAL.N that delivers a 34% pay increase over four years.
Air Canada's estimated 4,500 pilots who joined ALPA this week are not currently in negotiations, but could kick off bargaining this summer before the end of a decade-long agreement reached in 2014 with Canada's largest carrier.
ALPA president Jason Ambrosi recently told Reuters that a key priority is to narrow the pay gap between Air Canada pilots and their U.S. counterparts, echoing the union's demand for a "North American" contract at WestJet.
"It's going to be on AC's desk real soon," said John Gradek, a faculty lecturer in aviation management at McGill University in Montreal, referring to Air Canada.
Gradek added there is a group of Air Canada pilots "who have been chomping at the bit" to get a significant bump in wages.
Montreal-based Air Canada has said it is premature to discuss the timing of talks, pointing out it has a collective agreement in force with its pilots for up to 10 years.
The carrier, hit hard by Canadian lockdowns during COVID-19, is now growing capacity to meet robust demand for travel.
Air Canada pilots, who have received a 2% wage increase per year since 2014, have complained Delta’s latest hourly pay rates are up to 45% higher.
Some industry analysts argue it will be tough to price salaries similarly for the two markets, due to Canada's high taxes and fees and a sparse population.
"It's a much tougher place to make money," said aviation consultant Mike Boyd.
While there are differences between Air Canada and the U.S. legacy carriers, pilots tend to believe there should be pay parity across the board, said TD Cowen analyst Helane Becker.
"Pilots across the board believe they are underpaid relative to the job they do," she said.
(Reporting By Allison Lampert in Montreal; Additional reporting by Nilutpal Timsina in Bengaluru; Editing by Sonali Paul)
((Allison.Lampert@thomsonreuters.com; 514-796-4212; Reuters Messaging: allison.lampert.reuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Allison Lampert MONTREAL, May 18 (Reuters) - A faceoff this week between WestJet Airlines and its pilots over pay could set the stage for aviators' demands in future bargaining with Air Canada AC.TO. ALPA president Jason Ambrosi recently told Reuters that a key priority is to narrow the pay gap between Air Canada pilots and their U.S. counterparts, echoing the union's demand for a "North American" contract at WestJet. The airline said it remained at the bargaining table with the pilots but was ready to "weather labour action for as long as it takes to arrive at a reasonable outcome." | By Allison Lampert MONTREAL, May 18 (Reuters) - A faceoff this week between WestJet Airlines and its pilots over pay could set the stage for aviators' demands in future bargaining with Air Canada AC.TO. The airline said it remained at the bargaining table with the pilots but was ready to "weather labour action for as long as it takes to arrive at a reasonable outcome." It would be the first major pilots' strike in Canada since 1998, according to a spokesperson for Canada's Labor Minister Seamus O'Regan, who is at the talks. | By Allison Lampert MONTREAL, May 18 (Reuters) - A faceoff this week between WestJet Airlines and its pilots over pay could set the stage for aviators' demands in future bargaining with Air Canada AC.TO. Air Canada's estimated 4,500 pilots who joined ALPA this week are not currently in negotiations, but could kick off bargaining this summer before the end of a decade-long agreement reached in 2014 with Canada's largest carrier. The airline said it remained at the bargaining table with the pilots but was ready to "weather labour action for as long as it takes to arrive at a reasonable outcome." | By Allison Lampert MONTREAL, May 18 (Reuters) - A faceoff this week between WestJet Airlines and its pilots over pay could set the stage for aviators' demands in future bargaining with Air Canada AC.TO. The airline said it remained at the bargaining table with the pilots but was ready to "weather labour action for as long as it takes to arrive at a reasonable outcome." It would be the first major pilots' strike in Canada since 1998, according to a spokesperson for Canada's Labor Minister Seamus O'Regan, who is at the talks. |
34795.0 | 2023-05-18 00:00:00 UTC | Canada's WestJet Airlines to cancel flights as pilot strike looms | AC | https://www.nasdaq.com/articles/canadas-westjet-airlines-to-cancel-flights-as-pilot-strike-looms | nan | nan | Adds response from Air Canada in paragraph 5 and 6
May 18 (Reuters) - Onex Corp's ONEX.TO WestJet Group said on Thursday it will cancel flights ahead of a possible pilots' strike, as a pilot union and the airline are yet to come to an agreement over a new contract.
The pilots gave a notice on Monday that could allow for strike action as early as 0300 MT on May 19, raising the possibility of travel disruptions during the upcoming Victoria Day holiday weekend.
"We remain at a critical impasse with the union and have been left with no choice but to begin taking the painful steps of preparing for the reality of a work stoppage," CEO Alexis von Hoensbroech said in a statement.
Calgary-based WestJet said it will park the majority of its 737 and 787 fleet, but WestJet Encore, Link and some 737 flights will continue to operate.
"Our fleet is already fully deployed so we have minimal ability to increase capacity further; however, our staff are aware of the situation and prepared to assist", Air Canada AC.TO said while responding on the situation.
Air Canada added it would try to accommodate passengers looking for new bookings with the remaining available seats when possible.
North American pilots are pressing for higher salaries and better scheduling after aviators made big gains in a recent deal with Delta Air Lines DAL.N that delivers a 34% pay increase over four years. In Canada, pilots want better scheduling and to close the gap between their pay and higher amounts earned by their U.S. counterparts.
(Reporting by Shivani Tanna and Nathan Gomes in Bengaluru and Allison Lampert in Montreal; Editing by Sherry Jacob-Phillips and Krishna Chandra Eluri)
((ShivaniJayesh.Tanna@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The pilots gave a notice on Monday that could allow for strike action as early as 0300 MT on May 19, raising the possibility of travel disruptions during the upcoming Victoria Day holiday weekend. Adds response from Air Canada in paragraph 5 and 6 May 18 (Reuters) - Onex Corp's ONEX.TO WestJet Group said on Thursday it will cancel flights ahead of a possible pilots' strike, as a pilot union and the airline are yet to come to an agreement over a new contract. "Our fleet is already fully deployed so we have minimal ability to increase capacity further; however, our staff are aware of the situation and prepared to assist", Air Canada AC.TO said while responding on the situation. | Adds response from Air Canada in paragraph 5 and 6 May 18 (Reuters) - Onex Corp's ONEX.TO WestJet Group said on Thursday it will cancel flights ahead of a possible pilots' strike, as a pilot union and the airline are yet to come to an agreement over a new contract. "Our fleet is already fully deployed so we have minimal ability to increase capacity further; however, our staff are aware of the situation and prepared to assist", Air Canada AC.TO said while responding on the situation. Air Canada added it would try to accommodate passengers looking for new bookings with the remaining available seats when possible. | Adds response from Air Canada in paragraph 5 and 6 May 18 (Reuters) - Onex Corp's ONEX.TO WestJet Group said on Thursday it will cancel flights ahead of a possible pilots' strike, as a pilot union and the airline are yet to come to an agreement over a new contract. "Our fleet is already fully deployed so we have minimal ability to increase capacity further; however, our staff are aware of the situation and prepared to assist", Air Canada AC.TO said while responding on the situation. The pilots gave a notice on Monday that could allow for strike action as early as 0300 MT on May 19, raising the possibility of travel disruptions during the upcoming Victoria Day holiday weekend. | Adds response from Air Canada in paragraph 5 and 6 May 18 (Reuters) - Onex Corp's ONEX.TO WestJet Group said on Thursday it will cancel flights ahead of a possible pilots' strike, as a pilot union and the airline are yet to come to an agreement over a new contract. The pilots gave a notice on Monday that could allow for strike action as early as 0300 MT on May 19, raising the possibility of travel disruptions during the upcoming Victoria Day holiday weekend. "Our fleet is already fully deployed so we have minimal ability to increase capacity further; however, our staff are aware of the situation and prepared to assist", Air Canada AC.TO said while responding on the situation. |
34796.0 | 2023-05-17 00:00:00 UTC | Air Canada nears 787 Dreamliners deal with Boeing - Bloomberg News | AC | https://www.nasdaq.com/articles/air-canada-nears-787-dreamliners-deal-with-boeing-bloomberg-news | nan | nan | Adds details from the report, background
May 17 (Reuters) - Air Canada AC.TO is closing in on the purchase of as many as 20 787 Dreamliners from Boeing Co BA.N to renew and expand its long-haul fleet, Bloomberg News reported on Wednesday citing people familiar with the matter.
Shares of Boeing were up 3.6% at $208.13 in afternoon trade.
Airlines are looking to shore up their wide-body fleet amid a rebound in demand for long-haul flying ahead of a busy summer travel season.
The Canadian carrier has neared an agreement to order between 15 and 20 of the twin-aisle aircraft, according to the report.
An Air Canada spokesman told Bloomberg News that the airline has not made any decisions yet.
Air Canada and Boeing did not immediately respond to Reuters' requests for comment.
(Reporting by Priyamvada C in Bengaluru; Editing by Krishna Chandra Eluri)
((Priyamvada.C@thomsonreuters.comhttps://twitter.com/priyamouli1812?lang=en;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adds details from the report, background May 17 (Reuters) - Air Canada AC.TO is closing in on the purchase of as many as 20 787 Dreamliners from Boeing Co BA.N to renew and expand its long-haul fleet, Bloomberg News reported on Wednesday citing people familiar with the matter. The Canadian carrier has neared an agreement to order between 15 and 20 of the twin-aisle aircraft, according to the report. Airlines are looking to shore up their wide-body fleet amid a rebound in demand for long-haul flying ahead of a busy summer travel season. | Adds details from the report, background May 17 (Reuters) - Air Canada AC.TO is closing in on the purchase of as many as 20 787 Dreamliners from Boeing Co BA.N to renew and expand its long-haul fleet, Bloomberg News reported on Wednesday citing people familiar with the matter. The Canadian carrier has neared an agreement to order between 15 and 20 of the twin-aisle aircraft, according to the report. An Air Canada spokesman told Bloomberg News that the airline has not made any decisions yet. | Adds details from the report, background May 17 (Reuters) - Air Canada AC.TO is closing in on the purchase of as many as 20 787 Dreamliners from Boeing Co BA.N to renew and expand its long-haul fleet, Bloomberg News reported on Wednesday citing people familiar with the matter. The Canadian carrier has neared an agreement to order between 15 and 20 of the twin-aisle aircraft, according to the report. Air Canada and Boeing did not immediately respond to Reuters' requests for comment. | Adds details from the report, background May 17 (Reuters) - Air Canada AC.TO is closing in on the purchase of as many as 20 787 Dreamliners from Boeing Co BA.N to renew and expand its long-haul fleet, Bloomberg News reported on Wednesday citing people familiar with the matter. The Canadian carrier has neared an agreement to order between 15 and 20 of the twin-aisle aircraft, according to the report. Shares of Boeing were up 3.6% at $208.13 in afternoon trade. |
34797.0 | 2023-05-16 00:00:00 UTC | WestJet union seeks to narrow pay gap between Canada and U.S. pilots as strike looms | AC | https://www.nasdaq.com/articles/westjet-union-seeks-to-narrow-pay-gap-between-canada-and-u.s.-pilots-as-strike-looms | nan | nan | By Allison Lampert
May 16 (Reuters) - Higher pay remains an obstacle for Canada's WestJet Airlines and its pilots to secure an agreement and avert a possible work stoppage on Friday, as a smaller rival on Tuesday said it was adding flights in case of a strike or lockout.
Pilots at Onex Corp-owned ONEX.TO WestJet gave that could allow for strike action as early as May 19, raising fears of travel disruptions during Canada's Victoria Day holiday weekend. The carrier has similarly issued a lockout notice.
North American pilots are pressing for higher salaries and better scheduling after aviators made big gains in a recent deal with Delta Air LinesDAL.N that delivers a 34% pay increase over four years.
"There is a path for a deal I think on job protection. We're getting closer on scheduling. Pay is still the outlier," said Bernard Lewall, a union representative with the Air Line Pilots Association (ALPA).
"We need to narrow that gap between the North American carriers and WestJet," he said on Tuesday in an interview.
Lewall declined to give a specific wage target, but said the airline must pay more to retain pilots.
Calgary-based WestJet wants an agreement that is competitive within Canada's airline industry.
"The union maintains its expectation of closing in towards U.S.–like wages, despite living and working in Canada," the carrier said in a statement on Monday.
Calgary-based WestJet a pilot strike in 2018.
Canadian Transport Minister Omar Alghabra on Twitter urged both sides to find a "fair and reasonable deal."
Canadian budget carrier Flair Airlines said on Tuesday it was adding additional domestic flights between Vancouver, Calgary and Edmonton starting May 19.
"We hope this measure will help WestJet passengers who otherwise could not travel due to the pilots’ strike,” said Flair CEO Stephen Jones.
WestJet's larger rival Air Canada AC.TO said its fleet was already fully deployed and had minimal ability to increase capacity further.
WestJet has said impacted travelers would be refunded or re-accommodated, as applicable.
(Reporting by Allison Lampert in Montreal Editing by Mark Potter)
((Allison.Lampert@thomsonreuters.com; 514-796-4212; Reuters Messaging: allison.lampert.reuters.com@reuters.net))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Allison Lampert May 16 (Reuters) - Higher pay remains an obstacle for Canada's WestJet Airlines and its pilots to secure an agreement and avert a possible work stoppage on Friday, as a smaller rival on Tuesday said it was adding flights in case of a strike or lockout. Pilots at Onex Corp-owned ONEX.TO WestJet gave that could allow for strike action as early as May 19, raising fears of travel disruptions during Canada's Victoria Day holiday weekend. WestJet's larger rival Air Canada AC.TO said its fleet was already fully deployed and had minimal ability to increase capacity further. | By Allison Lampert May 16 (Reuters) - Higher pay remains an obstacle for Canada's WestJet Airlines and its pilots to secure an agreement and avert a possible work stoppage on Friday, as a smaller rival on Tuesday said it was adding flights in case of a strike or lockout. Pilots at Onex Corp-owned ONEX.TO WestJet gave that could allow for strike action as early as May 19, raising fears of travel disruptions during Canada's Victoria Day holiday weekend. WestJet's larger rival Air Canada AC.TO said its fleet was already fully deployed and had minimal ability to increase capacity further. | By Allison Lampert May 16 (Reuters) - Higher pay remains an obstacle for Canada's WestJet Airlines and its pilots to secure an agreement and avert a possible work stoppage on Friday, as a smaller rival on Tuesday said it was adding flights in case of a strike or lockout. Pilots at Onex Corp-owned ONEX.TO WestJet gave that could allow for strike action as early as May 19, raising fears of travel disruptions during Canada's Victoria Day holiday weekend. WestJet's larger rival Air Canada AC.TO said its fleet was already fully deployed and had minimal ability to increase capacity further. | By Allison Lampert May 16 (Reuters) - Higher pay remains an obstacle for Canada's WestJet Airlines and its pilots to secure an agreement and avert a possible work stoppage on Friday, as a smaller rival on Tuesday said it was adding flights in case of a strike or lockout. Pilots at Onex Corp-owned ONEX.TO WestJet gave that could allow for strike action as early as May 19, raising fears of travel disruptions during Canada's Victoria Day holiday weekend. WestJet's larger rival Air Canada AC.TO said its fleet was already fully deployed and had minimal ability to increase capacity further. |
34798.0 | 2023-05-12 00:00:00 UTC | CANADA STOCKS-TSX recovers as commodity stocks rise, Air Canada shines | AC | https://www.nasdaq.com/articles/canada-stocks-tsx-recovers-as-commodity-stocks-rise-air-canada-shines-0 | nan | nan | By Johann M Cherian
May 12 (Reuters) - Canada's main stock index bounced back on Friday after two straight sessions of losses, helped by gains in commodity-linked stocks, while Air Canada hit a near three-month high on smaller-than-expected quarterly loss.
Air Canada AC.TO rose 2.1% after the country's largest airline benefited from resilient travel demand.
"The numbers that Air Canada put out were good, especially in terms of guidance they gave last week," said Greg Taylor, chief investment officer at Purpose Investments.
"It goes to show that there's a lot of pent-up demand for travel, and consumers still seem to be spending on airlines and travel experiences."
The industrial sector .GSPTTIN, housing the airline, added 0.9%.
At 10:07 a.m. ET (1407 GMT), the Toronto Stock Exchange's S&P/TSX composite index .GSPTSE was up 20.84 points, or 0.1%, at 20,438.45.
The utilities sector .SPTTEN also added 0.7%.
Still, the TSX is set for its third straight week of losses, the longest streak of weekly declines since late February.
For the week, commodity-linked sectors such as miners and energy firms are among the top decliners as concerns of slowing economic growth out of the U.S. and China weighed on the sentiment.
Among other movers, Silvercrest Metals Inc SIL.TO jumped 13.1% to log its best day in six months, after the precious metals miner reported a strong end to the first quarter of the year.
Sun Life Financial Inc SLF.TO added 0.1% after Canada's second-biggest life insurer reported upbeat first-quarter profit, helped by strong sales at home and in the U.S.
Investors are awaiting April domestic consumer inflation data, due on May 16.
(Reporting by Johann M Cherian and Vansh Agarwal in Bengaluru; Editing by Shilpi Majumdar)
((johann.mcherian@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | By Johann M Cherian May 12 (Reuters) - Canada's main stock index bounced back on Friday after two straight sessions of losses, helped by gains in commodity-linked stocks, while Air Canada hit a near three-month high on smaller-than-expected quarterly loss. Air Canada AC.TO rose 2.1% after the country's largest airline benefited from resilient travel demand. For the week, commodity-linked sectors such as miners and energy firms are among the top decliners as concerns of slowing economic growth out of the U.S. and China weighed on the sentiment. | By Johann M Cherian May 12 (Reuters) - Canada's main stock index bounced back on Friday after two straight sessions of losses, helped by gains in commodity-linked stocks, while Air Canada hit a near three-month high on smaller-than-expected quarterly loss. Air Canada AC.TO rose 2.1% after the country's largest airline benefited from resilient travel demand. Among other movers, Silvercrest Metals Inc SIL.TO jumped 13.1% to log its best day in six months, after the precious metals miner reported a strong end to the first quarter of the year. | By Johann M Cherian May 12 (Reuters) - Canada's main stock index bounced back on Friday after two straight sessions of losses, helped by gains in commodity-linked stocks, while Air Canada hit a near three-month high on smaller-than-expected quarterly loss. Air Canada AC.TO rose 2.1% after the country's largest airline benefited from resilient travel demand. "The numbers that Air Canada put out were good, especially in terms of guidance they gave last week," said Greg Taylor, chief investment officer at Purpose Investments. | By Johann M Cherian May 12 (Reuters) - Canada's main stock index bounced back on Friday after two straight sessions of losses, helped by gains in commodity-linked stocks, while Air Canada hit a near three-month high on smaller-than-expected quarterly loss. Air Canada AC.TO rose 2.1% after the country's largest airline benefited from resilient travel demand. Still, the TSX is set for its third straight week of losses, the longest streak of weekly declines since late February. |
34799.0 | 2023-05-12 00:00:00 UTC | CANADA STOCKS-TSX recovers as commodity stocks rise, Air Canada shines | AC | https://www.nasdaq.com/articles/canada-stocks-tsx-recovers-as-commodity-stocks-rise-air-canada-shines | nan | nan | May 12 (Reuters) - Canada's main stock index rose at the open on Friday, helped by gains in commodity-linked stocks, while Air Canada hit a near three-month high on better-than-expected quarterly results.
At 9:38 a.m. ET (1338 GMT), the Toronto Stock Exchange's S&P/TSX composite index .GSPTSE was up 60.85 points, or 0.3%, at 20,478.46.
(Reporting by Johann M Cherian in Bengaluru)
((johann.mcherian@thomsonreuters.com;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | May 12 (Reuters) - Canada's main stock index rose at the open on Friday, helped by gains in commodity-linked stocks, while Air Canada hit a near three-month high on better-than-expected quarterly results. ET (1338 GMT), the Toronto Stock Exchange's S&P/TSX composite index .GSPTSE was up 60.85 points, or 0.3%, at 20,478.46. (Reporting by Johann M Cherian in Bengaluru) ((johann.mcherian@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | May 12 (Reuters) - Canada's main stock index rose at the open on Friday, helped by gains in commodity-linked stocks, while Air Canada hit a near three-month high on better-than-expected quarterly results. ET (1338 GMT), the Toronto Stock Exchange's S&P/TSX composite index .GSPTSE was up 60.85 points, or 0.3%, at 20,478.46. (Reporting by Johann M Cherian in Bengaluru) ((johann.mcherian@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | May 12 (Reuters) - Canada's main stock index rose at the open on Friday, helped by gains in commodity-linked stocks, while Air Canada hit a near three-month high on better-than-expected quarterly results. ET (1338 GMT), the Toronto Stock Exchange's S&P/TSX composite index .GSPTSE was up 60.85 points, or 0.3%, at 20,478.46. (Reporting by Johann M Cherian in Bengaluru) ((johann.mcherian@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | May 12 (Reuters) - Canada's main stock index rose at the open on Friday, helped by gains in commodity-linked stocks, while Air Canada hit a near three-month high on better-than-expected quarterly results. ET (1338 GMT), the Toronto Stock Exchange's S&P/TSX composite index .GSPTSE was up 60.85 points, or 0.3%, at 20,478.46. (Reporting by Johann M Cherian in Bengaluru) ((johann.mcherian@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.